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1.1 EPIDEMIOLOGY OF BREAST CANCER 
 
Cancer is a major public health problem, being the second leading cause of death, after 
cardiovascular diseases1. Among women, breast cancer is the first neoplasm for incidence and the 
second for mortality all over the world. World-wide, an incidence of 1.4 million new cases and a 
mortality of 0.7 million (in both males and females) are expected in year 20121. Breast cancer 
incidence and mortality rates strongly vary all around the world2. A woman’s lifetime risk of 
developing the disease is 1 in 8 in the United States as well as in the Netherlands3. More than two-
thirds of cases of breast cancer in 2010 were in women aged 50 years and older, most of which 
were in developed countries. For women aged 15–49 years, twice as many breast cancer cases 
were registered in developing countries than in developed countries. An increase in the number of 
cases in all regions during the past three decades has been registered, but this increase is more 
prominent in the Middle East, South Asia, South-East Asia, and Central Latin America. This could be 
partly due to the transition process of these countries toward a western life-style and/or 
improvement in diagnosis. In North America, Western Europe, and Southern Latin America the 
increase in breast cancer is lower than the global average. On average, the number of new cases of 
breast cancer increases, but a part of the recorded increase is because of the global increase of the 
population. 
In the Netherlands, the cumulative probability of breast cancer incidence for individuals aged 15–
79 years was 9.3 in 1980, 10.0 in 1990, 11.5 in 2000, and 10.5 in 20102. The gradual increase is due to 
an increase in the average life span of the population, leaving a larger percentage of women in an 
age group where breast cancer is frequently diagnosed. Another reason is the introduction of the 
nation-wide breast cancer screening program in 1989 for women aged 50-69 years. As a result, 
there was a substantial increase in the incidence rates of breast cancer among women of age 50-69 
years after 1989, but not for women younger than 50 years or aged 70 years and older. 
Additionally, among women aged 50-69 years, there was an increase in the rate of stage I cancers 
and a decrease in stage III+ cancer and therefore as from 1989 women aged 70-74 years were also 
invited for the national screening program. In contrast to this, the cumulative probability of breast 
cancer death for individuals aged 15–79 years decreased in the Netherlands being 3.9 in 1980, 3.9 
in 1990, 3.7 in 2000, and 2.9 in 20102, which can be attributed to earlier diagnosis through 
increased awareness and the breast cancer screening program and to improved treatment4. 
 
1.2 MORPHOLOGY OF THE NORMAL AND MALIGNANT BREAST 
 
1.2.1. Anatomy of the normal breast 
The breast of a normal adult female is a mass of glandular, fatty and fibrous tissues located over the 
pactoral muscle of the chest wall attached to the chest through a strand called Cooper’s ligament 
and occupying the entire area between the 2nd and the 6th rib of the rib cage (Figure 1.1). The 
terminal part of each breast has pink or brown pigmented circular area called areola surrounding a 
small protrusion called nipple through which milk can flow out to nurture the baby during the 
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entire period of lactation. The nipples are embedded with accessory mammary glands, sweat 
glands, and sebaceous glands that form tubercles during pregnancy that produce lubricating 
hormone and thus facilitate nourishment of the baby. Each breast contains 15 to 20 lobes. Each 
lobe is further composed of many smaller lobules, which are hormonal responsive and connected 
to a large number of tiny bulbs through a small duct. These bulbs are called terminal ductal lobular 
units (TDLUs). The TDLUs are functional parts of the mammary glands, which produce milk. The 
milk produced in the TDLUs is collected in the intra-lobular spaces and from where it is transported 
via the ductal system to the nipple. The ductal system is a branching system, which is comprised of 
on average 9-10 ducts that open into the nipple. Each breast is also supplied with blood and lymph 
vessels to feed nutrition and oxygen to the actively dividing cells and to drain out the waste 
material from mammary tissue. The lymph vessels lead to a series of small kidney-shaped organs 
called lymph nodes, which are scattered in all parts of the body including armpits, neck, and chest. 
Lymph nodes are also part of the breast drainage system. 
 
1.2.2. Normal histology 
The epithelium lining the entire lobular-ductal system is composed of an inner secretory luminal 
epithelial layer and an outer contractile basal myoepithelial layer. The inner epithelial layer consists 
of columnar or cuboidal shaped cells, which form a polarized continuous layer lining the entire 
lumen. These columnar cells are responsible for milk production and secretion into the lumen of 
the lobule. The outer myoepithelial layer comprises of cells, which are typically elongated and 
reside between luminal epithelial cells and basement membrane. These myoepithelial cells form 
nearly a continuous layer in the ducts, whereas they form a discontinuous basket-like structure 
around the lobules or acini in the lobules5. The myoepithelial cells also contain oxytocin receptors 
that are activated by the release of the hormone oxytocin from the posterior lobe of the pituitary 
gland6. The activated myoepithelial cells stimulate the contraction of muscle cells, thereby pushing 
secreted milk towards the nipple for the nourishment of the baby7.  
Luminal epithelial and basal myoepithelial cells are structurally distinct and can be distinguished 
on the basis of expression of various cytokeratin (CK) proteins and smooth muscle actin (SMA). 
Luminal cells express cytokeratins CK7, CK8, CK18, and CK19 and basal myoepithelial cells express 
CK5, CK14, CK178,9. Expression of luminal CK is restricted to only luminal cells whereas expression of 
myoepithelial CK is restricted to only myoepithelial cells but not to the luminal cells. Additionally, 
myoepithelial cells have high concentrations of actin microfilaments and stain positive for SMA, 
whereas these actins are low or not expressed in luminal epithelial cells7,10. It is thought that these 
two distinct epithelial cell lineages of the entire ducto-lobular system are descendent of a single 
mammary stem cell10-12. In addition, two types of luminal-restricted and one myoepithelial-
restricted progenitor have been identified13,14. However, studies are underway to elucidate the 
exact cellular hierarchy present in the breast epithelium. 
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childbirth, nulliparity, small number of children, use of oral contraceptives, high socioeconomic 
status, dense breast tissue on mammography and high postmenopausal obesity body mass index, 
and waist-hip ratio16-19. The hormone exposure-related factors showed expected patterns of 
association with estrogen receptor (ER) positive (+)/progesterone receptor (PGR) positive (+) but 
not with ER-negative (-)/PGR+ or ER-/PGR- breast cancers20. Genetic factors and their role, especially 
in the development of hereditary breast cancers, are extensively discussed in the section 1.6 
“Genetics of breast cancer” of this chapter. 
 
1.4 BREAST CANCER STAGING AND GRADING 
 
1.4.1. Tumor staging 
Tumor staging is a standard way of summarizing the size of the tumor and how far cancer has 
spread in the body. The most common system used to describe the breast cancer stages is the TNM 
system developed by the American Joint Committee on Cancer (AJCC)21. In the TNM system T refers 
to tumor size, N indicates whether or not tumor is spread to the lymph nodes, and M indicates 
whether tumor has spread to distant organs. Based on these three features, breast tumors are 
classified into five stages from 0 to IV. Stage 0 refers to a carcinoma in situ with no regional lymph 
node metastasis and it has 93% 5-year survival rate whereas stage IV describes a disease in which 
primary tumor has spread to the lymph nodes and a detectable metastases and distant organ is 
evident. Five year survival rate of this stage is poor and generally less than 15%. Tumor stages are 
strong predictors of prognosis of breast cancer. Tumor stages based on TNM classification along 
with brief description is given in Table 1.1 below. 
 
1.4.2. Tumor grading 
The grading of breast tumor is a term used to describe how closely a tumor resembles the normal 
tissue, which is an indication how quickly a cancer can progress. There are several grading systems 
available to assign a grade to breast tumors, however, the Scarff-Bloom-Richardson grading 
system, modified by Elston and Ellis is widely accepted and frequently used all over Europe22. 
According to this system, a tumor is inspected by a trained pathologist and a grade is given based 
on three microscopic features of the tumor: (i) degree of tubule or gland formation, (ii) nuclear 
pleomorphism, and (iii) mitotic count (Table 1.2). Each feature is scored on a scale from 1-3. After 
combining these feature scores, breast tumor can be of three grades: well differentiated (grade I), 
moderately differentiated (grade II), and poorly differentiated (grade III)23. Tumor grade has been 
demonstrated as an independent prognostic factor by numerous studies and high-grade tumors 
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Table1.1 Staging of human breast cancer21 
Stage TNM system Description 
5-year 
survival 
0 Tis N0 M0 Carcinoma in situ, no regional lymph node metastasis, no 
distant organ metastasis. 
 
93% 
I T1 N0 M0 Tumor is < 2 cm in greatest dimension, no regional lymph 
node metastasis and no distant organ metastasis. 
 
88% 
IIA T0 N1 M0 
 
T1 N1 M0 
 
T2 N0 M0 
No evidence of primary tumor, metastasis to movable 
ipsilateral nodes, no distant organ metastasis. 
Tumor is less than or equal to 2 cm, metastasis to movable 
ipsilateral node, no distant organ metastasis. 
Tumor is between 2 and 5 cm, no regional lymph node 
metastasis and no distant organ metastasis. 
 
81% 
IIB T2 N1 M0 
 
T3 N0 M0 
Tumor is between 2 and 5 cm, metastasis to movable 
ipsilateral nodes, no distant organ metastasis. 
Tumor is > 5 cm, no tumor in regional lymph node, no 
distant organ metastasis. 
 
74% 
IIIA T0 N2 M0 
 
T1 N2 M0 
 
T2 N2 M0 
 
T3 N2 M0 
No evidence of primary tumor, metastasis to fixed ipsilateral 
nodes, no distant organs metastases. 
Tumor is < 2 cm, metastases to fixed ipsilateral nodes, no 
distant organs metastases. 
Tumor is between 2 and 5 cm, metastases to fixed ipsilateral 
nodes, no distant organs metastases.  
Tumor is > 5 cm, metastasis to movable or fixed ipsilateral 
nodes, no distant organ metastasis. 
 
67% 
IIIB T4 N0 M0 
 
 
T4 N1 M0 
 
 
T4 N2 M0 
Tumor of any size with direct extension to the chest wall or 
skin tissue, no evidence of regional lymph node as well as 
distant organ metastasis. 
Tumor of any size with direct extension to the chest wall or 
skin tissue, no metastasis to movable ipsilateral nodes, no 
distant organ metastasis. 
Tumor of any size with direct extension to the chest wall or 




IIIC AnyT N3 M0 Any primary tumor involvement, metastasis in ipsilateral 




IV Any T Any N 
M1 
Any primary tumor involvement, any nodal involvement, 




T = Status of primary tumor; N = Regional lymph nodes; M = Distant metastasis. 
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Table 1.2 Grading of breast cancer23 
Tubule or Gland formation (% of carcinoma composed of tubular structures) Score 
More than 75% of the tumor contains tubule formation 1 
10 to 75% of the tumor has tubule formation 2 
Less than 10% of the tumor contains tubule formation 3 
  
Nuclear pleomorphism (change in cells) Score 
Nuclei are small and uniform in shape and size 1 
Nuclei are moderate in size and variation 2 
Nuclei possess marked variation in size and shape with multiple prominent nucleoli 3 
  
Mitosis count (per 10 high-power fields (hpf) with field area of 0.274 mm2) Score 
0 to 9 cell divisions 1 
10-19 cell divisions 2 
Equal or more than 20 cell divisions 3 
  
Tumor grade Brief description 
Feature 
scores 
I Well-differentiated (normal appearing, slowly growing, not aggressive). 3-5 
II 
Moderately-differentiated (semi-normal, growing moderately fast, 
and intermediately aggressive). 6-7 
III Poorly differentiated (abnormal, very fast growing, and very aggressive). 8-9 
 
1.5 GENETICS OF BREAST CANCER 
 
Breast cancer is a genetic disease that arises due to abnormalities (mutations) in one or more rate-
limiting genes in cells. There are two basic types of genetic mutations: germline and acquired. If the 
mutation is passed directly from a parent to a child, it is called a germline mutation. This would 
mean that the mutation is present in all cells of an individual including the reproductive cells. 
Breast cancer caused by germline mutations is called inherited breast cancer (hereditary breast 
cancer), which is less common and it accounts for about 20% of all breast cancer cases. On the 
other hand, the acquired mutations occur in a single cell of the target tissue during a person’s life, 
and they are passed on to all cells that originate from that single affected cell. These mutations are 
also known as somatic mutations and they are generally caused by various environmental factors, 
such as UV radiations, viruses, cigarette smoke, and alcohol consumption. Breast cancer caused by 
somatic mutations is called sporadic cancer. Sporadic breast cancer is more frequent and it 
accounts for the remaining 80% of breast cancer cases. Mutated genes in breast cancer are 
generally classified into two groups depending on their effect or gain and loss functions. One 
group includes genes known as tumor suppressor genes, which, when mutated, are unable to 
control unnecessary growth of cells and thereby cause cancer. It is important to note that the 
tumor suppressor genes are generally recessive and therefore their complete loss of function 
requires both alleles to be affected. The other and opposite group includes genes known as 
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oncogenes, which, when mutated, produce an active variant of the proteins that constitutively 
induce cell proliferation or inhibition of cell death and thereby leading to cancer. The oncogenes 
are dominant and activations of them generally require only one allele to be mutated. 
 
1.5.1. Hereditary breast cancer 
A family history of breast cancer is present in about 20% of women with newly diagnosed disease. 
The suspicion of hereditary breast cancer is increased if a family tree includes multiple cases of 
breast cancer, breast cancer occurring below the age of 50 year, cases with bilateral breast cancer, 
male relative with breast cancer, and cases with cancer in the ovary, fallopian tube, or primary 
peritoneum. Also, individuals of Ashkenazi Jewish heritage are at increased risk of having 
hereditary breast cancer, particularly a disease with a BRCA1 mutant gene. Family members of such 
individuals can be considered at an increased risk of developing breast cancer and may be 
considered for more intense screening or genetic counseling. In the last decade of the 20th century, 
several high-risk breast cancer susceptibility genes have been discovered24-26. More recently, with 
the advent of array technologies and using case control studies numerous moderate- and low-risk 
breast cancer susceptibility loci have been discovered27.  
 
1.5.1.1. High-risk breast cancer susceptibility genes 
Linkage studies in families have identified mutations in genes, which are associated with high-risk 
of breast cancer. These high-risk breast cancer susceptibility genes include BRCA1, BRCA2, TP53, 
PTEN, STK11, and CDH1 (Table 1.3).  
 
Table 1.3 High-risk breast cancer susceptibility genes 
Locus Genes in/near region Variants
* MAF RR References 
17q21.0 BRCA1 c.185delAG, c.5382insC 0.0006 5-45 31, 32, 33 
13q12.3 BRCA2 c.6174delT 0.001 9-21 32, 34 
17p13.1 TP53 c.13964G>C rare 2-10 35 
10q23.3 PTEN p.L22X, p.Q109X, p.R188X, p.V332E, 
p.R334X, p.R232X 
rare 2-10 36, 37 
19p13.3 STK11 p.Y60X, p.C759A, p.G2412A, c.716delGGTC,  c.843delG rare 2-10 
38, 30 
16q22.1 CDH1 p.W20X,  p.Q23X, c.1009-1delAG, c.1075insA rare 2-10 
29, 39 
*The most commonly identified variants in breast cancer families. MAF: Minor Allele Frequency. RR: Relative 
Risk. 
 
Oncogenic mutations in one of these genes predispose women to 60-80% life time risk of 
developing breast cancer compared to approximately 10% breast cancer risk estimated for the 
general population. BRCA1 and BRCA2 are tumor suppressor genes, which predispose to both 
breast and ovarian cancers. Germline mutations in these two genes are very rare in the general 
population with carrier frequency of about 0.1%, yet these are identified in about 20% breast 
cancer families24-26. Besides BRCA1/2 genes, germline mutations in other high-risk genes are 
associated with syndromes. For example, mutations in TP53 cause Li Fraumani syndrome, in PTEN 
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cause Cowden syndrome, in STK11 cause Peut Jegher syndrome, and in CDH1 cause gastric 
syndrome. Mutations in these genes altogether account for less than 1% of all familial breast 
cancer cases24,28-30. 
 
1.5.1.2. Moderate-risk breast cancer susceptibility genes 
Moderate-risk breast cancer susceptibility genes have often been identified by a combination of 
candidate-based and population-based approaches. Using these approaches, six moderate-risk 
breast cancer susceptibility genes have been identified. These genes include CHEK2, ATM, BRIP1, 
PALB2, RAD50, and NBS140-45 (Table 1.4). The CHEK2 gene is activated in response to DNA damage46. 
Germline variants in CHEK2 gene including 1100delC allele have been associated with a 2 to 4-fold 
increased risk of breast cancer. Germline variants in ATM gene cause ataxia-telangiectasia and have 
been associated with a 2-fold increased risk of breast cancer risks. The BRIP1 and PALB2 genes 
encode BRCA1-interacting and BRCA2 interacting proteins, respectively. Studies have found many 
germline variants in these two genes to be associated with about a 2-fold higher risk of breast 
cancer risks. Both the RAD50 and NBS1 genes encode proteins that make MRE11–RAD50–NBS1 
protein complexes, which is critical for proper maintenance of genomic integrity and tumor 
suppression. Germline variants in these genes confer to 2 to 3-fold increased risk of breast cancer. 
As a whole, women inheriting mutations in one of these moderate-risk breast cancer susceptibility 
genes predispose 20-40% elevated risks of developing breast cancer compared with the 10% in the 
general population. Altogether, these genes explain about 5% of familial breast cancer and 1 % of 
total breast cancer cases. 
 
Table 1.4 Moderate-risk breast cancer susceptibility genes 
Locus Genes in/near 
region 
Variants* MAF RR References 
11q22.3 ATM c.790delT, c.170G > A, c.687delA, 0.003 2-3 43, 47, 48 
22q12.10 CHEK2  p.I157T, c.1100delC, p.S428F, 0.004 2-3 42 , 46 
17q22-24 BRIP1 c.141delC, p.Q944E, c.2392C > T 0.001 2-3 44, 49 
16p12.1 PALB2 p.G796X, p.W1038X, p Y1183X rare 2-4 45 
5q31.1 RAD50 p.Q350X, c.687delT,  rare 2-3 40, 50 
8q21.3 NBS1 c.657del5 rare 2-4 51 
*The most commonly identified variants in breast cancer families. MAF: Minor Allele Frequency. RR: Relative 
Risk. 
 
1.5.1.3. Low-risk breast cancer susceptibility loci 
Low-risk breast cancer susceptibility loci are common in the general population with population 
frequency ranging from 5 to 50%24. These low-risk breast cancer susceptibility loci are scattered all 
over the genome and usually identified through genome-wide association studies (GWAS). GWAS 
have analyzed hundreds of thousands of single nucleotide polymorphisms (SNPs) as markers 
capturing genome-wide genetic variability of samples from affected (cases) and normal (controls) 
individuals52,53. Generally, GWAS are performed in three stages, with a relatively small initial cohort, 
which are then replicated in independent second and third cohorts with up to tens of thousands of 
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cases and controls. The identification of SNPs associated with disease in GWAS studies is based on a 
large number of statistical tests, which increases false discoveries and therefore stringent 
acceptance levels for statistical significance are used54. For example, a threshold of P < 5x10-8 is 
considered to be an appropriate threshold for one million analyses. Another important aspect of 
GWAS is the availability of large cohorts of cases and controls. The requirement of large study 
cohorts has led to the establishment of international consortia, e.g. Breast Cancer Association 
Consortia (BCAC), The Consortium of Investigators of Modifiers of BRCA1/2(CIMBA), Breast Cancer 
Family Registry (BCFR), Baltic Familial Breast Ovarian Cancer Consortium (BFBOCC), and Breast 
Cancer Surveillance Consortium (BCSC) etc. For example, BCAC includes more than 68 international 
collaborative research groups, with a combined samples size of about 70,000 breast cancer cases 
and 68,000 controls27. To date, 21 low-risk breast cancer susceptibility loci have been convincingly 
identified to be associated with modest-breast cancer risks of ~ 1.2 to 1.3-fold (Table 1.5). 
Altogether, these loci are estimated to account for approximately 9% of familial breast cancer cases 
and 2% of breast cancer cases overall27,55. 
 
Table 1.5 Low-risk breast cancer susceptibility loci 
Locus 
Genes in/near 
region Variants MAF RR References 
10q26 FGFR2 rs2981582 0.38 1.26 56 
16q12 TOX3 rs3803662 0.25 1.20 56 
5q11 MAP3K1 rs889312 0.28 1.13 56 
8q24 FAM84B/MYC rs13281615 0.40 1.08 56 
11p15 LSP1 rs3817198  0.30 1.07 56 
3p24 NEK10/SLCA4A7 rs4973768 0.46 1.11 57 
17q23.2 COX11 rs6504950 0.27 0.95 57 
10p14 CASP8(D302H) rs1045485 0.13 0.88 58 
2q35 TNP/IGFBP2,5/TNS1 rs13387042 0.52 1.12 59 
1p11.2 NOTCH2/FCGR1B rs11249433 0.40 1.14 60 
14q24.1 RAD51L1 rs999737 0.24 0.84 60 
5p12 MRPS30/FGFR10 rs10941679 0.26 1.19 61 
6q25.1 ESR1 rs2046210 0.35 1.29 62 
9p21.3 CDKN2A, CDKN2B rs1011970 0.17 1.29 63 
10p15 ANKRD16, FBXO18 rs2380205 0.43 0.89 63 
10q21 ZNF365 rs10995190 0.15 0.83 63 
10q22.3 ZMIZ1 rs704010 0.39 1.13 63 
11q13 Intergenic rs614367 0.15 1.27 63 
12p11 PTHLH rs10771399 0.12 0.79 27 
12q24 MK5 or TBX3 rs1292011 0.41 0.88 27 
21q21 RIP140 rs2823093 0.26 0.96 27 
MAF: Minor Allele Frequency. RR: Relative Risk. 
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1.5.1.4. Low-risk breast cancer loci and polygenic susceptibility  
In addition to high-risk genes like BRCA1and BRCA2 and TP53, several low-risk breast cancer genes 
or loci are found to be associated with increased breast cancer risk (see section 1.5.1.3). These 
susceptibility alleles are common in the population and carry essentially low effect size (per-allele 
relative risks of 0.83–1.3)27. This has suggested that breast cancer disease is not predisposed by 
merely an individual gene, but many common genetic variants contribute to the disease 
susceptibility. It is therefore more likely that the inheritance of breast cancer is polygenic in which a 
number of susceptibility variants combined additively or multiplicatively confer increased breast 
cancer risk. According to this model, a woman harboring several susceptibility alleles would be at 
high risk compared to one with no or few breast cancer susceptibility variants. This model has been 
found to be well-fitting to genetic data obtained from a series of non-BRCA1and BRCA2 mutant 
multiple-case families64. It is probably also an appropriate model for many other cancers and other 
complex diseases. The model is based on the assumption that the risk conferred by the common 
genetic variants in a population is predicted to be log-normally distributed. This will provide 
sufficient information to set up breast cancer screening programs in such a way that women 
harboring large numbers of risk-loci would be subjected to breast cancer screening such as 
mammography at early age compared to those harboring no or few risk-loci65,66. This would 
eventually allow a targeted screening and early diagnosis of breast cancer. 
 
1.5.1.5. The biology of low-risk breast cancer susceptibility loci 
The biological mechanisms by which low-risk breast cancer susceptibility loci confer their increased 
breast cancer risks are poorly understood. Although, the identified SNPs have been shown to be 
significantly associated with increased breast cancer risk, yet it is not clear whether the SNPs by 
themselves are causal or whether they associate with causal variants in the surrounding. To unravel 
exact biological disease mechanisms, various approaches have been applied. The first approach 
included the determination of mutant variants through deep sequencing of the entire coding 
genes containing or located close to these risk SNPs and subsequently correlating mutations to the 
corresponding risk SNP. Unfortunately, this approach has not yet yielded any causal variants in the 
coding part of the genome56. The second approach was setting-up functional studies on the 
identified loci. The rational of this approach was based on the observation that the majority of the 
low-risk loci (for example FGFR2, MAP3K1, 8q24 and 5p loci) are strongly correlated with ER-positive 
disease, some loci, such as TOX3, are associated with both ER-positive and ER-negative diseases and 
also some with triple-negative breast cancer56,59,67,68. The FGFR2 gene is highly expressed in ER-
positive compared with ER-negative cell lines and tumors and has been implicated in the genesis 
of ER-positive tumors69-74. This approach worked out successfully for only FGFR2 and 8q24 risk loci. 
In case of the FGFR2 risk variant, the risk-associated SNP rs2981582 (located in intron 2 of FGFR2) 
was itself found to be a causal variant as this variant regulates increased FGFR2 expression by 
altering the binding affinity of transcription factors Oct1/Runx2 and C/EBPβ75. In case of the 8q24 
risk variant (rs13281615), it was functionally shown that risk is conferred by expression regulation 
of the MYC gene through a tissue-specific physical interaction of enhancers from the 8q24 region76. 
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The third approach was to analyze the association of low-risk loci with expression modulation of 
genes that either contain these loci or located nearby to them on the same linkage-disequilibrium 
block. This approach revealed only a significant association of the rs3803662 risk variant with lower 
expression of the TOX3 gene (previously known as TNRC9) indicating a tumor suppressor role of the 
TOX3 gene (chapter 4 of this thesis). However, functional support of this observed association is 
required. The TOX3 gene encodes a high mobility group box nuclear protein involved in calcium-
dependent transcription and structural modification of chromatin. Altogether, these data support 
the notion that the low-risk breast cancer loci do not confer their breast cancer risk through one 
general mechanism, but rather multiple disease mechanisms can be envisioned. However, more 
ongoing and future sequencing, fine-mapping and functional studies will help in elucidating the 
most relevant biological mechanisms underlying these common low-risk breast cancer loci. 
 
1.5.2. Sporadic breast cancer 
Approximately 80% of breast cancers are sporadic tumors (Figure 1.3). The sporadic breast cancers 
arise due to somatic mutations in functionally important genes. Whole genome sequencing of the 
consensus coding sequences of the breast cancer genome has revealed a variety of somatic 
mutations in large numbers of genes77-79. These mutations include both synonymous (not altering 
an amino acid) and nonsynonymous (altering an amino acid) mutations. The nonsynonymous 
mutations comprised of missense and nonsense mutations, insertions, deletions, rearrangements, 
copy number alterations and mutations in splice sites, in the regulatory elements, and in UTRs. In 
sporadic breast cancer, somatic mutations confer selective growth advantage to cells and therefore 
promote tumorigenesis. The causal somatic mutations are known as ‘driver’ mutations and they 
typically occur through misincorporation of nucleotides during DNA replication or through 
exposure to exogenous and endogenous mutagens. In contrast, some somatic mutations are 
biologically inert and do not confer any growth advantage to the cells. Such mutations are called 
‘passenger’ mutations. These mutations normally occur in cells that have already acquired growth 
advantage. Mutational activation of oncogenes, coupled with mutational inactivation of tumor 
suppresser genes is an early event in the development of a sporadic tumor, which might be 
followed by independent mutations in a dozen of genes along the line of breast cancer 
progression.  
 
1.5.2.1. Prevalence of driver and passenger mutations in cancers 
Greenman and his coworkers, for first time, investigated numbers of driver and passenger 
mutations by sequencing the coding exons of the 518 kinase genes in 210 diverse human 
cancers77. They compared an observed ratio of non-synonymous/synonymous mutations with that 
expected by chance with an underlying hypothesis that biological selection is exerted on non-
synonymous mutations because these carry functional implications. Conversely, synonymous 
mutations are generally biologically neutral and therefore cannot be selected for biological 
consequences. The presence of a driver or a passenger mutation is inferred by determining a ratio 
of non-synonymous and synonymous mutations. A higher mutational ratio compared to that 
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expected by chance indicates overall positive selection (selection pressure <1), which suggests a 
driver mutation whereas a lower non-synonymous/synonymous ratio indicates no overall selection 
(selection pressure <1) and is suggestive of a passenger mutation. To distinguish genes that are 
statistically likely to contribute to tumorigenesis from those in which passenger mutations occur by 
chance, Sjoblomand and coworkers developed a statistical method that provides a cancer 
mutation prevalence (CaMP) score as an output for each gene analyzed80. According to their study, 
90% of the genes with CaMP score >1.0 were predicted to have mutation frequencies higher than 
the background mutation frequency80. 
Using these criteria, large numbers of driver and passenger mutations have been estimated from a 
number of studies. Greenman and coworkers have found 921 base substitution mutations 
identified in 518 kinase genes, out of which 763 mutations were estimated to be passenger 
mutations and are not likely implicated in cancer development. The remaining 198 mutations were 
therefore estimated to be driver mutations, which were predicted to be distributed over 119 kinase 
genes77. These results, therefore, provide a statistical support for a large set of protein kinase genes 
to be implicated in one-third of the cancer cases. Curtis and co-workers have analyzed somatic 
copy number variations (CNVs) in 2000 breast cancers and introduced a new approach to identify 
new deriver genes81. This approach involves an identification of CNVs through an integrated 
genomic/transcriptomic analysis of breast cancers and then their association with the expression 
changes of genes located in cis and trans. This has revealed several known and unknown putative 
driver genes including deletions in PPP2R2A, MTAP, and MAP2K481.  
 
1.5.2.2. Breast cancer candidate genes  
About 122 breast cancer candidate genes (CAN-genes) have previously been identified and 
assigned to a functional group based on Gene Ontology molecular groups or biological processes 
groups77. Functional groups identified through this way are of special interest, for instance 22 of 
the 122 (18%) breast CAN-genes are transcriptional regulators. In the same study, it was revealed 
that at least one of these CAN-genes is mutated in more than 80% of the breast tumors82. The 
mutation prevalence in CAN-genes has been evaluated more precisely in a cohort of 183 breast 
cancer tumors (59 = ERBB2-positive, 65 = HR+ (ER/PGR-positive), and 59 = TNBC (ER/PGR/ERBB2-
negative). This study identified 10, 6, and 5 genes that harbor significantly prevalent protein 
altering mutations in hormone receptor positive tumors, ERBB2-positive and triple-negative 
tumors, respectively78. A recent mutation analysis study has identified 32 CAN-genes in primary 
TNBC whose expression was significantly influenced by the presence of somatic mutations83. 
Among these genes TP53 and PIK3CA are the most variable and somatically mutated genes83. These 
mutations have been evaluated for their possible effect on predicted protein function of the CAN-
genes and pathways in which these CAN-genes were involved in breast cancer84. For example, in 
breast cancer, PIK3CA or PTEN, and TP53 are frequently mutated, which obstruct PI3K and p53 
signaling pathways, respectively83. Altogether, somatic mutations in the CAN-genes may explain 
the susceptibility for breast cancer associated with non-familial human breast cancer (Figure 1.2).  
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1.6 MOLECULAR CLASSIFICATION OF BREAST CANCER 
 
1.6.1. Steroid hormone receptor expression   
One of the earliest molecular classifiers of the breast tumors is the presence of the hormonal 
receptor molecules ER and PGR in the tumors. Approximately 75% of breast cancers are positive for 
ER, PGR, or both, and estrogen stimulation of ER is a significant factor in the development and 
growth of breast cancer. Few (<1%) of breast tumors are ER negative and PGR positive and about 
15% of all breast cancers lack expression of both hormone receptors85. The ER and PGR expression 
is determined by multiple techniques among which immunochemistry (IHC) is the preferred 
technique and currently being used in the clinic. Generally the tumors are considered positive for 
ER or PGR if >10% of nuclei are stained positive immunohistochemically. The presence of ER and 
PGR are significantly negatively correlated with histological grade and its mitotic index. ER and PGR 
positive tumors are commonly grade I, well-differentiated tumors, and they are generally less 
aggressive compared to ER-negative tumors, which are often poorly differentiated. ER is a target 
for endocrine therapy such as tamoxifen, which inhibits the growth of breast cancer through 
competitive antagonism of estrogen at ER86. Tamoxifen is used for premenopausal patients with 
ER-positive disease. The second therapeutic agent to treat ER-positive postmenopausal breast 
cancers are aromatase inhibitors, which specifically blocks the aramotase-mediated conversion of 
androgen to estrogen and therefore less estrogen is available to stimulate ER-positive tumor cells 
in postmenopausal women87.  
 
1.6.2. ERBB2 expression  
The ERBB2 oncogene encodes a transmembrane tyrosine kinase receptor, which has evolved as a 
major classifier of invasive breast cancer. It is amplified and/or overexpressed in approximately 16% 
of breast cancer in the Netherlands. The ERBB2 overexpression is routinely determined by IHC 
and/or fluorescent in-situ hybridization (FISH) techniques in all cases of invasive breast carcinoma, 
although variability in testing remains a significant issue with both methodologies. Tumors are 
considered ERBB2 overexpressed on IHC, when at least 10% of cells show strong membranous 
staining and/or on FISH when a gene copy-to–CEP-17 ratio is found greater than 2. Clinically, ERBB2 
overexpression has been associated with increased tumor aggressiveness, increased recurrence 
rates, and increased mortality rates in node-positive patients, while this relationship in node-
negative patients is more variable88-92. Histologically, ERBB2 overexpressing tumors are often 
intermediate or poorly differentiated with the presence of lymph-node metastases at 
presentation93. According to recent molecular classification of breast cancer, tumors with a positive 
ERBB2 status do not constitute a unique molecular category and are identified in both the ER-
positive and ER-negative tumor classes94. ERBB2-positive breast cancer is treated by monoclonal 
antibodies such as trastuzumab, which is directed against ERBB2 protein95,96. Nevertheless, some 
tumors develop resistance to trastuzumab and the therapy may fail and therefore more treatments 
options are constantly being investigated97. 
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1.6.3. Molecular subtypes of breast cancer 
Microarrays-based gene expression profiling of breast cancer has provided a novel working model 
for the taxonomy of breast cancer, which is based on gene expression analysis of breast tumors 
and classifying them into several molecular subtypes with different prognosis and therapeutic 
responses98. A microarray includes a collection of DNA fragments (cDNA or oligonucleotides) 
spotted on a solid surface (a ‘chip’) in an ordered pattern of grids. Each spot consists of a high 
concentration of unique fragments of DNA, which hybridize to a specific gene sequence present in 
a mixture of cDNAs derived by reverse transcription of mRNA extracted from a tumor sample 99-101. 
The intensity signal of cDNA hybridized to their corresponding sequences spotted on the array is 
an indication of the expression level of the genes in the sample. In this way, global expression 
patterns of hundreds and thousands of genes in a large number of tumor sample and normal 
tissues are determined and consequently tumor samples are classified based on their similar gene 
expression patterns.  
 
1.6.3.1. Five intrinsic molecular subtypes 
For the first time, using cDNA microarrays, Perou and coworkers determined gene expression 
profiles of invasive breast cancers, which included paired samples from the same tumors as 
well102,103. Unsupervised cluster analysis revealed two main clusters of the tumors, which were 
primarily discriminated into ER-positive and ER-negative tumors. The expression patterns of both 
types of the tumors were remarkably different. Additionally they found a set of 496 “intrinsic 
genes” whose expression differed most between tumors compared to replicates from the same 
tumors. Intrinsic gene expression divides both ER-positive and ER-negative invasive breast tumors 
into five distinct molecular subtypes. These five subtypes include: luminal A and B; ERBB2-positive; 
basal-like; and normal-like102-104 (figure 1.2). With the advancement of array technology and 
bioinformatics tools, more and more gene expression profiles have been generated and 
consequently new molecular subtypes of the breast cancer have been identified (as discussed 
below)  
The tumors in luminal A and B subtypes are characterized by high expression of ER and ER-
regulated genes (GATA3, XBP1, TFF3, HNF3α, and LIV1) and low expression of myoepithelial cell-
associated genes (KRT5, KRT17, ANXA8, CXCL1, and TRIM29) and proliferation related-genes (Ki-67). 
The difference between the luminal A and the luminal B subtypes is that the tumors in the luminal-
B subtype have comparatively low expression of ER and ER-regulated genes and high expression of 
the Ki-67 gene and other proliferated genes. ERBB2-positive subtype tumors are characterized by 
higher expression of the ERBB2 gene and other genes transcribed from this genomic region (Entrez 
Gene cytogenetic band: 17q11.2-q12) including GATA4, GRB7, NFКB and high expression of 
proliferation related genes and low expression of luminal genes. The ERBB2-positive tumors are 
mainly hormone receptor negative but a substantial number of ERBB2-positive tumors are ER-
positive and usually cluster together with the luminal B tumors. The basal-like tumors are 
characterized by low or no expression of luminal and ERBB2 gene clusters (KRT8, KRP18, GATA3, 
XBP1, TFF3, and HNF3α) and high expression of the typical basal gene cluster (KRT5, KRT14, KRT17, 
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ITGβ4, LAMA3, c-Kit, ITGα6, MT1X, CDH3, B-FABP)102,103. Also, basal-like tumors often exhibit high 
expression of EGFR. Generally, basal-like tumors display poor prognosis and can only be treated 
with chemotherapeutics as no drug-related targets are known for these tumors. The normal-like 
subtype is the smallest and a poorly characterized group of breast cancer. The main characteristic 
of these tumors is that they consistently cluster together with normal breast tissue samples and 
fibroadenomas102. Importantly the intrinsic subtyping of breast tumors is very robust classification 
method as the existence of these five intrinsic subtypes has consistently been replicated by a 
number of subsequent studies using various array platforms and patient series with different 
ethnic background88,105,106. 
Several studies have shown that the intrinsic subtyping of the breast tumors carries prognostic 
significance107-109 for example luminal A and luminal B tumors show distinct but better prognostic 
behavior compared to basal-like tumors and ERBB2-positive tumors. Furthermore, the basal-like 
subtype is enriched for tumors lacking the expression of ER, PGR, and ERBB2 expression (triple-
negative). Intrinsic subtyping also has predictive power since basal-like and ERBB2-positive tumors 
respond more frequently to neo-adjuvant chemotherapy than other subtypes but they are more 
refractory to endocrine agents. Moreover, the intrinsic subtypes of breast cancer are also 
associated with the ability to disseminate to different distant organs110,111. Breast tumors of the 
luminal intrinsic subtypes more frequently relapse to bone and pleura, whereas tumors of the 
basal-like and ERBB2-positive subtypes frequently metastasize to the brain and liver110,112. 
 
1.6.3.2. Claudin-low and apocrine subtypes 
Besides the five well-known intrinsic subtypes, microarray gene expression analyses have identified 
two more subtypes within ER-negative breast cancers: claudin-low and apocrine subtypes (Figure 
1.2). The claudin-low subtype is non-basal, uncommon but an interesting subtype because it 
includes tumors that are characterized by the expression of genes associated with epithelial to 
mesenchymal-transition (EMT) such as low expression of E-cadherin and claudins and high 
expression Vimentin and stem cell markers (CD24lowCD44high and ALDH1)113. The apocrine subtype 
includes ER-negative tumors that are also not of the basal-like subtype, but these tumors, however 
exhibit high expression of androgen receptor and other hormonally regulated genes (SREBF1, 
CDH1, SCD, FASN, RND1, and GHR)114. Patients with tumors displaying both the claudin-low and 
apocrine subtype features show poor overall survival compared to patients with the luminal 
subtype tumors113. 
 
1.6.3.3. Triple-negative breast cancer subtypes  
Triple-negative breast cancer (TNBC) is a highly diverse group of breast cancers with varied 
response to the available chemotherapy. Recently, Lehmann and co-workers re-analyzed gene 
expression profiles of an extensive number of triple-negative breast tumors from 21 publically 
available data sets and identified 6 molecular subtypes within triple-negative disease115. These 
subtypes were characterized on the basis of gene ontology terms associated with differentially 
expressed genes and were named as: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), 
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mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR). These 
subtypes exhibit distinct relapse free-survival (RFS), which was significantly lower in the LAR 
subtype compared with the BL1 subtype. The M subtype showed shorter RFS compared with BL1, 
while the MSL subtype had longer RFS than the M subtype. Microarray gene expression-based 
molecular subtypes including TNBC subtypes are schematically represented in Figure 1.3. It is 
worth mentioning however that the molecular classification of the breast cancer in general and 
TNBC in particular has led to the identification of active cellular pathways specific to each identified 




Figure 1.3 schematic representation of molecular subtypes of human breast cancer. 
 
 
1.7 PROGNOSIS OF BREAST CANCER 
 
Breast cancer is heterogeneous disease with respect to biological behavior and clinical outcome. 
Several prognostic markers have been identified and used in the clinic to accurately predict course 
of the disease in the patients. The currently available prognostic markers are generally divided into 
three classes:  
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2. Tumor-related prognostic factors, which include tumor size, tumor stage, axillary lymph 
node involvement, tumor differentiation status (grading), tumor ER, PGR, and ERBB2 
expression status.  
3. Molecular prognostic factors which include mRNA, miRNA, and protein expression 
signatures as well as epigenetic signatures including changes in DNA methylation and 
histone modification.  
Clinical utility and significance of these prognostic markers have been extensively reviewed 
elsewhere116-118.  
 
1.8 BIOLOGY OF THE BREAST CANCER 
 
Human mammary tissue is characterized by active cellular growth and proliferation. Mammary 
epithelial cells are organized in three dimensional structures, which are strongly dependent on a 
polarized morphology, specialized cell–cell contacts and specific attachments to an underlying 
basement membrane. These features are necessary for proper control of cell proliferation, survival, 
differentiation, migration and milk-protein secretion. Breast cancer develops through a multistep 
process in which cells become abnormal and multiply out of control. The whole process is 
governed by the genetic abrasions which occur in functionally important genes controlling the 
division of cells. Such mutated genes can be tumor suppressers and oncogenes. This escape can 
occur through the activation of a variety of molecular signaling pathways. In breast cancer, several 
biological signaling pathways are activated. These activated signaling pathways provide selective 
growth advantage to tumor cells over the normal cells located in the same tissue. Recently, non-
coding RNAs such as microRNAs (miRNAs) also have emerged as important biological molecules 
that are involved in regulation of several genes involved in breast cancer initiation and 
progression119-125.  
 
1.8.1. MicroRNAs and breast cancer biology 
MicroRNAs (miRNAs) are a class of 20-25 nucleotide-long non-coding RNAs that regulate gene 
expression through a complementary base-pairing with seed sequence present mostly in the 3' 
untranslated region (3’ UTR) of target mRNAs. miRNA biogenesis starts with RNA polymerase II 
mediated transcription of primary miRNA sequence (pri-miRNA). The pri-miRNA is then 
microprocessed to a 70-nucleotide stem loop known as the precursor miRNA (pre-miRNA) by the 
enzymatic activity of two endonucleases Drosha and DGCR8. The pre-miRNA is then actively 
transported to the cytoplasm via exportin 5 in a Ran-GTP-dependent manner. In the cytoplasm, the 
pre-miRNA is recognized by another RNase III endonuclease called Dicer, and is cleaved to 
generate a mature 20-nucleotide miRNA duplex126. Generally, only one strand is biologically 
selected and the other strand is degraded. The mature miRNA is loaded into RNA-induced silencing 
complex (RISC), which contains Argonaute (Ago) and a single stranded target RNA. The mature 
miRNA allows the RISC to recognize target mRNA via partial sequence complementarity present 
between the seed sequence of the miRNA and seed matching sequences of the target mRNA. 
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There are two known mechanisms by which the RISC can inhibit the expression of the target genes: 
1- RISC removes the poly-A tail of the target mRNA (deadenylation) by fostering the activity of 
deadenylases and exposes mRNA for its nuclease mediated degradation, 2- RISC blocks the 
initiation of mRNA by either inhibiting the factors required to start mRNA initiation and elongation 
or by causing ribosome stalling. The RISC-bound mRNAs can be localized to sub-cytoplasmic 
compartments, known as P-bodies where they are either stored in reversible manner or degraded 
by the activity of Ago protein127 
Over the past few years, miRNA profiling studies have led to the identification of several miRNAs 
that are aberrantly expressed in human breast cancer and much of research is focused on 
understanding their underlying biology. In breast and many other cancers, some miRNAs can 
function as tumor suppressors while other can act as oncogenes. Tumor formation may therefore 
occur by deletion of a tumor suppressor miRNAs and/or amplification or overexpression of an 
oncogenic miRNAs128. For instance, hsa-miR-15, hsa-miR-16, hsa-let-7, hsa-miR-34b, hsa-miR-10b, 
hsa-miR-125b, and hsa-miR-145 are downregulated or deleted in leukemia, lung cancer and breast 
cancer129-131 on the other hand hsa-miR-155, and hsa-miR-21 are overexpressed or amplified in 
breast cancer131,132. Growing evidence demonstrated that miRNAs being novel modulators in 
cancer can also be efficiently therapeutically targeted, and consequently cancer progression can be 
reversed. For example, hsa-miR-155 alone is sufficient to induce tumorigenesis, a systematic 
knockdown of hsa-miR-155 as anti-tumor therapy may reduce tumorigenesis133,134, similarly hsa-
miR-21 has been shown to increase metastatic ability of breast cancer cells and knockdown of 
which may lead to treat advanced breast cancer135. 
 
1.9 BREAST CANCER RESEARCH MODELS 
 
To become a fully malignant cell, a mammary cell undergoes considerable amount of 
transformations at the genomic level. These changes enable the malignant cells to disentangle 
from their primary site, pass through the tumor basement membrane, enter into the circulation 
and disseminate to secondary sites to give rise to metastatic tumors. As a part of the metastatic 
process, the tumor cells are able to resist anoikis, evade immune recognition, and physical stress 
like low oxygen pressure and finally manage to coexist in a foreign microenvironment with the 
cells of different organs136. Every step of the metastatic process is triggered through inter- or/and 
intra-cellular communication involving expression modulation of many genes and proteins136. In 
fact, hundreds to a few thousand of genes have now been reported to be deregulated by genomic 
alteration in breast cancer137,138. The functional assessment of these genes is therefore imperative to 
gain biological insights, which will eventually help in designing targeted therapies for improved 
treatment. Successful unfolding of these processes in cancer biology will require appropriate study 
models that can mimic the real scenario of human malignant cells in vivo. Depending on the 
aspects to study in breast cancer, several model systems have been employed and scientific 
knowledge has been extrapolated to humans and then accordingly possible treatment options are 
explored. Although, it is unlikely that the complexity of cancer in human patients is entirely 
General Introduction  | 29 
modeled but by understanding the strengths and weakness of the available models, it is possible 
to choose an appropriate model to study an individual scientific problem and question. This holds 
true while using breast cancer cell lines and mice as models to understand breast carcinogenesis 
and to design preventive therapeutics. 
 
1.9.1. Well-established human breast cancer cell lines 
Breast cancer cell lines are renewable resources, which have been widely used for laboratory 
research particularly as an in vitro model for breast cancer. A significant amount of our current 
knowledge on breast cancer disease has been accumulated using breast cancer cell lines cultured 
in both in vitro and in vivo conditions. The fundamental aspects of breast carcinogenesis studied 
using breast cancer cell line models are growth factors-induced responses in malignant cells, 
evaluation of the functional role of clinically important genes through loss and gain of function 
studies, global gene expression profiling of pure tumor cells, and drug sensitivity studies. The first 
ever described human breast cancer cell line is BT20 that was established in 1958 from a patient 
who was treated in a hospital of Baltimore, (USA). Since then, more than 100 human breast cancer 
cell lines have been established and propagated as a continuous in vitro culture (Table 1.6). Despite 
of the fact many cell lines are successfully established, a handful number of them are used in 
studies. For example, MCF7, T-47D, MDA-MB-231, BT20, BT549, MDA-MD-468, SK-BR-3, SK-BR-7, ZR-
75-1, and CAMA1 have frequently been reported as models to investigate breast cancer biology.  
Cell lines have been generated from both primary tumors (BT20, BT474, BT549, and HCC-cell lines 
series) and metastasis (MDA-MB-231, MDA-MB-436, MDA-MD-468, and DU4475). The majority of 
the cell lines from metastatic origin have been isolated from pleural effusions and only some of 
them have been obtained from metastatic organs. For instance, MCF-7 has been isolated from 
pleural effusion and MDA-MB-361 and ZR-75-1 have been established from brain metastasis and 
ascitic fluid, respectively. Many breast cancer cell lines are typically placed into a group or as a 
series since they were isolated from the same patient or they were generated by one research 
group from different patients and propagated in similar laboratory conditions. Examples are the 
‘Hamon Cancer Center’ (HCC) series, which comprises of 18 cell lines, which were successfully 
derived from a series of 177 tumor tissues.  
A number of cell line variants have been generated from the most widely used cell lines to learn 
resistance and sensitivity level of clinically important genes. For instance, various clones of an anti-
estrogen responsive ZR-75-1 cell lines showing varied anti-estrogen sensitivity level have been 
generated after transfection it with different constructs of BCAR1 gene, a known tamoxifen 
resistance conferring gene. The ZR-75-1/BCAR1 is a completely resistant clone towards anti-
estrogen ICI182,780 added at 100nm concentration in the culture medium, whereas ZR-75-
1/BCAR1Δ135 and ZR-75-1/BCAR1ΔSH3 clones show partial resistance in the medium containing 
ICI182,780139. The second example is MDA-MB-231 cell line variants, which were isolated based on 
their ability to preferentially disseminate to different metastatic sites (bones, lungs, and 
brain)111,140,141 and have different latency142,143.  
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A particularly subset of tumors develops in women due to germline mutations in BRCA1, BRCA2, 
and CHEK2 genes. It is however important to note that only limited or no corresponding cell lines 
are available to mimic biological characteristics of these germline tumors. For example, only 
HCC1937 cell lines have been derived from a primary tumor of a patient with known history of 
germline BRCA1 mutation144. Mutational screening of 41 cell lines by our group, however, has 
revealed three additional breast cancer cell lines (MDA-MB-436, SUM149PT, and SUM1315MO2) 
with deleterious mutations in BRCA1 gene and one cell line (UACC812) with the CHEK2-1100delC 
mutation145. This group of 4 BRCA1 mutant cell lines can serve as a model to unravel underlying 
biology of germline BRCA1 mutant breast cancers.  
 
1.9.1.1. Breast cancer cell lines in 2-D and 3-D cultures 
Breast cancer cell lines have conventionally been cultivated in two-dimensional (2-D) culture 
conditions to investigate global gene expression, global genetic profiling as well as breast cancer 
biology underlying cellular interactions involved in tumor-initiation, tumor cell proliferation, 
induction of apoptosis and migratory behavior during the progression of breast cancer, to study 
efficacy of the therapeutic agents, and many other applications146-148. In 2-D culture conditions, cells 
are grown on flat culture dishes made of either polystyrene plastic (Figure 1.4a). The principle 
limitation of 2-D culture systems, however, is that the cell lines propagated in these conditions 
markedly differ from the breast microenvironment and therefore the data obtained from these 
studies cannot always be linearly extrapolated to the clinical situation. Kenny and colleagues have 
developed a 3-D culture system in which cells are grown in 3-D reconstituted basement membrane 
cultures (Figure 1.4b)149. They compared molecular profiles of 25 breast cancer cell lines cultured in 
2-D versus 3-D culture conditions. Though not surprisingly, molecular profiles of breast cancer cell 
lines were more similar to themselves than to other cells that were grown under the same culture 
conditions, suggesting that the 3-D culture environment does not promote global changes at the 
gene expression level 149. However, a group of signal transduction genes were determined, which 
were significantly correlated with cells grown in 3-D culture conditions. The expression changes of 
these genes may accounts for the morphological and behavioral differences of the breast cancer 
cell lines grown in 3-D culture compared with 2-D cultures149,150. Importantly, critical signaling 
interactions between epithelial cells and stromal cells during breast cancer pathogenesis have 
been widely studied by culturing cells in 3-D culture conditions51,152. For example, the effect of 
stromal rigidity on tumor development and morphogenesis has elegantly been modeled by 
reducing the matrix compliance in 3-D culture system, which promotes tumor-like morphogenesis 
in normal mammary epithelial cells (Figure 1.4c). Altogether, these studies indicate that depending 
on requirement breast cancer cell lines can be used in both 2-D and 3-D cultures to investigate the 
complex nature of breast cancer development and progression.  
 
1.9.1.2. Breast cancer cell lines in xenografts 
Human breast cancer cell lines are grown as xenografts in animals such as mice and rats. The 
xenografts have generally been raised by injecting cancer cells into animals. One method involves 
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tail-vein injection of the tumor cells with the help of a fine needle (Figure 1.4d). This procedure is 
considered to be physiologically less relevant as it allows the tumor cells to colonize the organs 
directly without going through all metastatic steps commonly seen in patients such as invasion, 
extravasation, circulation, and colonization of organs. This method is however particularly suitable 
to investigate the preference of tumor cells to disseminate to various distant organ. A second 
method is subcutaneous injection of the tumor cells into the flank of the mouse (Figure 1.4d). The 
limitation of this method is that tumor cells are injected in a different type of microenvironment, 
which may alter the growth and metastatic potential of the implanted cells. The third and 
commonly preferred method is an orthotopic implantation of the tumor cells under the mammary 
fat pad of the mouse (Figure 1.4d). This method is thought to be physiologically most relevant to 
the human scenario, though, there are crucial differences between the mouse and human 
mammary stroma but it provides a more comparable microenvironment to that of human than 
subcutaneous implantation. Moreover, the implanted cells experience all essential steps necessary 
to establish metastasis in the distant organs including the complex tumor–stromal cell interactions 
that facilitate tumor formation and progression.  
With regard to breast cancer cell line xenograft models, a fundamental question arises whether or 
not these xenograft experiments share any relevance to human breast cancer. This question has 
been elegantly addressed by Massague and colleague in 2005. They labeled MDA-MD-231 breast 
cancer cells with a reporter marker and injected them into the mouse body through tail-vein 
injection. Subsequently, they were able to select MDA-MD-231 variants that were preferentially 
metastasizing to lungs, bone, and brain111,140,141. By doing molecular profiling of these MDA-MD-231 
variants, unique metastatic gene signatures were identified for bone, lungs, and brains relapse. 
Importantly, such signatures were recognized to have predictive value in patients who relapsed to 
bone, lungs, and brain141. All these studies together demonstrate relevance and utility of the 
xenograft assay in general and xenograft of breast cancer cell lines in particular to understand 
cancer initiation and metastasis. 
 
1.9.1.3. Breast cancer cell lines as preclinical models 
The anticancer activity of a drug has been evaluated by its ability to inhibit proliferation of a 
particular cancer cell typically growing in vitro conditions and this anticancer activity have often 
been predictive for breast cancer in the clinic. Human breast cancer cell lines have frequently been 
used as preclinical models both in vitro and in vivo as xenografts. Two recent studies, one by 
Garnett and coworker and another by Barretina and coworkers, have remarkably underscored the 
efficacy of cell lines as preclinical models148,153. These studies have used 40 and 56 breast cancer cell 
lines, respectively, to study the anti-cancer efficacy of many drugs. Additionally, several features 
including expression level, mutation status, deletion, and amplification of clinically important 
genes have been identified as robust predictors of sensitivity to the tested anticancer agents. For 
instance, activating mutations in BRAF and NRAS are predictors of sensitivity in models generated 
for MEK inhibitor PD-0325901. Other examples are EGFR mutation and ERBB2 amplification/ 
overexpression, for erlotinib and lapatinib sensitivity, respectively 154; HGF expression and MET 
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Table 1.6 Tumor origin, tumor type, and clinicopathological characteristics of well-established human breast 
cancer cell lines. 




type ER PGR ERBB2 TP53 PIK3CA 
E-
cad. Ref.
SUM185PE M (PE) DC NA N - - - Mt Mt Wt 157
MDA-MB-175VII M (PE) IDC 49, 48 L + - - Wt Wt Wt 158
BT483 P IDC 72 L + - - Mt Mt Wt 159
T47D M (PE) IDC 66 L + + - Mt Mt Wt 160
MDA-MB-415 M (PE) AC 72 L + + - Mt Wt Wt 161
ZR75-1 M (As) IDC 71-72 L + + - Wt Wt Wt 162
MCF-7 M (PE) IDC 88 L + + - Wt Mt Wt 163
SUM52PE NA IDC NA L + + - Mt Wt Wt 164
UACC812 P IDC 58-64 L + + + Wt Wt Wt 165
MDA-MB-361 M (Br) AC 52 L + + + Mt Mt Wt 161
SUM190PT P IBC NA L NA NA NA Mt Mt Wt 166
BT474 P IDC 55 L - - + Mt Mt Wt 159
MDA-MB-330 M (PE) ILC 64 L + - + Mt Wt Wt 161
SUM225CWN M IDC NA L - - + Mt Nd Wt 167
UACC893 P IDC 62 L - - + Mt Mt Wt 165
EVSA-T M (As) IDC 84 L - + + Mt Wt Mt 168
MDA-MB-453 M (PE) AC 45 L - - + D Mt Mt 161
SK-BR-3 M (PE) IDC 84 L - - + Mt Wt D 166
ZR75-30 M (As) IDC 81 L + - + Wt Wt Mt 162
SK-BR-5 NA NA NA L - - + Mt Mt Mt 166
OCUB-F, -M M (PE) RBC 84 L - - + Mt Mt D 167
MPE600 NA IDC 46 L + - + Wt Wt D 169
MDA-MB-134VI M (PE) IDC 43 L + - - Mt Wt D 158
SUM44PE M (PE) HBC 60 L + + - Mt Nd Mt 166
CAMA-1 M (PE) C 78 L + - - Mt Wt Mt 170
DU4475 M (Sk) IDC 87-90 B - - - Wt Wt Wt 171
MDA-MB-468 M (PE) AC 35 B - - - Mt Wt Wt 172
HCC1937 NA NA NA L - - - Mt Wt Wt 144
BT20 P IDC 49 C - - - Mt Mt Wt 173
SUM149PT M (PE) IBC NA C - - - Mt Wt H 166
SUM229PE NA NA NA L - - - Mt Wt H 166
SK-BR-7 NA NA NA L - - - Wt Wt H 166
SUM102PT P IFL 48 Apo NA NA NA wt Mt H 174
Hs578T P CS 58 N - - - Mt Wt H 175
MDA-MB-231 M (PE) IDC 64 N - - - Mt Wt H 158
SUM1315M02 NA NA NA N - - - Mt Wt H 166
MDA-MB-436 M (PE) AC NA N - - - Mt Wt H 161
BT549 P PIDC 74 N - - - Mt Wt H 159
MDA-MB-157 M (PE) MC 65 N - - - Mt Wt H 176
SUM159PT NA NA NA N - - - Mt Mt H 164
MDA-MB-435s M (PE) IDC 64 N - - - Mt Wt H 161
HCC1008 M (LN) DC NA NA NA NA NA Mt Wt Wt 177
HCC1500 P DC NA L + + - NA Wt Wt 177
HCC202 P DC NA L - - + Mt Wt Wt 177
HCC1419 P DC NA L + - + Mt Wt Wt 177
HCC2218 P DC NA L - - + NA Wt Mt 177
HCC1569 P MC NA N - - + Mt Wt Wt 177
HCC1954 M (PE) AC NA C - - + Mt Mt Wt 177
HCC1599 P DC NA C - - - Mt Wt Wt 177
HCC1806 P DS NA C - - - Mt Wt Wt 177
HCC1187 P DC NA C - - - Mt Wt Wt 177
HCC70 P DC NA C - - - Mt Wt Wt 177
      
34 |  Chapter 1 







type ER PGR ERBB2 TP53 PIK3CA 
E-
cad. Ref.
HCC1143 P DC NA C - - - Mt Wt Wt 177
HCC1395 P DC NA N - - - NA Wt Wt 177
HCC38 P DC NA NA NA NA NA Mt Wt Wt 177
184A1 NA RM NA B NA NA NA NA NA NA 178
CAL-51 M (PE) AC NA B NA NA NA NA NA NA 179
EFM-19 M (PE) IDC NA L NA NA NA NA NA NA 180
EFM-192A M (PE) AC NA L NA NA + NA NA NA 181
hTERT-HME1 NA RM NA B - NA - NA NA NA 182
AU565 M (PE) IDC NA NA - - NA NA NA NA 183
BOT-2 P IDC 63 NA NA NA NA NA NA NA 184
BRC-230 P IDC 60 NA - - NA NA NA NA 185
BrCa-MZ-01 P MC 66 NA + + NA NA NA NA 186
BrCa-MZ-01 M (PE) IBC 46 NA - - NA NA NA NA 186
BSMZ M (PE) IDC 80 NA + + NA NA NA NA 187
CAL-18A P C 71 NA - - NA NA NA NA 188
CAL-18B P C 65 NA - - NA NA NA NA 188
EP M (PE) IDC 53 NA + NA NA NA NA NA 189
GI-101 R (L) IDC 98 NA - - NA NA NA NA 190
GCS M (As) IDC NA NA + + NA NA NA NA 191
HBL-100 NA NA 63 B - - NA NA NA NA 192
HDQ-P1 P IDC 55-59 NA - - NA NA NA NA 193
HH315 M (O) C 113 NA - - NA NA NA NA 194
HH375 M (LN) C 64 NA - - NA NA NA NA 194
Ia-270 M (PE) IDC NA NA + + NA NA NA NA 195
IBEP-1 M (PE) IDC 52 NA - + NA NA NA NA 196
IBEP-2 M (PE) IDC 74 NA + - NA NA NA NA 196
IBEP-3 M (PE) IDC 57 NA - + NA NA NA NA 196
IIB-BR-G P IDC 56 NA - - NA NA NA NA 197
JCK M (PE) IDC NA NA + + NA NA NA NA 191
KPL-1 M (PE) IDC 77 NA + - NA NA NA NA 198
KPL-3C M (PE) IDC 63 NA - - NA NA NA NA 199
KPL-4 M (PE) IDC 53 NA - - NA NA NA NA 200
LCC15-MB M (F) C NA NA - - NA NA NA NA 201
MA11 M (Bm) ILC 64 NA - - NA NA NA NA 202
MAST M (As) IDC 60 NA + + NA NA NA NA 203
MaTu M (LN) IDC 66 NA - - NA NA NA NA 204
MFM-223 M (PE) IDC 46 NA - - NA NA NA NA 205
MT-1 P (Tr) C 46 NA - - NA NA NA NA 204
MT-3 P (Tr) C 47 NA - - NA NA NA NA 204
MW M (PE) IDC 67 NA - NA NA NA NA NA 189
PMC42 M (PE) C 66 NA NA NA NA NA NA NA 206
UISO-BCA-1 M (PE) IDC 58 NA - - NA NA NA NA 207
UISO-BCA-2 M (PE) IDC 62 NA - - NA NA NA NA 207
VHB-1 P IDC 70 NA + + NA NA NA NA 208
MCF-10A P F NA B - - NA NA NA NA 209
MCF-12A P F 67 B - - NA NA NA NA 210
IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; C: carcinoma; MC: medullary carcinoma; IBC: 
inflammatory breast carcinoma; PIDC: papillary invasive ductal carcinoma; AC: adenocarcinoma; CS: 
carcinoma sarcoma; F: fibrocystic disease; RM: reduction mammoplasty; P: primary tumor; M: metastasis; PE: 
pleural effusion; Br: brain; Sk: skin; Bm: bone marrow; CWN; chest wall nodule; As: ascites; Tr: transplanted; O: 
omenun; L: luminal type; B: basal-like; N: normal-like; Apo: apocrine subtype; Wt: wild-type; Mt: mutant; D: 
deleted; NA: not available; Chrom: chromosome; E-cad: E-cadherin; Ref: References 
¶ER, PGR, and ERBB2 status expression is based on both protein and gene expression array data.  
*Molecular subtype is based on microarray gene expression analysis.  
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1.9.2. Mice models for breast cancer study 
Mice models have been extensively used to investigate fundamental biology underlying mammary 
development and tumorigenesis. The first category of mouse models includes mice in which 
mammary tumor development is induced chemically or by ionizing radiation. These mouse models 
are generally used to understand basic biological events underlying preliminary malignant lesions 
including ductal hyperplasia, atypical ductal hyperplasia, ductal carcinoma in-situ and their 
potential to develop invasive breast cancers211,212. The second category of the mouse models 
include genetically engineered mice (GEM) in which tumor development involves a comprehensive 
experimental driven genetic manipulation. The GEM models are typically used to unravel the 
biological roles of the tumor suppressor genes (TP53, BRCA1, BRCA2, PTEN, CDH1) and oncogenes 
(PyMT, RAS, c-MYC, ERBB2, CCD1), which have been frequently implicated in breast cancer 
development and progression. GEM expressing oncogenes under the control of the MMTV-CK14 or 
WAP typically initiate tumors in the mammary glands, leading to primary tumors and then 
metastasis to distant organs during lateral stages of cancer progression213. Examples of GEM 
models are MMTV-PyMT, MMTV-Neu, MMTV-NeuNDL, MMTV-Wnt1, and WAP-Ras213-216.  
Although, mice model studies have recapitulated the behavior and properties of human breast 
cancer tumors and revealed interaction between tumor cells and their microenvironment as well as 
explored molecular changes during metastasis, but data obtained from animal models as such is 
often not applicable to breast cancer patients due to several differences between human and 
mouse. For instance, no single mouse model fully recapitulates the molecular subtypes commonly 
present in human tumors and also very few ER-positive GEM exist. Furthermore, therapeutic 
strategies developed using GEM models could sometime lead to unexpected outcomes owing to 
fundamental differences in the components of the immune system217.  
 
1.10. SUMMARY 
In summary, breast cancer is the most prevalent disease in the western world and a leading cause 
of cancer related deaths in females. The average lifetime risk of breast cancer varies between 9-12% 
all over the world. Major risk factors include female gender, age, endogenous and exogenous 
hormones, reproductive history, breast density, and a family history of cancer17,18. Breast cancer is a 
genetic disease of both the inherited and sporadic predisposition. Three well-defined groups of 
breast cancer susceptibility genes or loci have been identified: high-risk genes, moderate-risk 
genes, and low-risk loci, which altogether can explain about 35% of familial breast cancer risk. A 
vast majority of breast cancer is sporadic and somatic mutations conferring selective growth 
advantage on the cells are considered deriver mutations whereas somatic mutation with 
biologically neutral effect are considered passenger mutations. Historically, the breast cancer has 
been classified based on the presence of hormone receptors (ER and/or PGR). ER+ tumors accounts 
for about three quarters of the breast cancer and generally display better prognosis with targeted 
anti-hormonal therapeutic options. In contrast to it, ER- tumors are aggressive with worse outcome 
with no specific therapeutics options available. About 25-30% breast tumors have overexpression 
of ERBB2 protein and these tumors are treated with monoclonal antibodies such as trastuzumab. 
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Microarray-based gene expression profiling of the breast tumors have revealed several intrinsic 
molecular subtypes each with clinically distinct prognostic and prediction values. Biological 
complexity of the breast cancer is unfolded using many experimental models, among them human 
breast cancer cell lines and mouse models are more frequently applied models. More than 100 
breast cancer cell lines have been established and cultured both in vitro under 2-D and 3-D culture 
conditions and in vivo as xenografts. Besides many possibilities of studying biology and genetics, 
breast cancer cell lines are also being frequently used as a preclinical model to screen potential 
breast cancer drugs. Moreover, several mouse models are being used to explore fundamental 
aspects of breast cancer carcinogenesis, especially, the onset of tumors and their metastasis to 
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AIMS AND OUTLINES OF THE THESIS 
 
Breast cancer, a world-wide leading cause of cancer deaths, is initiated by aberrations arising in the 
genome of tumor initiating cells that line the ducto-lobular epithelium of breast mammary tissue1-3. 
These aberrations disrupt normal biological signaling taking place amongst epithelial cells and 
between epithelial cells and surrounding stromal cells. This aberrant signaling leads to 
uncontrolled growth of these tumor initiating epithelial cells, which subsequently acquire 
additional genetic and epigenetic modifications driving aberrant expression of numerous crucial 
regulatory molecules including transcription factors and microRNAs and therefore might become 
highly aggressive and refractory to the currently available therapeutics. Genetic aberrations driving 
the initiation of breast cancer appear, depending on the risk they confer, in three flavors: highly 
penetrant genes, intermediate, and low-risk genes. Successful management of breast cancer can 
be improved, firstly, by performing systematic studies on the biological consequences of known 
genetic variants and molecules involved in biologically important signaling pathways, secondly, by 
discovering novel genetic variants causal to breast cancer susceptibility, and thirdly, by 
determining novel markers, which can accurately predict the course of disease in patients. Finally, 
to better study and understand the biological consequences of revealed genetic drivers the 
development of new model systems and thorough characterization of in vitro and in vivo model 
systems is also of utmost importance. 
 
The study described in this thesis focused on two topics:  
1. The discovery of novel susceptibility loci and the determination of the clinical and 
biological significance of the newly discovered low-risk breast cancer 
susceptibility loci.  
2. The characterization of current in vitro experimental model system and the 
development of in vivo xenografts models.  
 
After the discovery of CHEK2 1100delC as a novel polygenic intermediate risk allele for hereditary 
breast and colorectal cancer (HBCC) families4-5, we aimed in chapter 3 to find additional polygenic 
drivers for these families. As germ-line mutations in MSH6 predispose to Lynch syndrome and as 
previous work had shown, in a limited number of cases, the co-existence of CHEK2 1100delC and 
MSH6 mutations, we therefore focused on genetic variants in MSH6 gene. In chapters 4-5, the 
newly discovered low-risk breast cancer susceptibility alleles rs2981282 (FGFR2), rs3817198 (LSP1), 
rs889312 (MAP3K1), rs3803662 (TOX3 or TNRC9), rs2107425 (H19), rs13281615 (POUF3/MYC), and 
rs13387042 (2q35) were investigated. These SNPs, despite of being very common in the general 
population only confer relative to BRCA1 and even CHEK2 a modest increase of risk to virtually all 
breast cancers6-7. As most SNPs do not alter the coding sequence and are often not even located in 
the vicinity of genes their mode of action is poorly understood. It was hypothesized that the low-
risk SNPs modulate the expression levels of nearby located genes8. To shed light on this we 
determined minor allele frequency (MAF) of these low-risk breast cancer loci in both breast cancer 
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cell lines (chapter 4) and primary breast tumors (chapter 5) and measured the mRNA expression 
levels of the corresponding genes located nearby in the genome. In addition, as for the primary 
breast tumors investigated (chapter 5) we also had extensive clinical follow-up, we therefore 
determined if these SNPs contribute to disease progression beyond the stage of tumor initiation by 
evaluating their prognostic significance. To further understand breast cancer progression, in 
chapter 6 we investigated in primary breast cancer patients the prognostic and biological 
significance of TWIST1, an emerged marker for epithelial to mesenchymal transition (EMT). For this, 
TWIST1 mRNA expression was determined in a cohort of 1,427 primary breast cancer patients with 
extensive clinical follow-up to determine its association with disease progression and to reveal 
whether in clinical breast cancer specimen TWIST1 also related to EMT. For the latter, we extracted 
TWIST1’s biological context in silico from co-expressed genes measured on gene expression arrays. 
In chapter 7 and 8, we focused on our large collection of 51 well-characterized human breast 
cancer cell lines to find further support whether these cell lines represent clinical breast tumors 
(Chapter 8) and, to further explore their intrinsic and genetic diversity (Chapter 7). For this, we 
performed genome-wide profiling, at the mRNA and miRNA transcriptome levels of this entire 
panel of cell lines in which the genetic mutation diversity had previously been characterized by 
sequencing the most common tumor suppressor- and oncogenes9. In chapter 7, we associated the 
intrinsic subtypes and common genetic variation with the miRNA transcriptome. In chapter 8, we 
developed in mice preclinical xenograft models equipped with a luciferase reporter gene to allow 
in vivo imaging. Such models can be used to gain biological insights of breast cancer biology in vivo 
and they might also have potential use as preclinical xenograft model for in vivo drug screening. 
For this thesis we selected multiple cell lines from each intrinsic subtype to address whether these 
models recapitulate the in vivo observed diversity among subtypes with regard to growth 
characteristics and metastatic behavior. The results of the experiments performed in chapter 3 to 8 
and their clinical and biological implications are discussed in chapter 9 and are summarized in 
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ABSTRACT 
 
Germline mutations in the mismatch repair genes MLH1, MSH2, MSH6 and PMS2 predispose to 
Lynch syndrome (also known as hereditary non-polyposis colorectal cancer). Recently, we have 
shown that the CHEK2 1100delC mutation also is associated with Lynch syndrome/Lynch 
syndrome-associated families albeit in a polygenic setting. Two of the ten CHEK2 1100delC positive 
Lynch syndrome families additionally carried a pathogenic MLH1 or MSH6 mutation, suggesting 
that mutations in mismatch repair genes may be involved in CHEK2 1100delC associated cancer 
phenotypes. A phenotype of importance is hereditary breast and colorectal cancer (HBCC), with the 
CHEK2 1100delC mutation present in almost one-fifth of the families – again in a polygenic setting. 
To evaluate the involvement of MSH6 in polygenic CHEK2 cancer susceptibility, we here have 
analyzed the entire MSH6 coding sequence for genetic alterations in 68 HBCC breast cancer 
families. Rare MSH6 variants, with population frequencies below 1%, were identified in 11.8% of 
HBCC breast cancer families whereas the same variants were identified in only 1.5% of population 
controls, suggesting that rare MSH6 variants are associated with HBCC breast cancer (P <0.00001). 
However, screening of the entire MSH6 coding sequence in 68 non-HBCC breast cancer families 
showed a similar association (8.8% vs. ~1. 4% in controls, P <0.001), suggesting that rare MSH6 
variants are not confined to HBCC breast cancer. Together, our data suggest that rare MSH6 
variants may predispose to familial breast cancer. However, none of the rare MSH6 variants are 
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INTRODUCTION 
 
In 2002, we and others have identified the truncating CHEK2 1100delC mutation as the first 
moderate-risk breast cancer susceptibility allele, present in about 5% of Dutch breast cancer 
families1,2. In addition, we have shown that the CHEK2 1100delC mutation was also present among 
Lynch syndrome/Lynch syndrome-associated families and was particularly prevalent among breast 
cancer families with a hereditary breast and colorectal cancer (HBCC) phenotype (4% and 18%, 
respectively)3,4. However, in each of these instances, CHEK2 1100delC appeared to confer cancer 
risks in a polygenic setting. 
The association of CHEK2 1100delC with colorectal cancer phenotypes suggested known colorectal 
cancer genes as likely candidates for polygenic CHEK2 cancer susceptibility4. Germline mutations in 
the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 have been identified as the 
major causes for Lynch syndrome (previously also known as hereditary non-polyposis colorectal 
cancer, HNPCC5-7. Interestingly, in two of the ten CHEK2 1100delC-positive Lynch syndrome-
associated families we had also identified pathogenic mutations in MHL1 or MSH64. Concomitance 
of CHEK2 and MSH6 mutations had reportedly also been identified in a Finnish breast cancer family 
and in the colorectal cancer cell line HCT158-11. During repair of DNA damage, activated CHEK2 is 
known to signal to BRCA1, which in turn acts as a scaffold protein for several DNA damage 
response proteins, including MSH612-14. The close functional relation of CHEK2 and MSH6, together 
with the observed concomitance of mutations in the two genes suggested that MSH6 mutations 
may be involved in CHEK2 polygenic cancer susceptibility. This hypothesis was particular appealing 
for the HBCC phenotype as CHEK2 1100delC is prevalent among these families whereas MSH6 
mutations are identified among Lynch syndrome families that also include breast cancer3,15-17. Here, 
we therefore have screened the MSH6 gene for genetic alterations in 68 HBCC and 68 non-HBCC 
breast cancer families.  
 
PATIENTS AND METHODS 
 
Breast cancer families and population controls 
One hundred thirty-six breast cancer families were selected from 578 breast cancer families 
registered at the Rotterdam Family Cancer Clinic at Erasmus MC. Breast cancer families were 
classified as hereditary breast and colorectal cancer (HBCC) families (n=68) or non-HBCC families 
(n=68). All families included at least two first or second-degree relatives (DGRs) with breast cancer 
of whom at least one was diagnosed before the age of 60 years. HBCC families additionally 
included at least one patient with breast and colorectal cancer or at least one patient with 
colorectal cancer diagnosed before the age of 50 years who is within second DGR of a breast 
cancer patient or at least two colorectal cancer patients of whom at least one is within second DGR 
of a breast cancer patient3.  
All breast cancer families were screened for germline mutations in the BRCA1 and BRCA2 genes and 
the CHEK2 1100delC mutation, identifying 26 BRCA1 mutant families, 6 BRCA2 mutant families and 
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18 families with the CHEK2 1100delC mutation. Two families were double mutant for BRCA1 and 
the CHEK2 1100delC mutation. As part of our matching procedure, mutant BRCA1, BRCA2 and 
CHEK2 1100delC families were equally divided over HBCC and non-HBCC families. Pathogenic 
germline mutations in the MLH1 and MSH2 gene were not identified in any of the 68 HBCC families. 
MLH1 and MSH2 mutation status had not been determined for the 68 non-HBCC families. 
All breast cancer families originated from the southwestern Netherlands and have consented to 
search for cancer susceptibility genes. The 166 control individuals were geographically-matched to 
the familial breast cancer cases and included spouses of heterozygous carriers of cystic fibrosis 
gene mutations, ascertained through the department of Clinical Genetics at Erasmus MC. The 
medical ethical committee of Erasmus MC approved this study. 
 
MSH6 mutation analysis 
The mismatch repair gene MSH6 (NM_000179.2) was screened for mutations in blood-derived DNA 
of the youngest diagnosed breast cancer case in the family (index case). The complete coding 
sequence of the MSH6 gene, including intron/exon boundaries up to 25 bases in the intron, was 
amplified by standard PCR. Amplified fragments were subsequently analyzed for genetic 
alterations by denaturing gradient gel electrophoresis (DGGE) or by direct sequencing as described17-
19. Unique sequence alterations were confirmed at least once by sequence analysis of an 




The difference between the mutation frequency in breast cancer patients versus controls was 
analysed using Fisher’s Exact Test. P-values of 0.05 or smaller were considered significant. All 
statistical analyses were performed with STATA statistical package, release 10 (STATA Corp, College 
Station, TX).  
 
RESULTS AND DISCUSSION 
 
Rare MSH6 variants associate with HBCC breast cancer 
We analyzed the entire MSH6 coding sequence in 68 breast cancer families with hereditary breast 
and colorectal cancer (HBCC). Sequence analysis identified 25 different sequence alterations 
among 68 HBCC families, including 10 intronic and 15 exonic variants (Table 3.1). To evaluate the 
significance of the identified MSH6 variants for HBCC, all variants were subsequently genotyped in 
166 geographically-matched controls. Rare variants, with population frequencies below 1%, 
represented 56% (14/25) of the MSH6 variants and each of these were identified only once or twice 
among the HBCC cohort. Four of the fourteen rare MSH6 variants identified among HBCC families 
were also identified in the control cohort. Thus, although none of the rare MSH6 variants associated 
significantly with HBCC families, the combined frequency of the rare variants was significantly 
higher among HBCC families compared to controls (16/136 (11.8%) vs. 5/306-332 (~1.5%), P 
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<0.00001; Table 3.1). These results suggested that rare MSH6 variants may predispose for HBCC 
breast cancer. 
 
Table 3.1 MSH6 mutation analysis among 68 HBCC and 68 non-HBCC breast cancer families 
MSH6 gene sequencea Predicted protein effect
Minor allele/Total tested alleles (%) 
HBCC Non-HBCC All BRC Controls 
Prevalent variants (>1%)     
c.260 +22C > G – 31/136 (22.8) 23/136 (16.9) 54/272 (19.9) 58/332 (17.5) 
c.3438 + 14A > T – 58/136 (42.6) 58/136 (42.6) 116/272 (42.6) 126/322 (39.1)
c.3557-4dupT – 26/136 (19.1) 26/136 (19.1) 52/272 (19.1) 56/324 (17.3) 
c.4002-10delT – 35/136 (25.7) 39/136 (28.7) 74/272 (27.2) 2/328 (25.6) 
c.4002-10dupT – 14/136 (10.3) 16/136 (11.8) 30/272 (11.0) 41/312 (13.1) 
c.116G > A p.G39E 25/136 (18.4) 24/136 (17.6) 49/272 (18.0) 52/332 (15.7) 
c.186C > A p.= 31/136 (22.8) 23/136 (16.9) 54/272 (19.9) 58/332 (17.5) 
c.276A > G p.= 29/136 (21.3) 22/136 (16.2) 51/272 (18.9) 53/332 (16.0) 
c.540T > C p.= 42/136 (30.9) 39/136 (28.7) 81/272 (29.8) 95/332 (28.6) 
c.642C > T p.= 12/136 (8.8) 14/136 (10.3) 26/272 (9.6) 38/332 (11.4) 
c.1286C > G p.L396V 2/136 (1.5) 0/136  – 2/272 (0.7) 6/332 (1.8) 
Rare variants (< 1%) 
Intronic (up to 25 bases) 
c.457 + 13A > G – 1/136 (0.7) 0/136  – 1/272 (0.4) 1/332 (0.3) 
c.3439-16C > T – 2/136 (1.5) 0/136  – 1/272 (0.4) 1/332 (0.3) 
c.3647-11T > G – 0/136  – 1/136 (0.7) 1/272 (0.4) 0/254  – 
c.4001+12_4001+15delACTC – 2/136 (1.5) 1/136 (0.7) 3/272 (1.1) 2/328 (0.6) 
c.4002-10delTT – 1/136 (0.7) 0/136  – 1/272 (0.4) 0/312  – 
c.4002-10delTTT – 0/136  – 1/136 (0.7) 1/272 (0.4) 1/312 (0.3) 
c.4002-10delTTTT – 0/136  – 1/136 (0.7) 1/272 (0.4) 0/312  – 
c.4002-10dupTTT – 1/136 (0.7) 1/136 (0.7) 2/272 (0.7) 0/312  – 
Exonic synonymous 
c.1053C > T p.= 1/136 (0.7) 0/136  – 1/272 (0.4) 0/332  – 
c.1164C> T p.= 0/136  – 1/136 (0.7) 1/272 (0.4) 0/332  – 
c.2272C > T p.= 0/136  – 1/136 (0.7) 1/272 (0.4) 0/332  – 
c.2775A > C p.= 1/136 (0.7) 0/136  – 1/272 (0.4) 0/332  – 
c.3246G > T p.= 1/136 (0.7) 2/136 (1.5) 3/272 (1.1) 0/332  – 
c.3306T > A p.= 1/136 (0.7) 1/136 (0.7) 2/272 (0.7) 0/332  – 
Exonic non-synonymous 
c.73G > T p.A25S 1/136 (0.7) 1/136 (0.7) 2/272 (0.7) 1/332 (0.3) 
c.751A > G p.I251 V 1/136 (0.7) 0/136  – 1/272 (0.4) 0/332 – 
c.1508C> G p.S503C 1/136 (0.7) 0/136  – 1/272 (0.4) 1/332 (0.3) 
c.2045C> T p.S682F 1/136 (0.7) 0/136  – 1/272 (0.4) 0/332 – 
c.2633T > C p.V878A 1/136 (0.7) 0/136  – 1/272 (0.4) 0/332 – 
c.4072_4075dupGATT p.K1358fsX2b 0/136 – 1/136 (0.7) 1/272 (0.4) 0/332 – 
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Table 3.1 continued (Summary rare variants) 
 Minor alleles/Total tested alleles (%) 
 
All Intronic Exonic all Exonicsynonymous 
Exonic non-
synonymous 
HBCC families 16/136 (11.8) 7/136 (5.1) 9/136 (6.6) 4/136 (2.9) 5/136 (3.7)
Controls 5/306–332 (~1.5) 3/306–332 (~0.9) 2/332 (0.6) 0/332 (~0.0) 2/332–332 (0.6)
P value < 0.00001  
Non-HBCC families 12/136 (8.8) 5/136 (3.7) 7/136 (5.1) 5/136 (3.7) 2/136 (1.5)
Controls 4/254–332 (~1.4) 3/254–328 (~1.1) 0/332 (~0.0) 0/332 (~0.0) 1/332 (0.3)
P value <0.001  
All BRC families 28/272 (10.3) 12/272 (4.4) 16/272 (5.9) 9/272 (3.3) 7/272 (2.6)
Controls 6/254–332 (~2.1) 4/254–332 (~1.4) 2/332 (0.6) 0/332 (~0.0) 2/332 (0.6)
P value <0.0001   
a Numbering of nucleotide changes according to MSH6 GenBank sequence NM_000179.2 
b Frame shift mutation is indicated by the first changed codon and the number of newly encoded codons, 
including premature termination codon X 
This particular variant locates 30 in the gene sequence predicting a protein shortened with only two amino 
acids. BRC breast cancer, HBCC hereditary breast and colorectal cancer 
 
Rare MSH6 variants associate with familial breast cancer 
To evaluate if rare MSH6 variants associate with HBCC breast cancer or rather with familial breast 
cancer in general, we also screened the entire MSH6 coding sequence in 68 matched non-HBCC 
families (Table 3.1). Non-HBCC families were matched to the HBCC families with respect to their 
cancer pattern, i.e. the number of cancer patients per family, the number of cancer patients overall 
and the number of patients with single, double, triple or more cancers (Table 3.2). To avoid 
selection for HBCC, the non-HBCC families have been counter-selected for the presence of 
colorectal cancer. Six additional rare MSH6 variants were identified among the non-HBCC families 
of which only one was also identified among the controls (Table 3.1). The combined frequency of 
rare MSH6 variants was also significantly higher among non-HBCC families compared to controls 
(12/136 (8.8%) vs. 4/254-332 (~1.4%), P <0.001; Table 3.1). Hence, the prevalence of rare MSH6 
variants among non-HBCC families is equally high as among HBCC families, indicating that rare 
MSH6 variants are not only associated with HBCC breast cancer but more likely with breast cancer 
in general. Combining the data on HBCC and non-HBCC families revealed a prevalence of rare 
MSH6 variants of 10.3% among all breast cancer families whereas the same variants were identified 
in approximately 2.1% of controls (P <0.0001; Table 3.1), strongly suggesting that rare MSH6 
variants may predispose for familial breast cancer. 
 
Do rare MSH6 variants predispose for familial breast cancer? 
Two aspects may question whether rare MSH6 variants indeed predispose for familial breast cancer. 
First, we have not screened the entire MSH6 coding sequence in the control cohort. Our strategy 
had been to genotype in the controls only those MSH6 variants that had been identified among the 
familial breast cancer cohorts. Apart from the genotyped variant sequence, our primer design 
allowed analysis of the sequence surrounding the genotyped variant often including entire exon 
sequences and intron sequences up to 25 base pairs. In this way we were able to analyse 75% of 
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the MSH6 coding sequence in all controls. In addition to the five rare MSH6 variants that already 
had been identified in the breast cancer families, two variants (c.59C>T, p.A20V and c.4002-
10delCT) were once identified exclusively among the controls. Based on this low prevalence of rare 
MSH6 variants that are exclusively present among the controls (2/254 (0.8%); Table 3.1), it may be 
anticipated that screening of the remaining quarter of the MSH6 coding sequence in the controls is 
unlikely to identify many more rare MSH6 variants. 
Another aspect is the underlying disease mechanism of how rare MSH6 variants may predispose to 
breast cancer. We found that the prevalence of rare MSH6 variants was consistently higher among 
the breast cancer families than the controls, whether they were intronic or exonic and whether 
they were synonymous or non-synonymous. However, none of the identified rare MSH6 variants 
are known pathogenic mutations. Evaluation of each of the rare MSH6 variants with the splice 
prediction programs Berkeley Drosophila Genome Project (www.fruitfly.org/seq_tools/splice.html) 
and NetGene2 (www.cbs.dtu.dk./services/NetGene2/) did not predict structural effects. It thus 
remains unclear how these rare MSH6 variants exert their putative oncogenic effect, particularly for 
the intronic variants and the non-synonymous exonic variants. But then, are obvious pathogenic 
effects to be expected in a polygenic setting? Importantly, the statistical evidence from our analysis 
that rare MSH6 variants associate with familial breast cancer is compelling (P<0.001), strongly 
suggesting cancer predisposition by rare MSH6 variants. Obviously, our analysis requires replication 
in independent familial breast cancer cohorts, and it seems also warranted to screen familial 
colorectal cancer cohorts, with particular focus to rare variants that are not obviously pathogenic. 
In this respect, our current findings are consistent with a report by Nevanlinna and colleagues in 
which 15 different MSH6 variants were identified among 38 breast cancer families with colorectal 
cancer and/or endometrial cancer20. Three of the MSH6 variants classified as rare variants, including 
two synonymous exonic variants and one intronic variant. The prevalence of rare MSH6 variants in 
their familial breast cancer cohort is similar to the prevalence we report here (3/38=7.9% versus 
10.3% in our cohort) and supports our conclusion that rare MSH6 variants are associated with 
familial breast cancer. Their and our observations both seem to point towards a currently unknown 
disease mechanism in breast carcinogenesis such as modulation of transcript expression levels or 
mediation of non-coding RNAs located in the genomic regions associated with these variants. 
Therefore, one may wonder whether this mechanism is similar to the as-yet unresolved disease 
mechanism underlying the more prevalent low-risk breast cancer alleles that recently have 
received much attention21-26 
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ABSTRACT 
 
Introduction Low-risk breast cancer susceptibility alleles or SNPs confer only modest breast cancer 
risks ranging from just over 1.0 to1.3 fold. Yet, they are common among most populations and 
therefore are involved in the development of essentially all breast cancers. The mechanism by 
which the low-risk SNPs confer breast cancer risks is currently unclear. The breast cancer 
association consortium BCAC has hypothesized that the low-risk SNPs modulate expression levels 
of nearby located genes.  
Methods Genotypes of five low-risk SNPs were determined for 40 human breast cancer cell lines, 
by direct sequencing of PCR-amplified genomic templates. We have analyzed expression of the 
four genes that are located nearby the low-risk SNPs, by using real-time RT-PCR and Human Exon 
microarrays. 
Results The SNP genotypes and additional phenotypic data on the breast cancer cell lines are 
presented. We did not detect any effect of the SNP genotypes on expression levels of the nearby 
located genes MAP3K1, FGFR2, TNRC9 and LSP1. 
Conclusions The SNP genotypes provide a base line for functional studies in a well-characterized 
cohort of 40 human breast cancer cell lines. Our expression analyses suggest that a putative 
disease mechanism through gene expression modulation is not operative in breast cancer cell 
lines. 
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INTRODUCTION 
 
About ten percent of breast cancer patients have a history of multiple breast cancer cases in their 
family, suggesting the inheritance of breast cancer susceptibility alleles in these families. Germline 
mutations in the BRCA1 and BRCA2 genes are identified in about one quarter of the families with 
breast cancer. Female carriers of BRCA1 and BRCA2 mutations have an estimated 50-90% life-time 
risk to develop breast cancer, classifying both genes as high-risk susceptibility genes1-2. Other high-
risk breast cancer genes include the TP53, PTEN and STK11 genes, but mutations in these genes 
account for only few familial breast cancers. CHEK2 was the first moderate-risk breast cancer gene 
being identified3-5. Germline mutations in CHEK2 are identified in upto 5% of breast cancer families, 
albeit that their prevalence varies widely among populations. Female carriers of CHEK2 mutations 
have a moderate two to three fold increased risk to develop breast cancer. By now, several other 
moderate-risk breast cancer genes have been identified, including ATM, BRIP1 and PALB26-9. 
Mutations in these genes all confer increased breast cancer risks of two to three fold and mutations 
in each of these genes are identified in about 1% of the familial breast cancers. Recently, the 
international breast cancer association consortium (BCAC) has conducted a large genome-wide 
association study and identified five single nucleotide polymorphisms (SNPs) that associated with 
breast cancer10. Four of these SNPs were within haplotype blocks that contained genes: SNP 
rs2981582 locates in intron 2 of the FGFR2 gene at chromosome 10q; SNP rs889312 locates near 
MAP3K1 at 5q; SNP rs3803662 locates between TNRC9 and the LOC643714 gene at 16q; and SNP 
rs3817198 locates intronic in LSP1 at 11p. SNP rs13281615 locates at 8q24 in a region without any 
annotated genes. Importantly, independent genome-wide association studies have associated 
other SNPs in FGFR2 with breast cancer11-12. As FGFR2 had already been implicated in breast 
cancer13-20, the significance of the FGFR2 SNPs as susceptibility alleles seemed evident. The TNRC9 
SNP had also been associated with breast cancer in another study21. Lastly, the 8q24 SNP was of 
particular interest because other SNPs at 8q24 had been associated with increased risks of prostate 
cancer and colorectal cancer 22-26. BCAC estimated that each of the five identified SNPs associated 
with rather small increased breast cancer risks, ranging from just over 1.0 to 1.3 fold, classifying 
them as low-risk susceptibility alleles10. However, these low-risk SNPs are very common and their 
impact is therefore still substantial, together accounting for almost 5% of the familial breast 
cancers. 
The mechanism by which the low-risk susceptibility alleles confer breast cancer risks was obscure10. 
In analogy with the high-risk and moderate-risk breast cancer genes, it had been anticipated that 
the identified SNPs associated with disease-causing alleles in the coding sequences of nearby 
located genes. However, extensive sequencing efforts have not identified such alleles in the SNP-
associated haplotype blocks, suggesting that the SNPs themselves might be the disease-causing 
susceptibility alleles10. BCAC therefore proposed an alternative disease mechanism that involves 
expression modulation of genes located in the vicinity of the identified SNPs, thereby conferring 
low breast cancer risks. Here, we have evaluated expression modulation in a well-characterized 
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cohort of 40 human breast cancer cell lines, allowing us to specifically address whether this 




Breast cancer cell lines 
The 40 human breast cancer cell lines used in this study are listed in Table 1 and have been 
described in detail elsewhere27. Microsatellite analysis with nearly 150 polymorphic markers had 
shown that all cell lines are unique and monoclonal28. 
 
Genotyping 
Genotypes of five low-risk susceptibility alleles have been determined: rs889312 (A>C) near the 
MAP3K1 gene; rs2981582 (C>T) in the FGFR2 gene; rs3803662 (C>T) near the TNRC9 gene; 
rs3817198 (T>C) in the LSP1 gene and rs13281615 (A>G) that located in a gene desert at 
chromosome 8q2410. Genotyping was performed by direct sequencing of PCR-amplified genomic 
templates, using the BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems) and an ABI 
3130xL Genetic Analyzer. Primer sequences are available upon request.  
Allele frequencies of cases and controls reported by BCAC have been obtained by using their 
reported Odds Ratio data10, and inferring allele frequencies by assuming that Odds Ratios reflect 
the ratio of minor allele carriers versus major allele carriers from the cases divided by the ratio of 
minor allele carriers versus major allele carriers from the controls. 
 
Expression analysis 
Transcript expression levels of four genes have been determined: MAP3K1, FGFR2, TNRC9 and LSP1. 
Quantitative real-time PCR (qRT-PCR) was performed on cDNA templates that had been generated 
with oligo-dT and random hexamer primers from total RNA isolates, using Power SYBR Green PCR 
Master Mix (Applied Biosystems) and an ABI Prism 7700. Ct values were normalized according HPRT 
and HMBS house keeper Ct values. Transcript expression had also been determined by Human 
Exon 1.0 ST microarrays (Affymetrix), as described elsewhere29 The exon array data have been 




Statistical analyses were performed with Statistical Package for the Social Sciences (SPSS) version 
11.5, considering P-values of less than 0.05 significant. Fisher's exact test was used to determine 
association of the SNP genotypes with the breast cancer cell lines. The Kruskal Wallis test was used 
to compare gene expression levels among three SNP genotype groups (major homozygotes, 
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Table 4.1 Continued 
Breast cancer cell lines 
SNP genotypes and allelic losses 









SUM44PE Het No Min H nd Maj H nd Het No Min H nd
T47D Het No Het No Maj H No Min H Yes Min H Yes
MDA-MB-361 Het No Het No Maj H No Het No Min H No
BT474 Het No Maj H No Maj H Yes Maj H No Maj H No
UACC812 Min H No Min H No Het No Het No Min H Yes
ZR75-30 Maj H nd Min H nd Min H nd Min H nd Maj H nd
OCUB-F Maj H nd Maj H nd Min H nd Min H nd Maj H nd
SK-BR-5 Het No Maj H nd Min H nd Min H nd Maj H nd
SUM190PT Min H nd Min H nd Maj H nd Min H nd Maj H nd
SUM225CWN Het No Maj H nd Maj H nd Maj H nd Het No
MDA-MB-330 Het No Min H Yes Min H Yes Het No Maj H No
MDA-MB-453 Het No Het No Min H Yes Maj H Yes Maj H Yes
SK-BR-3 Min H Yes Het No Het No Maj H Yes Min H No
EVSA-T Min H nd Min H nd Maj H nd Maj H nd Min H nd
UACC893 Maj H No Maj H No Maj H Yes Het No Maj H No
BT20 Min H No Maj H Yes Maj H Yes Maj H Yes Het No
HCC1937 Het No Min H nd Het No Het No Maj H nd
MDA-MB-468 Maj H Yes Maj H Yes Maj H Yes Maj H Yes Maj H Yes
SUM149PT Min H nd Het No Min H nd Min H nd Maj H Yes
SUM229PE Maj H nd Maj H nd Maj H nd Maj H nd Min H nd
BT549 Maj H No Maj H No Maj H Yes Het No Min H Yes
Hs578T Het No Maj H Yes Min H Yes Min H No Maj H No
MDA-MB-157 Maj H No Maj H Yes Maj H Yes Min H No Maj H Yes
MDA-MB-231 Maj H Yes Het No Het No Maj H Yes Het No
MDA-MB-436 Maj H Yes Maj H Yes Maj H No Min H No Maj H Yes
SK-BR-7 Het No Het No Min H nd Maj H nd Het No
SUM159PT Maj H nd Het No Min H nd Het No Maj H nd
SUM1315MO2 Het No Maj H nd Min H nd Het No Maj H nd
SUM102PT Het No Het No Maj H nd Het No Maj H nd
MDA-MB-435s Maj H No Maj H Yes Maj H Yes Maj H Yes Maj H No
     
Total major homozygotes 13  17 19 16 25  
Total heterozygotes 21  15 7 14 7  
Total minor homozygotes 6  8 14 10 8  
Percentage of allelic loss 13  25 52 32  37
Genotypes of five low-risk SNPs have been determined in the current study. Allelotype data have been 
reported eleswhere and involved microsatellite analysis. Loss: Yes, allelic loss at the indicated chromosomal 
region; and No, no allelic loss at the indicated chromosomal region. nd, not determined; 3-neg, triple-
negative; Maj H, major homozygotes; Min H, minor homozygotes; Het, heterozygote allele carriers. 
 
Expression levels of nearby located genes in breast cancer cell lines do not correlate with 
their SNP genotype 
Surprisingly, BCAC has not identified disease-causing gene variants within the haplotype blocks of 
the five low-risk SNPs10. They proposed an alternative disease mechanism, in which SNP genotypes 
modulate expression levels of nearby located genes. Such disease mechanism was conceivable 
because the minor SNP alleles confer only low risks for breast cancer. Here, we have evaluated 
whether gene expression modulation is operative in breast cancer cell lines, by associating SNP 
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are affected by allelic loss of the gene loci. We therefore also have compared gene expression 
levels in major and minor homozygotes with allelic loss to the gene expression levels in cell lines 
without allelic loss, but gene expression levels did not correlate with allelic losses either (Table 4.2).  
 








ER PgR ERBB2 3-neg 
SUM185PE Luminal-type Luminal - - - +
BT483 Luminal-type Luminal + - + -
MDA-MB-134VI Luminal-type Luminal + - - -
MDA-MB-175VII Luminal-type Luminal + - - -
MDA-MB-415 Luminal-type Luminal + - - -
MPE600 Luminal-type Luminal + - + -
SUM52PE Luminal-type Luminal + - + -
CAMA-1 Luminal-type Luminal + + + -
MCF-7 Luminal-type Luminal + + - -
ZR75-1 Luminal-type Luminal + + + -
SUM44PE Luminal-type Luminal + + - -
T47D Luminal-type Luminal + + - -
MDA-MB-361 Luminal-type Luminal + + ++ -
BT474 Luminal-type Luminal - + ++ -
UACC812 Luminal-type Luminal - + ++ -
ZR75-30 Luminal-type Luminal + - ++ -
OCUB-F Luminal-type Luminal - - ++ -
SK-BR-5 Luminal-type Luminal - - ++ -
SUM190PT Luminal-type nd - - ++ -
SUM225CWN Luminal-type nd - - ++ -
MDA-MB-330 Luminal-type ERBB2 + - ++ -
MDA-MB-453 Luminal-type ERBB2 - - ++ -
SK-BR-3 Luminal-type ERBB2 - - ++ -
EVSA-T Luminal-type ERBB2 - - ++ -
UACC893 Luminal-type ERBB2 - - ++ -
BT20 Basal-type Basal-like - - - +
HCC1937 Basal-type Basal-like - - - +
MDA-MB-468 Basal-type Basal-like - - - +
SUM149PT Basal-type Basal-like - - - +
SUM229PE Basal-type Basal-like - - - +
BT549 Basal-type Normal-like - - - +
Hs578T Basal-type Normal-like - - - +
MDA-MB-157 Basal-type Normal-like - - - +
MDA-MB-231 Basal-type Normal-like - - - +
MDA-MB-436 Basal-type Normal-like - - - +
SK-BR-7 Basal-type Normal-like - - - +
SUM159PT Basal-type Normal-like - - - +
SUM1315MO2 Basal-type Normal-like - - - +
SUM102PT Basal-type Normal-like nd nd nd nd
MDA-MB-435s Basal-type Normal-like - - - +
   
Total phenotype positives 14 8 13 16
Phenotypic characterizations have been reported elsewhere and involved protein expression patterns of the 
cell lines for the breast cancer subtyping (cytokeratins, ER, PgR and ERBB2) and expression of the intrinsic 
gene set for the intrinsic subtyping30. Protein expression: +, expressed; ++, over expressed; -, not detectable; 
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Table 4.3 Gene expression analysis of MAP3K1, FGFR2, TNRC9 and LSP1 in 40 human breast cancer cell lines 
by quantitative RT-PCR represented by normalized Ct values 
Breast cancer cell lines 
Transcript expression (normalized Ct values) 
MAP3K1 FGFR2 TNRC9 LSP1
BT20  23 30 45 38 
BT474  24 35 22 35 
BT483  22 31 25 36 
BT549  29 32 39 40 
CAMA-1  24 33 26 45 
EVSA-T  25 33 25 45 
HCC1937  26 32 37 45 
Hs578T  26 45 45 34 
MCF-7  25 34 28 39 
MDA-MB-134VI  22 37 24 35 
MDA-MB-157  25 44 33 29 
MDA-MB-175VII  24 35 23 36 
MDA-MB-231  26 45 45 35 
MDA-MB-330  26 32 27 33 
MDA-MB-361  23 34 23 44 
MDA-MB-415  23 28 20 33 
MDA-MB-435s  25 45 45 45 
MDA-MB-436  26 35 31 37 
MDA-MB-453  24 36 29 45 
MDA-MB-468  25 35 37 37 
MPE600  23 31 22 42 
OCUB-F  23 39 23 42 
SK-BR-3  25 32 26 37 
SK-BR-5  23 37 21 43 
SK-BR-7  26 39 45 35 
SUM102PT  25 35 32 29 
SUM1315M02  26 43 44 35 
SUM149PT  27 38 45 37 
SUM159PT  27 45 43 34 
SUM185PE  23 38 23 45 
SUM190PT  24 45 23 45 
SUM225CWN  24 36 23 39 
SUM229PE  25 39 33 36 
SUM44PE  22 41 26 36 
SUM52PE  24 24 24 37 
T47D  20 36 45 35 
UACC812  24 38 24 45 
UACC893  21 36 25 36 
ZR75-1  24 36 24 32 
ZR75-30   23 33 23 43 
    
Total high expressors (Ct<20)  1 0 1 0 
Total moderate expressors (Ct 20-30)  39 2 23 2 
Total low expressors (Ct >30-35)  0 12 4 5 
Total no expressors (Ct >35)  0 26 12 33 
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Table 4.4 Gene expression of MAP3K1, FGFR2, TNRC9 and LSP1 in human breast cancer cell lines according 
to their allelic loss status at the gene locus 
Gene Genotype
(Number of cell lines) 
Average expression level 
(Normalized Ct values) 
MAP3K1 Het (n=14) 24±2 
Maj H no loss (n=4) 24±4 
Min H no loss (n=2) 24±0 
Maj H allelic loss (n=1) 26 
Min H allelic loss (n=6) 25±1 
  
FGFR2 Het (n=7) 36±5 
Maj H no loss (n=4) 31±7 
Min H no loss (n=1) 33 
Maj H allelic loss (n=6) 35±6 
Min H allelic loss (n=6) 38±6 
  
TNRC9 Het (n=14) 30±8 
Maj H no loss (n=2) 24±2 
Min H no loss (n=3) 36±8 
Maj H allelic loss (n=1) 45 
Min H allelic loss (n=7) 36±9 
  
LSP1 Het (n=7) 37±4 
Maj H no loss (n=8) 37±4 
Min H no loss (n=2) 41±5 
Maj H allelic loss (n=3) 40±5 
Min H allelic loss (n=7) 38±6 
Although numbers are small for some sample groups, there are no apparent differences in gene expression 
levels related to allelic loss status. Allelic loss data and qPCR expression data are detailed in Table 4.1 and 





We present the genotypes of five low-risk susceptibility alleles or SNPs of 40 human breast cancer 
cell lines. Using this cell line model, we have evaluated the BCAC hypothesis that low-risk SNPs 
confer breast cancer risks by modulation of expression levels of nearby located genes. We found no 
evidence for expression modulation in the breast cancer cell lines, suggesting that such disease 
mechanism is more likely to operate in non-neoplastic epithelial or stromal cells or has been lost 
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ABSTRACT 
 
To understand the biology of low-risk breast cancer alleles and to investigate whether these loci 
also contribute to disease progression once established, we examined the association of SNPs 
tagging the low-risk breast cancer loci in or near FGFR2, LSP1, MAP3K1, H19, TOX3, POU5F1P1, MYC 
and 2q35, with clinical, pathological characteristics, prognosis, and mRNA expression of the nearest 
genes. Tumor DNA samples of 2,480 breast cancer patients were available. Out of this cohort, in 
1,290 patients with lymph-node negative disease who did not receive adjuvant systemic therapy, 
SNP status was associated with metastasis-free survival (MFS). In 1,401 patients, the mRNA 
expression levels of FGFR2, LSP1, MAP3K1, H19, TOX3, POU5F1P1 and MYC were determined and 
correlated with SNP genotypes. The SNP rs2981582 in FGFR2 was significantly associated with 
positive ER and PgR status (P <0.001 and P =0.003, respectively). No other significant associations 
with patient or tumor characteristics were observed. Only rs2107425 near H19 was significantly 
associated with shorter MFS in uni- and multivariate analysis (HR: 1.53, CI: 1.12-2.08, P = 0.006 and 
HR: 1.59, CI: 1.16-2.20, P =0.004, respectively), with the more aggressive minor allele displaying a 
recessive trait. The minor allele of SNP rs3803662 located near the TOX3 gene was associated with 
lower mRNA expression of this gene. In conclusion, except for the association of rs13283662 with 
TOX3 gene expression indicating a tumor suppressor role of TOX3, our findings suggest that breast 
cancer low-risk loci generally do not affect expression of the nearest gene in breast tumor tissue. 
Also the prognosis of patients is largely not affected by low-risk breast cancer loci except for the 
SNP near H19. How, this SNP affects prognosis warrants further study as it does not operate 
through altering H19 mRNA expression. 
 




Genome-wide association studies (GWAS) have recently identified various single nucleotide 
polymorphisms (SNPs) tagging several breast cancer predisposing loci1-3. The identified SNPs are: 
rs2981282 located within intron 2 of the fibroblast growth factor receptor 2 (FGFR2); rs3817198 in 
the lymphocyte-specific protein 1 (LSP1) gene; rs889312 located close to the mitogen-activated 
protein kinase kinase kinase 1 (MAP3K1) gene; rs3803662, rs12443621 and rs8051542 located near 
the trinucleotide repeat containing 9 (TNRC9) gene, also known as TOX3; rs2107425 located close to 
the imprinted H19 gene and rs13387042 and rs13281615 in the 2q35 and 8q24 regions, 
respectively, which lack nearby annotated genes. The most nearest genes to rs13281615 in the 
8q24 region are POU5F1P1, a transcription factor with a POU homeodomain, and MYC, a proto-
oncogene. Although several independent GWAS have replicated the association of these SNPs with 
increased cancer risk3-6, the mechanisms by which these loci in the target tissue may exert their 
effect are poorly understood. 
In analogy to high-risk and moderate-risk breast cancer genes, it was speculated that the identified 
SNPs tag causal variants in the coding region of nearby genes1. However, extensive sequencing 
efforts of the nearest gene by1 have not identified such variants in the SNP-associated haplotype 
blocks. This suggests that an alternative disease mechanism in which low-risk loci might involve 
expression modulation of nearby located genes and hence predispose to breast cancer. For 
example, Meyer et al observed an association of risk alleles in FGFR2 with increased FGFR2 mRNA 
expression in 63 invasive breast cancer samples 7, and Sun et al reported an association of the 
normal allele with higher FGFR2 mRNA expression in 81 normal breast tissue samples 8. Besides that 
these results appear contradictory, both studies lacked substantial power to test, conclusively, the 
hypothesis of expression modulation of the nearest genes by risk loci.  
To further test the hypothesis that in breast cancer these SNPs may operate through expression 
modulation of the nearest genes, we measured in a large subset of 1,401 primary breast cancer 
samples, mRNA transcript levels of the most plausible genes located nearest to the respective 
SNPs. In addition, we investigated whether these low-risk breast cancer loci not only relate to onset 
of breast cancer, as previously reported, but also contribute to its progression once established. 
Therefore, we have studied in the present study the association of SNP genotypes of seven low-risk 
breast cancer loci with patient and clinico-pathological tumor characteristics, as well as with tumor 
aggressiveness.  
 
MATERIALS AND METHODS  
 
Patients and tumor characteristics 
This retrospective study was approved by the medical ethical committee of the Erasmus Medical 
Centre Rotterdam, the Netherlands (MEC 02.953). The study was performed in accordance with the 
Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands 
(http://www.federa.org/?s=1&m=99), consent was not required, and, wherever possible, has been 
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reported in line with the Reporting Recommendations for Tumor Marker Prognostic Studies 
guidelines9. Frozen primary tumor samples from patients who entered the clinic between 1978 and 
2004, and from whom detailed clinical follow-up was available, were used. The median follow up of 
patients alive was 106 (range, 3-315) months and mean age was 55.9 (range, 22-88) years.  
Tumor estrogen receptor (ER) and progesterone receptor (PgR) analyses were performed by 
routine ligand binding assay or enzyme-linked immunoassay10. The cutoff used to classify the 
tumors as ER and/or PgR positive was 10 fmol/mg cytosolic protein. Patients with missing values 
for ER and PgR were indicated as an unknown category in Table 5.1. Details of patients and tumor 
characteristics are presented in Table 5.1. Transcript level expression of nearby located candidate 
genes and HER2 were determined in a subset of 1,401 tumors. Details of patients and tumor 
characteristics of this subgroup are presented in Supplementary Table S5.1.  
 
SNP genotyping 
Genomic DNA of 680 tumor homogenates has been isolated as described previously11 and the 
genomic DNA of 1,800 tissue sections were isolated from two to ten 30 μm cryostat sections (5 to 
20 mg) with the NucleoSpin®Tissue kit (Macherey-Nagel; Bioké, Leiden, The Netherlands) according 
to the protocol provided by the manufacturer. The quantity and quality of the isolated DNA was 
established by ultraviolet spectroscopy, by examination of the product size after agarose gel 
electrophoresis, and by the ability of the sample to be linearly amplified by real-time PCR in a serial 
dilution with a set of primers located in an intron of the hydroxymethylbilane synthase on 
chromosome 11 and thymidine kinase on chromosome 1712. Due to low sensitivity of the assay, 
SNP rs13281615 in the 8q24 region was genotyped in whole genome amplified (WGA) DNA of 
1,705 tumors as described before12. Briefly, 10 ng aliquots of genomic DNA of 1,705 tumors were 
amplified with the GenomiPhi V2 DNA amplification kit (GE Healthcare, Piscataway, NJ, USA) 
according to the protocol provided by the manufacturer12, typically yielding 4 μg amplified 
genomic DNA with the 20 kb band still visible on gel. Genotyping was performed by a fluorescent 
5′ exonuclease assay (TaqMan) using the ABI PRISM 7900HT Sequence Detection Sequence (PE 
Biosystems) according to the manufacturer’s instructions. Primers and probes for  SNPs rs2981582 
(C_2917302_10), rs3817198 (C_27493923_10), rs889312 (C_8886795_10), rs3803662 
(C_25968567_10), rs12443621 (C_30765260_10), rs8051542 (C_1230104_10),  rs13387042 
(C_32048042_10), rs13281615 (C_1332250_10) were purchased from Applied Biosystems as Made 
to Order, and for rs2107425 (forward: ATA ATG CCC GAC CTG AAG ATC TG, reverse: GCG TCG CAG 
GGT TCA C , VIC-probe:  CAC TCA TGG GAG CCG,  FAM-probe: ACA CTC ATA GGA GCC G) as Assay 
on Demand. All reactions were carried out with no template as negative controls. Duplicate 
samples (n = 352) extracted with the two different DNA isolation procedures as mentioned above 
were analyzed to assess concordance and quality of genotyping. High concordance was found 
between the SNPs mentioned indicating that both procedures were equivalent. Due to sensitivity 
issue of the assays, the SNP genotypes of some patients could not be determined and were 
regarded as missing values for the corresponding SNPs. The missing values for each of the analyzed 
SNPs are also presented in Table 5.1. 
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RNA isolation and quantitative RT-PCR 
RNA isolation, cDNA synthesis, quantification of specific mRNA species, and quality control checks 
were done as described in detail elsewhere13. In brief, total RNA was extracted with RNA-Bee 
(Campro, Veenendaal, the Netherlands) according to the manufacturer’s instructions and 2 to 5 μg 
of total RNA sample aliquots were reverse transcribed with oligo(dT)12-18 and random hexamer 
primers using the RevertAid H Minus First Strand cDNA Synthesis Kit from Fermentas (St. Leon-Rot, 
Germany) or the Superscript II RNase H- kit from Invitrogen (Breda, the Netherlands), respectively, 
according the protocols provided by the manufacturers. Prior to PCR, the resulting cDNA samples 
were treated with RNase H- (Ambion, Huntingdon, United Kingdom). The quantity and quality of 
the isolated RNA was established by UV spectroscopy, by examination of rRNA bands after agarose 
gel electrophoresis, and by the ability of the sample to be linearly amplified in a serial dilution with 
our housekeeping gene set (see next section for further details). Samples of total RNA not showing 
both the 18S and 28S bands (6%) or at 15 μg reverse-transcribed total RNA not amplifiable within 
26 cycles at our fixed threshold value of 0.02 with our housekeeping set were excluded. Real-time 
quantitative PCR was done in a Mx3000P Real-time PCR System (Agilent, Amsterdam, The 
Netherlands) according to the recommended protocol. Commercially available Taqman Gene 
Expression Assays (Applied Biosystems) were used for FGFR2 (Hs00240792_m1), MAP3K1 
(Hs00394890_m1), TOX3 (Hs00300355_m1), LSP1 (Hs00158885_m1), H19 (Hs00399294_g1),  
POU5F1/POU5F1P3/POU5F1P1 (Hs00999634_gH) and MYC (Hs00905030_m1). Forty rounds of 
amplification were performed according to the supplier’s protocol and at the end of the 
amplification fluorescent signals of the TaqMan probes were used to generate cycle threshold (Ct) 
values from which mRNA expression levels were calculated. To enable comparison of the levels of 
specific mRNAs in different samples, they were evaluated relative to the average expression levels 
of three reference genes, porphobilinogen deaminase (PBGD), hypoxanthine-guanine 
phosphoribosyltransferase (HPRT), and β-2-microglobulin (β2M). Expression levels of the target 
genes relative to the average expression levels of three reference genes was quantified as follows: 
mRNA target = 2(mean Ct reference-mean Ct target). The primer sequences for ER-α, PgR, ERBB2/HER2 and for the 
three reference genes, PBGD, HPRT, and β2M, have all been previously described13-14. 
 
Statistical analyses 
Pearson’s χ2 analysis was used to test for independence of the alleles [Hardy-Weinberg equilibrium 
(HWE)], the allelic distribution in breast tumors, to compare genotype frequencies between the 
three groups, and to check the relation of SNPs with patients and tumor characteristics. The hazard 
ratios (HRs) and their 95% confidence interval (95% CI) for the SNP alleles and traditional 
prognostic factors were determined with Cox proportional hazards models for both univariate and 
multivariate metastasis-free survival (MFS) analyses. MFS was defined as a time point before which 
a patient was found to be free from metastasis to distant organs. Differences between HR for SNP 
carrier vs. non-carriers were tested using the likelihood ratio test associated with the Cox 
regression analysis. The assumption of proportional hazards was investigated using a test based on 
the Schoenfeld residuals and was not violated for SNP rs2107425. In the multivariate model, the 
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contribution of the SNP alleles was adjusted for the classical prognostic factors; age, menopausal 
status, nodal status, tumor size, differentiation grade, and receptor status. MFS probabilities were 
calculated using the actuarial method of Kaplan-Meier and a log-rank test was used to test for 
differences between the survival curves.  
The association of SNPs and mRNA expression was determined using the Kruskal-Wallis test. A 
Bonferroni correction was applied to address the problem of multiple comparisons. All 
computations were carried out using the STATA statistical package, version 11.1 (Stata Corp., 
College Station, TX). A P-value ≤0.05 was considered statistically significant. All p-values are two-




Frequencies of low-risk alleles in tumor samples and association with patient and tumor 
characteristics 
We genotyped nine SNPs tagging linkage disequilibrium (LD) blocks containing seven loci, which 
have been reported to be associated with increased breast cancer risk1-2,15, in target tissue of breast 
cancer tumors from a cohort of 2,480 patients. Genotype determination and test for Hardy-
Weinberg equilibrium (HWE) revealed that all nine genotyped SNPs in this cohort were in Hardy-
Weinberg equilibrium (P >0.08 for all SNPs). The calculated minor allele frequencies (MAF) of the 
SNPs in our cohort are given in Table 5.2. To check whether risk alleles showed an association with 
specific clinico-pathological characteristics of the patients and tumors, we investigated the 
correlation of the SNPs with patient and tumor characteristics (Table 5.1). The risk alleles of the SNP 
rs2981582 in FGFR2 were significantly associated with ER- and PgR-positive tumors (P <0.001 and P 
=0.003, respectively). None of the other SNPs showed a strong association with either patient or 
tumor characteristics. After Bonferroni correction, only the association of FGFR2 allele with ER and 
PgR level remained significant. 
 
Table 5.2 Minor allele frequencies of low-risk breast cancer loci in the target tissues. 
SNP Locus Nearest gene MAF (European population) MAF (Target tissue) 
rs2881582 10q26 FGFR2 0.38 0.42 
rs3817198 11p15 LSP1 0.30 0.30 
rs889312   5q11 MAP3K1 0.28 0.30 
rs2107425 11p15 H19 0.31 0.30 
rs3803662 16q12 TOX3 0.25 0.29 
rs12443621 16q12 TOX3 0.46 0.46 
rs8051542 16q12 TOX3 0.44 0.45 
rs13281615   8q24 POU5F1P1/MYC 0.40 0.58 
rs13387042   2q35 Not analyzed 0.52 0.50 
 
Association of low-risk alleles with prognosis of primary breast cancer 
One of the aims of this study was to study a possible prognostic value of the low-risk SNPs. As 
prognosis is confounded by factors such as adjuvant treatment, we limited our analysis to our 
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genotypes. Therefore we argue that genetic changes in tumor samples of our cohort may not skew 
SNP genotype data. 
Additionally, the present retrospective study primarily aimed to address two important questions 
with regard to these risk alleles: firstly, do these alleles also affect the prognosis of the patients and, 
secondly, do these alleles affect the expression of adjacent genes? 
To address the first question, whether these SNPs were associated with the natural course of the 
disease, i.e., tumor aggressiveness, we focused in this retrospective study on the length of MFS in 
patients with lymph node-negative disease who did not receive any systemic adjuvant treatment. 
As adjuvant systemic therapy has a confounding effect on the development of metastases, a 
population like this one is the most optimal to address such question. Of all the risk alleles 
investigated, only homozygosity for risk alleles of rs2107425 (AA) in the imprinted gene H19 was 
significantly associated with poor prognosis in both univariate and multivariate analysis. To our 
knowledge, this is the first report showing the pure prognostic value of one of these low-risk loci1. 
However, the underlying biological mechanism accounting for this association is not yet evident. 
Since this SNP near H19 does not affect H19 mRNA expression, it is unlikely that this risk allele and 
prognostic SNP operates through altering H19 mRNA expression. This locus is located within the 
well-known imprinted IGF2/H19 locus on chromosome 11, which contains various imprinted 
transcripts22-23. Loss of imprinting and/or altered expression of other transcripts in this locus may be 
causal. Lack of an association of the other loci with prognosis could be related to lack of power of 
our study, but may also indicate that most risk alleles only relate to onset of breast cancer and not 
to its progression once established. One limitation of our study is that SNP genotype analysis was 
performed on tumor and not on germline DNA, which is not available for this cohort, and that 
somatic acquired genetic changes in tumor tissues might affect SNP genotype analysis. To address 
this, we analyzed a subset of the cohort from which we also had copy number variation data 
available21. In this subgroup, we found no evidence that copy number variation in the regions 
containing risk-associated SNPs significantly affected SNP genotype frequency. Therefore, we have 
no evidence that genetic changes in tumor samples of our cohort have skewed the presented SNP 
genotype data 
With regard to the second hypothesis that whether these loci modulate the expression of the 
nearest genes, we measured transcript expression levels of genes located nearby the risk loci in 
1,401 primary breast tumors. For transcript expression analysis, we only focused on the most 
plausible, non-hypothetical and the nearest genes to the haplotype blocks containing risk-
associated loci. The rs2981582 SNP located in the intronic region of the FGFR2 gene was not related 
to differences in FGFR2 mRNA expression. This is puzzling as the FGFR2 gene has been shown to be 
amplified and over-expressed in 5-10% of breast cancer patients24 and because the risk allele itself 
alters binding affinity for transcription factors of Oct-1/Runx2 and C/EBPβ, which has been causally 
linked with increased expression of FGFR2 in breast cancer cell lines7. However, such findings were 
not seen by Sun et al, who reported an association of the normal allele with higher FGFR2 
expression in 81 samples8. Of note, Sun et al analyzed normal breast tissue and not tumor tissue8. 
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Altogether, it is unlikely that this SNP acts through altering FGFR2 mRNA level in breast tumor 
tissue. 
We did not reveal an association of MYC transcript expression or MYC amplification with SNP 
genotype rs13281615 located in 8q24. Rs13281615 has no annotated gene in its vicinity. 
Nevertheless, a recent study showed a tissue-specific physical interaction of enhancers in the 8q24 
region with MYC expression16. However, our analysis does not provide further support for a link 
between MYC mRNA expression and this risk allele. We also measured transcript levels of the class 5 
homeobox transcription factor POU5F1P1, the nearest gene to this locus, which was recently shown 
to encode a functional nuclear transcriptional activator25 and to be over-expressed in prostatic 
carcinoma26. With our assay we could not establish a significant correlation between POU5F1P1 
mRNA expression and the rs13281615 genotype in 1,401 primary breast tumors. It should however 
be noted that our assay as recently indicated by Applied Biosystems also detects the pseudogene 
POU5F1P3 located on chromosome 12, and POU5F1, an intronless gene located on chromosome 6 
that can encode a protein highly similar to POU class 5 homeobox 1.  
For all other loci, we also did not observe any correlation of mRNA expression of the nearest genes 
with the genotype of the corresponding SNPs (Figure 5.2), except for the risk loci (rs12443621 and 
rs3803662) on 16q12. These SNPs reside in the LD block containing the 5′ end of the TOX3 gene 
and a hypothetical gene, LOC643714. A recent fine mapping of the LD block has further narrowed 
this risk-associated locus down to a region of 133 kb spanning the entire coding part of LOC643714 
and a small intergenic region. Moreover, this region exhibits evolutionary conservation and open 
chromatin conformation suggesting a regulatory function27. Our study shows that the alleles in this 
locus with strongest association with risk (rs3803662 and rs12443621) were significantly related 
with a lower expression of TOX3 mRNA. The lower expression of the TOX3 gene, which encodes a 
high mobility group box nuclear protein involved in calcium dependent transcription and 
structural modification of chromatin, in tumors with risk alleles of rs3803662, suggests that TOX3 
might act as a tumor suppressor gene. It is important to note that although the risk alleles of 
rs3803662 are significantly associated with lower expression of TOX3, yet another recent study 
showed an association of the rs3803662 SNP with an increased expression of the RBL2 gene, which 
is also located nearby this risk allele27. Although this study including only 77 breast tumors is 
underpowered compared with our analysis, it might however be possible that this locus 
differentially regulates more than one distant gene in cis or in trans.  
In summary, this study for the first time estimates the pure prognostic value of SNPs that are 
associated with low breast cancer risk. We have found that homozygous risk alleles of rs2107425 
SNP were associated with an aggressive course of the disease. Secondly, we associated these low 
risk SNPs with expression of nearby genes. Based on our findings that the risk alleles of rs3803662 
and rs12443621 near the TOX3 gene were associated with a lower expression of TOX3 mRNA, we 
hypothesize a tumor suppressor role of this gene. However, functional studies to determine reliably 
the role of the TOX3 gene in both normal and malignant settings are required. Finally, the breast 
cancer risk posed by rs2981582 SNP in FGFR2 and rs13181615 in the 8q24 region may not operate 
through the expression modulation of FGFR2 and MYC genes, respectively.   
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ABSTRACT 
 
Introduction TWIST homolog 1 (TWIST1) is a transcription factor that induces epithelial to 
mesenchymal transition (EMT), a key process in metastasis. The purpose of this study was to 
investigate whether TWIST1 expression predicts disease progression in a large breast cancer cohort 
with long-term clinical follow-up, and to reveal the biology related to TWIST1 mediated disease 
progression.  
Patients and Methods TWIST1 mRNA expression level was analyzed by quantitative real-time 
reverse polymerase chain reaction (RT-PCR) in 1,427 primary breast cancers. In uni- and 
multivariate analysis using Cox regression, TWIST1 mRNA expression level was associated with 
metastasis-free survival (MFS), disease-free survival (DFS) and overall survival (OS). Separate 
analyses in lymph node-negative patients (LNN, n = 778) who did not receive adjuvant systemic 
therapy, before and after stratification into estrogen receptor (ER)-positive (n = 552) and ER-
negative (n = 226) disease, were also performed. The association of TWIST1 mRNA with survival 
endpoints was assessed using Kaplan-Meier analysis. Using gene expression arrays, genes showing 
a significant Spearman rank correlation with TWIST1 were used to identify overrepresented Gene 
Ontology (GO) terms and KEGG-annotated biological pathways.  
Results Increased mRNA expression level of TWIST1 analyzed as a continuous variable in both uni- 
and multivariate analysis was associated with shorter MFS in all patients (hazard ratio (HR): 1.17, 
95% confidence interval, (95% CI):1.09-1.26; and HR: 1.17, 95% CI:1.08-1.26; respectively), in LNN 
patients (HR: 1.22, 95% CI:1.09-1.36; and HR: 1.21, 95% CI:1.07-1.36; respectively) and in the ER-
positive subgroup of LNN patients (HR: 1.34, 95% CI:1.17-1.53; and HR: 1.32, 95% CI:1.14-1.53; 
respectively). Similarly, high TWIST1 expression was associated with shorter DFS and OS in all 
patients and in the LNN/ER-positive subgroup. In contrast, no association of TWIST1 mRNA 
expression with MFS, DFS or OS was observed in ER-negative patients. Genes highly correlated with 
TWIST1 were significantly enriched for cell adhesion and ECM-related signaling pathways. 
Furthermore, TWIST1 mRNA expression was highly in tumor stroma and positively related to tumor 
stromal content (P <0.001). 
Conclusions TWIST1 mRNA expression is an independent prognostic factor for poor prognosis in 
LNN/ER-positive breast cancer. The biological associations suggest an involvement of the tumor 
microenvironment in TWIST1’s adverse role in breast cancer.  
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INTRODUCTION 
 
Breast cancer is one of the most frequently diagnosed cancers and the leading cause of cancer 
related deaths among females of the Western world1. Patients do not die from the primary tumor, 
but from metastases, which already are resistant or acquire resistance to systemic therapy. 
Metastasis is a complex multi-step process in which malignant cells undergo sequential molecular 
changes helping them to disengage from primary sites, intravasate into blood vessels, extravasate 
to distant organs and finally colonize secondary sites. Each of these metastatic steps is affected by 
aberrant expression of a variety of transcription factors and among them, TWIST homologue 1 
(TWIST1) is considered an important regulator of disease progression2.  
TWIST1 protein, encoded by the TWIST1 gene, is a member of a large protein family called basic 
helix-loop-helix (bHLH) transcription factors3. Most family members contain a bHLH domain, which 
enables it to target specific DNA sequences and thereby allowing them to regulate developmental 
processes in many organs and tissues. TWIST1 plays a key role in the regulation of embryogenesis, 
gastrulation, and mesoderm formation during early embryonic development of Drosophila and 
many other species4,5. An autosomal mutation pattern in the TWIST1 gene leads to Saethre-Chotzen 
syndrome, a genetic condition characterized by premature fusion of skull bones affecting 
symmetrical growth of head and face6. In children, TWIST1 protein is involved in adequate 
maturation of the skull and spine bones and normal development of arms and hind legs. 
More recently, TWIST1 protein has been implicated in various carcinomas including breast cancer, 
where it plays a role in metastasis through activation of a biologically latent developmental process 
called epithelial to mesenchymal transition (EMT)7,8. In the EMT process, malignant epithelial cells 
undergo cytoskeletal changes including the down-regulation of epithelial markers such as E-
cadherin and co-expressed catenins and up-regulation of mesenchymal markers such as vimentin, 
N-cadherin, and fibronectin. EMT transformed malignant cells are more motile and can be more 
efficient in invading the surrounding tissues and as a result metastasize to distant organs9. 
In this large retrospective study of 1,427 primary breast cancer patients, we determined whether 
TWIST1 gene expression level is a prognostic marker. To avoid possible confounding effects of 
therapy and to study the natural course of the disease, we particularly focused on the subgroup of 
778 lymph node-negative (LNN) patients who did not receive any adjuvant systemic therapy. 
Additionally, to understand the biological context of TWIST1, we have identified, using available 
Affymetrix U133A gene expression data10,11 genes and biological pathways co-expressed with 
TWIST1. By doing this, we identified a clear link between the tumor microenvironment and TWIST1 
expression in clinical breast cancer.  
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Moreover, these patients had no distant metastasis within first month after primary surgery and no 
prior cancer except basal skin carcinoma and cervical cancer stage I. ER, PGR and HER2 (ERBB2) 
levels were assessed by quantitative real-time reverse transcriptase PCR (qRT-PCR) as described 
before15-17. Lymph node involvement, tumor size and grade were extracted from the pathology 
reports as obtained from the hospitals. Primary surgical treatment was lumpectomy in 628 patients 
(44%) or modified mastectomy for 799 patients (56%). One thousand and nine patients (71%) 
received adjuvant radiotherapy at the thoracic wall only (n = 639) and either at the thoracic wall 
and nodal stations (n = 290) or at the nodal stations only (n = 80). Thirty-three percent of the 
patients had T1 tumors. The median age of the patients at surgery was 55 years (range, 23-89 
years). Routine post-surgical follow-up and the definition of the endpoints of MFS, DFS and OS 
were described before11,18. During follow-up, a local/regional relapse for 127 patients was not 
counted as an event in the analysis of MFS. The median follow-up time was 104 months (range, 4-
262 months) with 707 and 669 events in the analyses of MFS and OS, respectively. Study design, 
patient inclusion criteria, and patient subgroups included in the analyses are given in Figure 6.1. 
Other relevant clinico-pathological characteristics are listed in Table 6.1. 
 
Table 6.1 Association of TWIST1 mRNA expression with standard clinical and pathological characteristics of 
patients and tumors 
Characteristics  No. patients TWIST1 mRNA expression  
(Median value*)  P-value 
Age (years)      
< 40  188 0.025   
41-55  530 0.028   
56-70  471 0.030   
> 70  238 0.020  0.04† 
Menopausal status      
Premenopaual  603 0.027   
Postmenopausal  824 0.027  0.21‡ 
Tumor size      
pT1, < 2 cm  463 0.031   
pT2, > 2-< 5  807 0.025   
pT3, > 5 + pT4  157 0.028  0.009¶ 
Lymph nodes involved      
0  778 0.026   
1-3  288 0.025   
>3  361 0.030  0.007¶ 
Grade      
Poor  800 0.026   
Good/Moderate  230 0.027   
Unknown  397 0.029  0.47¶ 
Tumor histology      
IDC  957 0.027   
ILC  112 0.044  <0.001‡, § 
Medullary  31 0.016   
Mucinous  39 0.008  <0.001¶ 
ER status (mRNA)      
Negative  360 0.021   
Positive  1,067 0.029  0.06† 
94 |  Chapter 6 
Table 6.1 Continued      
Characteristics  No. patients TWIST1 mRNA expression  
(Median value*)  P-value 
PGR status (mRNA)      
Negative  572 0.023   
Positive  855 0.029  <0.001† 
ERBB2 status (mRNA)      
Negative  1,187 0.026   
Positive  240 0.032  <0.001† 
Abbreviation: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma. 
* Expression values after normalization to our set of 3 reference genes (B2M, HMBS and HPRT1). 
† P Spearman rank correlation test. 
‡ P for Mann-Whitney test. 
¶ P for Kruskal-Wallis test. 
§ TWIST1 expression was compared between IDC and ILC tumors. 
 
Tissue processing and estimation of the amount of epithelial tumor cells 
Tissue processing was done as described in detail before15,19. In brief, 20 to 60 cryostat sections of 
30 μm size corresponding to 30 to 100 mg weight were cut from frozen tissues. Three 5 μm 
sections were cut before, in between, and after cutting the sections for RNA isolation, and stained 
with hematoxylin and eosin (H&E) to assess the amount of tumor cells relative to the amount of 
surrounding stromal cells. The amount of nuclei evidently of epithelial tumor cell origin relative to 
the amount of surrounding stromal cells was estimated with a 100-fold magnification in 10 
different areas covering the area of each of the three H&E sections. Only specimen with at least 
30% of the nuclei of epithelial tumor cell origin and distributed uniformly over at least 70% of the 
section area were included. Like before16, these estimates were used to dichotomize our tumor 
cohort at the median level of 70% tumor cell nuclei in stromal-rich (SR) (primary tumors containing 
>30% stromal components) and stromal-poor (SP) (primary tumors containing at least 70% tumor 
cells).  
 
Laser capture microdissection  
Laser capture microdissection (LCM) was performed according to a previously published method20. 
Briefly, 8 μm sections of a fresh frozen tumor tissue were cryosectioned and pasted on UV sterilized 
polyethylene naphthalate (PEN) covered glass slides (P.A.L.M. Microlaser Technologies, Bernried, 
Germany). The slides were air dried for 10 sec at room temperature, fixed in ice-cold 70% ethanol, 
and washed shortly in Milli-Q water. The slides were then stained for 15 sec in Haematoxylin 
(Klinipath 4085.9005, Duiven, The Netherlands) and washed again in Milli-Q water. Subsequently, 
the slides were dehydrated twice in RNase-free 50, 70, 95, and 100% ethanol for 30 sec each, and 
air-dried. Next, LCM was performed directly on the stained sections. From consecutive cryosections 
of a tumor tissue, both the stromal content and tumor epithelial cells were collected separately in 
triplicate in P.A.L.M. tube caps containing 25μl of tissue lysis (RLT+) buffer (Qiagen 1053393, Venlo, 
The Netherlands) using a P.A.L.M. LCM device, type P-MB (P.A.L.M. Microlaser Technologies AG, 
Bernried, Germany). Both stromal and epithelial cell fractions were then spun down into 0.5-ml 
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Eppendorf Protein LoBind tubes (Eppendorf, Hamburg, Germany) containing 225μl RLT+ buffer 
and used for RNA isolation.  
 
RNA isolation, cDNA synthesis, and quantification of specific mRNA species 
RNA isolation, cDNA synthesis, quantification of specific mRNA species, and quality control checks 
were done as described previously by Sieuwerts et al15. qRT-PCR was performed in 25-μL reaction 
volume in a Mx3000P Real-time PCR System (Agilent, Amsterdam, the Netherlands) using a 
commercially available gene expression assays for TWIST1 (Hs00361186_m1) and VIM (Hs 
Hs00185584_m1) from Applied Biosystems/Life Technologies (Nieuwerkerk aan den IJssel, The 
Netherlands). For EPCAM mRNA measurement, a combination of the following primers and probe 
was used (F: 3’-AGT TTG CGG ACT GCA CTT CA, R: 3’- AAT ACT CGT GAT AAA TTT TGG ATC CA, FAM-
labeled MGB probe: AAG GAG ATC ACA ACG CGT). Primer sequences for estrogen receptor-α 
(ESR1), progesterone receptor (PGR), ERBB2 and the reference genes (HMBS, HPRT1 and B2M), as 
well as how PCR reactions and validations were carried out to ensure PCR specificity, were done as 
described before15,17. Levels of mRNA expression were quantified relative to the set of reference 
genes as described before15.  
 
Immunohistochemistry (IHC) 
Sections of 4 μm were cut from formalin-fixed paraffin-embedded tissues, pasted on glass slides, 
and dried overnight at 37°C. The slides were dewaxed in xylene solution and hydrated in series of 
different percentages of alcohol (100%, 95%, 75%, and 50%). The antigen was retrieved for 40 min 
in a hot water bath (at 95°C ) in Tris-EDTA buffer, pH 9.0 (DAKO; S2367, Glostrup, Denmark) and 
cooled down for 20 min at room temperature. After retrieval, slides were immersed in 3% hydrogen 
peroxide for 10 min to block endogenous peroxidase activity, and in a DAKO protein-free serum 
blocking solution for 30 minutes to block non-specific binding sites. The slides were then 
incubated overnight at 4°C with a mouse monoclonal primary antibody raised against a human 
recombinant fragment of TWIST1 (AbCam TWIST2C1a, ab50887, Cambridge, UK), diluted 1:100 in 
an antibody diluent (DAKO). Negative controls were made by replacing the primary antibody with 
mouse immunoglobulin at an appropriate dilution. Next, the slides were treated with a secondary 
antibody (envision mouse kit, DAKO) and visualized using DAB (envision kit, DAKO). The slides were 
counterstained with hematoxylin and dehydrated through graded alcohol and xylene. Evaluation 
of the immunostaining and histoscoring were performed according to a previously published 
method 21. Briefly, a histoscore of 0-300 was given to each tumor by multiplying the proportion of 
cells with nuclear staining in a tissue by the intensity of the staining as follows; histoscore = (0 × 
percentage not stained) + (1 × percentage weakly stained) + (2 × percentage moderately stained) 
+ (3 × percentage strongly stained). The histoscores calculated by this way were correlated with 
TWIST1 mRNA expression. The intensity of TWIST1 stromal expression in tumor tissues was scored 
as no, weak, moderate or strong staining. 
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Identification of TWIST1 co-expressed genes on Affymetrix U133A gene-chips and 
identification of Gene Ontology GO) terms and biological pathways 
In this analysis we used TWIST1 mRNA expression, which was previously measured by Affymetrix 
U133A gene-chips (Affymetrix, Santa Clara, CA, USA) (probe set 213943_at)10,11,22. The mRNA 
expression levels of TWIST1 measured on the Affymetrix-array and by qRT-PCR were highly 
correlated in an overlap of 193 LNN/ER-positive and 118 LNN/ER-negative tumor specimens using 
the Spearman-Rank correlation test (Spearman rank correlation, Rs = 0.7; P <0.001 for both). Genes 
showing a significant positive or negative correlation with TWIST1 were identified by using these 
Affymetrix-array data after all genes were corrected for multiple testing by applying a false 
discovery rate (FDR) of 5%23. Biological pathways and GO terms from genes significantly co-
expressed with TWIST1 were identified using the ArrayTrackTM software (NCTR/FDA, Jefferson, AR 
72079, USA)24. The overrepresented pathways and GO terms identified by ArrayTrack were based 
on Fisher’s exact statistics. Details about how ArrayTrackTM software functions can be retrieved from 
the website25. The gene expression data used have previously been deposited in the National 




Computations were done with the use of the STATA statistical package, release 11.2 (STATA Corp. 
College Station. TX). Differences in levels were assessed with the Mann-Whitney U test or Kruskal-
Wallis test. In these tests, patient and tumor characteristics were used as grouping variables. The 
strengths of the associations between continuous variables were tested with the Spearman rank 
correlation test. TWIST1 mRNA expression levels measured by qRT-PCR were log transformed to 
reduce the skewness (Skewness-Kurtosis normality test, P <0.05) and to attain symmetric 
distribution (Additional file 6.1, Figure S1). The prognostic value of the clinical and biological 
variables, with MFS, OS, and DFS as the end points in the univariate and multivariate analyses, were 
investigated with the use of the Cox proportional hazard model. The hazard ratio (HR) and its 95% 
confidence interval (95% CI) were derived from these models by analyzing TWIST1 mRNA 
expression levels as a continuous variable or after dividing their levels into quartiles. The 
proportionality assumption was investigated with a test based on the Schoenfeld residuals. Kaplan-
Meier survival analysis was performed and a log-rank test was used to assess a trend of survivor’s 
function across four quartiles of TWIST1 mRNA expression levels. All P-values are two sided, and P 




Association of TWIST1 mRNA expression with standard clinical and pathological 
characteristics of patients and tumors  
Association of TWIST1 mRNA expression levels with clinical and pathological characteristics of 
patients and tumors are shown in Table 6.1. Tumor TWIST1 mRNA expression was higher in patients 
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with >3 positive lymph nodes, and lower in pT2 tumors and in older patients. Furthermore, TWIST1 
mRNA expression was higher in invasive lobular carcinoma (ILC) compared with invasive ductal 
carcinoma (IDC). Mucinous and medullary-type of tumors showed the lowest TWIST1 mRNA 
expression levels. In addition, TWIST1 mRNA expression level was higher in PGR-positive and ERBB2-
overexpressing tumors, but was not associated with tumor grade and menopausal status.  
 
Association of TWIST1 mRNA expression with prognosis in primary breast cancer patients 
To explore the prognostic significance of TWIST1 mRNA expression in primary breast cancer 
patients, we first performed Cox uni- and multivariate analyses (traditional factors in the 
multivariate analysis were; age, menopausal status, number of positive lymph nodes, tumor size, 
tumor grade, ER status, PGR status and ERBB2 status) for MFS, DFS and OS as a function of 
continuous TWIST1 mRNA expression levels. In all 1,427 patients, increasing TWIST1 mRNA 
expression levels were associated with shorter MFS in both uni- and multivariate analysis (HR: 1.17, 
95% CI: 1.09-1.26; P <0.001 and HR: 1.17, 95% CI: 1.08-1.26; P <0.001; respectively) (Table 6.2).  
 
Table 6.2 Model for Uni-and Multivariate analysis for metastasis-free survival in all patients (n = 1,427) 
Factors No. patients 
Univariate Multivariate 
HR 95% CI P-values HR 95% CI P-values
Age (years)        
< 40 188 1 1  
41-55 530 0.92 0.73-1.16 0.47 0.88 0.69-1.12 0.30
56-70 471 1.02 0.80-1.29 0.88 0.85 0.59-1.21 0.36
> 70 238 0.80 0.66-1.06 0.12 0.69 0.47-1.03 0.07
Menopausal status        
Premenopaual 603 1 1  
Postmenopausal 824 1.07 0.92-1.25 0.35 1.23 0.94-1.62 0.14
Tumor size        
pT1, < 2 cm 463 1 1  
pT2, > 2-< 5 807 1.65 1.39-1.97 <0.001 1.38 1.15-1.65 <0.001
pT3, > 5 + pT4 157 2.80 2.20-3.58 <0.001 1.80 1.39-2.33 <0.001
Lymph nodes involved        
0 778 1 1  
1-3 288 1.79 1.48-2.17 <0.001 1.71 1.41-2.08 <0.001
>3 361 2.92 2.46-3.46 <0.001 2.63 2.19-3.16 <0.001
Grade        
Poor 800 1 1  
Good/Moderate 230 0.51 0.40-0.65 <0.001 0.64 0.50-0.82 <0.001
Unknown 397 0.89 0.75-1.05 0.17 0.99 0.83-1.17 0.87
ER status (mRNA)        
Negative 360 1 1  
Positive 1,067 0.82 0.70-0.97 0.02 0.83 0.67-1.04 <0.001
PGR status (mRNA)        
Negative 572 1 1  
Positive 855 0.75 0.64-0.87 <0.001 0.87 0.71-1.06 0.17
ERBB2 status (mRNA)        
Negative 1,187 1 1  
Positive 240 1.30 1.08-1.57 0.006 1.18 0.97-1.43 0.09
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Table 6.2 Continued        
Factors No. patients 
Univariate Multivariate 
HR 95% CI P-values HR 95% CI P-values
     Addition to the base model
TWIST1 mRNA level†  
(Continuous) 1,427 1.17 1.09-1.26 <0.001 1.17 1.08-1.26 <0.001 
TWIST1 mRNA level†        
TWIST1 quartile 1 360 1 1  
TWIST1 quartile 2 355 1.16 0.94-1.45 0.17 1.09 0.88-1.37 0.43
TWIST1 quartile 3 357 1.22 0.98-1.51 0.08 1.25 1.00-1.56 0.05
TWIST1 quartile 4 355 1.49 1.20-1.83 <0.001 1.43 1.15-1.77 0.001
†TWIST1 mRNA expression level (log-transformed after normalization to the expression of three reference 
genes) was separately added to the base multivariate model that included the factors age, menopausal 
status, tumor size, grade, lymph-node status, ER, PGR, and ERBB2 mRNA expression levels, tested both as a 
continuous variable and in four quartiles. 
 
To visualize the prognostic value of TWIST1 mRNA expression in Kaplan-Meier survival curves, we 
divided TWIST1 expression levels into four quartiles Q1 (low) to Q4 (high) (Figure 6.2). To exclude a 
possible confounding treatment effect, we also evaluated the prognostic value of TWIST1 mRNA 
expression in LNN-patients who did not receive any adjuvant systemic therapy. We also stratified 
these LNN patients into ER-positive and ER-negative subgroups as these subgroups are considered 
biologically distinct. In the analysis of all 778 LNN patients, an association of increasing TWIST1 
mRNA expression levels with shorter MFS was observed in both uni- and multivariate analysis 
(univariate HR: 1.22, 95% CI: 1.09-1.36; P =0.001 and HR: 1.21, 95% CI: 1.07-1.36; P =0.001; 
respectively) (Additional file 6.2, Table S1). Moreover, within the LNN subgroup of patients, the 
association of increasing TWIST1 mRNA levels with shorter MFS was confined to the ER-positive 
subgroup of patients [univariate (HR: 1.34, 95% CI: 1.17-1.53; P <0.001) and multivariate (HR: 1.32, 
95% CI: 1.14-1.53; P <0.001)] (Table 6.3). There was no association of TWIST1 mRNA levels with MFS 
in the ER-negative subgroup of patients (univariate HR = 1.05, 95% CI: 0.86-1.29; P =0.64) 
(Additional file 6.2, Table S2).  
Kaplan-Meier survival curves for all patients and subgroups of patients with LNN and LNN/ER-
positive and LNN/ER-negative disease, after dividing these cohorts in quartiles (Q1 to Q4), are 
shown in Figure 6.2A-D. Cox regression analysis for MFS showed that in the LNN/ER-positive group 
the quartile with the highest TWIST1 mRNA levels (Q4) had a 2-fold increased hazard ratio 
compared with the quartile with the lowest TWIST1 mRNA levels (Q1) (Table 6.3). 
We also related TWIST1 mRNA expression levels with OS in all patients, in the LNN cases as a whole 
and after stratifying by ER status. Similarly as observed for MFS, increasing TWIST1 mRNA 
expression levels were associated with shorter OS in all patients (univariate HR: 1.10, 95% CI: 1.08-
1.26, P =0.013; multivariate HR: 1.11, 95% CI: 1.03-1.20, P =0.006), in the LNN (univariate HR: 1.13, 
95% CI: 1.01-1.27, P = 0.03; multivariate HR: 1.16, 95% CI: 1.03-1.30, P =0.01) and in the LNN/ER-
positive group of patients (univariate HR: 1.26, 95% CI: 1.09-1.45, P =0.001; multivariate HR: 1.27, 
95% CI: 1.11-1.46, P =0.001). These associations were not significant in the LNN/ER-negative group 
of patients (univariate HR: 0.96, 95% CI: 0.78-1.18, P =0.69; multivariate HR: 0.98, 95% CI: 0.79-1.21, P 
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Table 6.3 Continued        
Factors No. patients 
Univariate Multivariate 
HR 95% CI P-values HR 95% CI 
P-
values 
Menopausal status                
Premenopaual 215 1 1  
Postmenopausal 337 0.76 0.57-1.00 0.05 0.99 0.56-1.74 0.98
Tumor size                
pT1, < 2 cm 251 1 1  
pT2, > 2-< 5 276 1.12 0.84-1.49 0.43 1.09 0.82-1.46 0.34
pT3, > 5 + pT4 25 1.62 0.84-3.11 0.15 1.92 0.99-3.75 0.06
Grade                
Poor 257 1 1  
Good/Moderate 124 0.53 0.35-0.79 0.002 0.56 0.37-0.85 0.007
Unknown 171 1.06 0.78-1.44 0.70 1.20 0.87-1.64 0.26
PGR status (mRNA)                
Negative 116 1 1  
Positive 436 0.67 0.49-0.92 0.013 0.71 0.51-0.99 0.04
ERBB2 status (mRNA)                
Negative 475 1 1  
Positive 77 1.51 1.06-2.15 0.02 1.39 0.97-2.00 0.08
     Addition to the base model
TWIST1 mRNA level†  
(Continuous) 552 1.34 1.17-1.53 <0.001 1.32 1.14-1.53 <0.001 
TWIST1 mRNA level†        
TWIST1 quartile 1 135 1 1  
TWIST1 quartile 2 125 1.02 0.65-1.61 0.92 0.90 0.57-1.43 0.67
TWIST1 quartile 3 149 1.28 0.85-1.94 0.24 1.09 0.71-1.68 0.70
TWIST1 quartile 4 143 2.06 1.39-3.04 <0.001 1.87 1.25-2.80 0.002
† TWIST1 mRNA expression level (log-transformed after normalization to the expression of three reference 
genes) was separately added to base multivariate model that included the factors age, menopausal status, 
tumor size, grade, ER, PGR, and ERBB2 mRNA expression levels, tested both as a continuous variable and in 
four quartiles. 
 
Investigation of TWIST1 related biological pathways in LNN breast cancer 
To explore the underlying biology of TWIST1-associated disease progression in breast cancer, we 
determined TWIST1 co-expressed genes previously measured on Affymetrix U133A gene-chips10,11. 
Since we found TWIST1 to be associated with poor prognosis in LNN/ER-positive patients only, we 
first decided to include only the LNN/ER-positive samples to examine the TWIST1 co-expressed 
genes. After using a Spearman correlation test followed by applying a multiple testing correction at 
a FDR of 5%, we found 1,847 genes to be positively correlated and 1,445 genes to be negatively 
correlated with TWIST1 mRNA expression (Additional file 6.3, Table S9A, B). To reveal which 
biological pathways might be associated with TWIST1 mRNA expression, we performed pathway 
analyses using the genes co-expressed with TWIST1 and the KEGG pathway database as input for 
the analysis in the ArrayTrack™ software package. The three most significantly overrepresented 
pathways containing these TWIST1 co-expressed genes were: Focal adhesion pathway (Fisher’s 
exact P =1.0×10-8), ECM-receptor interaction pathway (Fisher’s exact P =9.9×10-7), and TGF-beta 
signaling pathway (Fisher’s exact P =2.6×10-4) (Additional file 3, Table S10). In addition, GO term 
enrichments among TWIST1 co-expressed genes identified “cell adhesion”, “extracellular structure 
organization”, and “anatomical structure formation involved in morphogenesis” as the top three 
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significant GO terms (level > 3; gene hits > 5; P values <0.001) in the category of “biological 
processes”, and the GO terms, “extracellular matrix” proteinaceous extracellular matrix, and 
“extracellular matrix part” as the top three significant GO terms in the category “protein cellular 
components” (Additional file 6.3, Table S11).  
To evaluate a possible TWIST1 mediated biological difference between LNN/ER-positive and 
LNN/ER-negative patients, we also performed pathway analyses using TWIST1 co-expressed genes 
(n = 1,141 positively and n = 498 negatively correlated genes with TWIST1, respectively, Additional 
file 6.3, Table S12A & B) measured on Affymetrix arrays from LNN/ER-negative patients (n = 118). As 
observed in LNN/ER-positive patients, these analyses identified Focal adhesion and ECM-receptor 
interaction pathways as the two most significant pathways. But, in contrary to what unlike 
observed in LNN/ER-positive patients, the TGF-beta signaling pathway was not found to be the 
third most significant pathway in LNN/ER-negative patients (Additional file 6.3, Table S13). We also 
performed pathway analysis using TWIST1 co-expressed genes in all LNN patients irrespective of ER 
status. Analyses revealed only Focal adhesion and ECM-receptor interaction pathways as the two 
most significant pathways but TGF-beta signaling pathway was not found to be as the third top 
significant pathway in all patients (Additional file 6.3, Table S14). Altogether, these data suggest 
that the co-expression of TGF-beta signaling pathway with TWIST1 gene is more prominent in 
LNN/ER-positive cancer. 
 
Association of TWIST1 mRNA expression levels with stromal content 
The co-expression analysis suggested an association between stromal content of the tumor tissue 
and TWIST1 mRNA expression levels. Therefore, we studied the association of TWIST1 mRNA 
expression with tumor stromal content in more detail. For this, we performed LCM to separately 
isolate the stromal (S) and epithelial tumor cell (T) areas from 10 breast tumor tissues (n = 9 ESR1 
high, n = 1 ESR1 low) with sufficiently micro-dissectible fresh frozen tissue left. After LCM we 
measured TWIST1 mRNA by qRT-PCR in RNA isolated from both the stromal and the epithelial 
tumor cell fractions of these tissues, and normalized the expression levels to our set of reference 
genes. To ensure that our reference gene-set did not cause a bias in these analyses, and our LCM 
material was indeed enriched for stromal and epithelial cells, we also measured VIM and EpCAM 
(Epithelial Cell Adhesion Molecule) in these fractions (Figure 6.3A). In these analyses, EpCAM mRNA 
expression was high in the epithelial tumor cell fractions [3.4-fold, 2-sided paired t-test P =0.006] 
and VIM and TWIST1 mRNA expression were high in the stromal fractions [23.4-fold, P =0.0001 and 
14.6-fold, P =0.0004, respectively]. 
As the prognostic value for TWIST1 mRNA expression is confined to ER-positive breast cancer, we 
assessed whether ER expression might be of relevance for TWIST1 mRNA expression in tumor 
tissues with a variable amount of stromal content. For this, we compared TWIST1 mRNA expression 
levels between stromal rich (SR) and stromal poor (SP) tumors in the ER-positive and ER-negative 
subgroups. Notably, only in ER-positive tumors, TWIST1 mRNA expression was significantly higher 
in SR compared with SP tumors (Figure 6.3B, P <0.001); in ER-negative tumors the difference was 
not significant (Figure 6.3C, P= 0.41). 
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protein staining in the stroma. The staining of TWIST1 in the other tumors (71% of the ER-negatives 
and 23% of the ER-positives) was weak. These data based on limited number of samples further 
support our qRT-PCR based findings at the protein level that the stroma of ER positive tumors is 




The bHLH transcription factor TWIST1, which is essential in developmental processes such as 
gastrulation, has been shown to be oncogenic in various cancers26-33. Functional studies pin-
pointed a pivotal role for this protein in EMT, a fundamental biological process considered to be 
crucial for metastatic spread in various carcinomas, including breast cancer. This prompted us to 
analyze mRNA expression of this gene in primary breast tumors from a large retrospective cohort 
of patients with complete clinical follow-up and address two basic questions. First, can TWIST1 
mRNA expression in breast cancer tissue predict disease progression? Second, as we had 
Affymetrix U133A gene-chips data available for a subset of samples10,11,22, can we reveal which 
biological pathways are co-expressed with TWIST1 in breast cancer?  
Our current study shows that high TWIST1 mRNA expression is an independent marker of poor 
outcome in breast cancer patients. As TWIST1 mRNA expression was also a predictor of poor 
outcome in patients with LNN disease who did not receive any adjuvant systemic treatment, we 
may conclude that TWIST1 mRNA expression is a pure prognostic marker and is associated with the 
natural course of disease progression. This suggests that tumors with high expression of TWIST1 are 
more aggressive, a finding that fits with experimental data where overexpression of TWIST1 
resulted in increased extravasation during the dissemination of tumor cells7. Also in line with this is 
the increased lymph node involvement of breast tumors exhibiting higher TWIST1 expression as 
observed by us and others34. The first seminal paper on TWIST1 in breast cancer also showed higher 
TWIST1 mRNA expression in infiltrative lobular carcinoma7, which we also confirmed though the 
implications if this remain unclear.  
What we further unexpectedly observed was that the association of TWIST1 expression with poor 
prognosis was confined to ER-positive cases and not seen in ER-negative breast cancer. Similar 
observations were recently made by Van Nes and colleagues21. This group, by studying TWIST1 
expression in a smaller-sized cohort using IHC on tissue microarrays, also found significantly more 
cumulative relapses in the ER-positive subgroup of tumors. This observation was not significant in 
their entire cohort, which also included ER-negative cases. Using the same antibody, we observed, 
in a subset of formalin-fixed specimen available from our cohort, clear nuclear TWIST1 expression. 
This protein expression was not only confined to the nuclei of invasive tumor cells but also present 
in nuclei of other cells, such as fat cells, fibroblasts, endothelial cells and inflammatory cells. 
Furthermore, although based on small numbers, TWIST1 protein staining was high in those 
specimens in which we had measured high TWIST1 mRNA expression in a matched fresh-frozen 
sample of the same tumor, while in specimens with low TWIST1 mRNA expression the protein 
staining was overall weaker or absent. 
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To study the potential biological mechanisms in disease progression connected to TWIST1 
expression, we identified genes co-expressed with TWIST1 in LNN/ER-positive tumors from which 
genome wide gene expression data were available. Three related pathways were revealed. The first 
pathway was “Focal adhesion” which involves interaction of ECM with integrin-A and -B ligands. 
The second pathway, “ECM-receptor interaction” is related to ECM, and it involves collagen, 
laminin, fibronetic, tenascin and integrin-A and -B proteins. The third pathway is the “TGF-beta 
signaling”. How these pathways, involving well-known cancer-related genes are connected to 
TWIST1 expression in relation to disease progression in LNN/ER-positive cancer warrants functional 
validation. A common denominator among these three pathways, however, is their involvement in 
ECM remodeling. There is a growing body of evidence showing that changes in the tumor 
microenvironment can promote proliferation of the tumor cells and therefore can influence 
outcome of patients35, and our data connect this to TWIST1 expression. Furthermore, our work also 
shows that the stroma is a significant source of TWIST transcript expression. Indeed, the current 
data reinforces recent observations made by Roman-Perez and colleagues after evaluating gene 
expression patterns in 72 breast tissue samples36. They identified two distinct subtypes, Active and 
Inactive, in the cancer-adjacent extra-tumoral microenvironment of breast tissues and 
demonstrated that TWIST1 was highly expressed along with other stromal associated genes such as 
VIM, ADAMTS2, COL4A2, COL4A1, ITGA7, and ITGB1 in the Active subtype. This could suggest a 
potential involvement of TWIST1 in the activation of stroma in malignant breast tissue. 
Furthermore, the Active subtype was associated with expression of TGF-beta induced fibroblast 
activation signatures, and showed a strong association with OS among specifically ER-positive 
patients. Intriguingly, also in our data set, the association of TWIST1 with the TGF-beta signaling 
pathway appears to be more prominent in ER-positive tumors. 
Another recent study also demonstrated that TWIST1 protein can be found in both compartments 
of malignant breast tissue, with a predominant expression in the stromal compartment37. More 
importantly, they found that, although rare in their hands, nuclear expression of TWIST1 protein in 
the epithelial tumor cell compartment to be associated with poor prognosis (OS). TWIST1 protein 
expression in the stromal compartment was not associated with OS, but positively associated with 
a positive ER or PGR status of the tumors.  
This mutual dependence of TWIST1 expression on the presence of a notable stromal component 
and an ER-positive status of the tumor tissue in our and other studies is in line with the observed 
prognostic value of TWIST1 in ER-positive disease only. Although our study is a correlative study 
and cannot reveal causality, it is intriguing and points to a novel role of TWIST1 in breast cancer.  
What is surprising about our results, which associate high TWIST1 mRNA expression with poor 
prognosis in ER-positive breast cancer and with ECM and stromal content, is the fact that up until 
now the process of EMT has been more frequently assigned to ER-negative cancer and was rarely 
observed in ER-positive breast cancer. Also, previously studied breast cancer cell lines with clear 
EMT-like features were ER-negative38. This left us with an apparent contradiction. We, therefore, 
specifically explored whether markers of EMT present on gene expression arrays 11 were associated 
with TWIST1 expression. Of the eight markers analyzed, we found Zinc finger E-box-binding 
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homeobox 1 (ZEB1), Zinc finger E-box-binding homeobox 2 (ZEB2), Snail2 (SNAI2), Smooth muscle 
actin also known as Alpha-actin-2 (ACTA2) and VIM clearly positively correlated with TWIST1 
expression (Rs = 0.34, 0.34, 0.35, 0.42, and 0.28 respectively; all P values <0.001; Additional file 6.3, 
Table S15). This does, in line with the recent study of Roman-Perez and colleagues [28] suggest that 
markers of EMT are co-expressed with TWIST1. However, the lack of a clear negative association of 
E-cadherin mRNA (CDH1) with TWIST1 mRNA expression in our data set could indicate that EMT 
may not be fully established. Alternatively, and more in line with our findings, is that some markers 
of EMT such as Vimentin and Smooth muscle actin are also expressed in re-activated stroma39. 
Therefore, our findings are a starting point for more functional studies to be certain about TWIST1 




In summary, we have found that TWIST1 mRNA expression level is associated with small tumor size, 
invasive lobular carcinoma, stromal-rich tumors and with PGR and ERBB2 (over)expression. More 
importantly, TWIST1 mRNA expression predicts, independently of the traditional prognostic factors, 
poor prognosis in patients with primary breast cancer. This association with poor prognosis is 
particularly observed in ER-positive disease. For this large retrospective study that involved 1,427 
breast cancer specimens, we made use of all clinical material available that met the preset criteria 
described in Figure 1, thus reaching Level of Evidence III (LOE-III). To reach LOE-I or II, a prospective 
randomized study or pooled meta-analysis is required. Studying TWIST1 co-expressed genes, we 
found that ECM related pathways as well as stromal content are correlated with TWIST1 mRNA 
expression in LNN/ER-positive breast cancer. Functional studies are therefore required to 
determine the causal relation between these pathways and the prognostic value of TWIST1 mRNA 




ACTA2: alpha-actin-2; BM2: beta-2-microglobulin; CI: confidence interval; ECM: extracellular matrix; 
EMT: epithelial to mesenchymal transition; EpCAM: epithelial cell adhesion molecule; ER: estrogen 
receptor; PGR: progesterone receptor; ERBB2: erythroblastic leukemia viral oncogene homolog 2; 
ESR1: estrogen receptor 1; GEO: gene expression omnibus; GO: gene ontology; H&E: hematoxylin 
and eosin; HER2: human epidermal growth factor receptor 2; HMBS: hydroxymethylbilane 
synthase; HPRT1: hypoxanthine phosphoribosyltransferase 1; HR: hazard ratio; IDC: invasive ductal 
carcinoma; IHC: immunohistochemistry; ILC: invasive lobular carcinoma; KEGG: kyoto encyclopedia 
of genes and genomes; LCM: laser capture microdissection; LNN: lymph node-negative; MFS: 
metastasis-free survival; OS: overall survival; PEN: polyethylene naphthalate; Q: quartile; RT-PCR: 
reverse transcriptase polymerase chain reaction; SP: stromal poor; SR: stromal rich; TWIST1: Twist-
related protein 1, also known as a basic helix-loop-helix protein 38 (bHLHa38); VIM: vimentin; ZEB1: 
zinc finger e-box-binding homeobox 1; ZEB2: zinc finger e-box-binding homeobox 2.  
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ABSTRACT 
 
Introduction Breast cancer is a genetically and phenotypically complex disease. To understand the 
role of microRNAs (miRNAs) in this molecular complexity, we performed miRNA expression analysis 
in a cohort of molecularly well-characterized human breast cancer (BC) cell lines to identify miRNAs 
associated with the most common molecular subtypes and the most frequent genetic aberrations.   
Methods Using a microarray carrying LNA™ modified oligonucleotide capture probes (Exiqon), 
expression levels of 725 human miRNAs were measured in 51 BC cell lines. MiRNA expression was 
explored by unsupervised cluster analysis and then associated with the molecular subtypes and 
genetic aberrations commonly present in breast cancer.  
Results Unsupervised cluster analysis using the most variably expressed miRNAs divided the 51 BC 
cell lines into a major and a minor cluster predominantly mirroring the luminal and basal intrinsic 
subdivision of BC cell lines. One hundred and thirteen miRNAs were differentially expressed 
between these two main clusters. Forty miRNAs were differentially expressed between basal-like 
and normal-like/claudin-low cell lines. Within the luminal-group, 39 miRNAs were associated with 
ERBB2 overexpression and 24 with E-cadherin gene mutations, which are frequent in this subtype of 
BC cell lines. In contrast, 31 miRNAs were associated with E-cadherin promoter hypermethylation, 
which, contrary to E-cadherin mutation, is exclusively observed in BC cell lines that are not of 
luminal origin. Thirty miRNAs were associated with p16INK4 status while only a few miRNAs were 
associated with BRCA1, or PIK3CA/PTEN, TP53 mutation status. Twelve miRNAs were associated with 
DNA copy number variation of the respective locus.  
Conclusion Luminal-basal and epithelial-mesenchymal associated miRNAs determine the 
subdivision of miRNA transcriptome of BC cell lines. Specific sets of miRNAs were associated with 
ERBB2 overexpression, p16INK4aor E-cadherin mutation or E-cadherin methylation status, which 
implies that these miRNAs may contribute to the driver role of these genetic aberrations. 
Additionally, miRNAs, which are located in a genomic region showing recurrent genetic 
aberrations, may themselves play a driver role in breast carcinogenesis or contribute to a driver 
gene in their vicinity. In short, our study provides detailed molecular miRNA portraits of BC cell 
lines, which can be exploited for functional studies of clinically important miRNAs.    
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INTRODUCTION 
 
It is becoming apparent that breast cancer (BC) is genetically and epigenetically not just one 
disease but a diverse group of diseases with diverse clinically relevant biological and phenotypical 
features. Recent technological advances in molecular profiling have led to the identification of an 
increasing number of molecular subtypes in breast cancer, each with distinct co- and anti-
regulated genes. However, the biology of these molecular subtypes and their underlying genetic 
drivers may be affected by numerous biological factors including miRNAs. MiRNAs are a class of 
small non-protein-coding genes, which regulate the expression of genes post-transcriptionally via 
sequence-specific interaction with the 3’ untranslated region (UTR) of target mRNAs resulting in 
inhibition of translation and/or mRNA degradation1,2. A large number of studies have established 
that miRNAs play essential roles in biological processes, such as development3,4, cell proliferation 5, 
apoptosis 6, stress response, and tumorigenesis 7,8. Aberrant expression levels of miRNAs have been 
observed in many solid cancers including breast cancer. In breast cancer, the expression levels of 
several miRNAs are significantly different between normal and cancerous tissues, between breast 
cancers of different molecular subtypes9-11, with a different prognosis12-14, and with breast cancers 
showing different response to endocrine therapy15,16. Despite the significant progress in the last 
few years, the exact biological functions and the genetic factors driving their expression have been 
revealed for only a limited number of breast cancer miRNAs. 
Human BC cell lines are excellent experimental models and renewable resources to investigate 
biological functions of clinically important miRNAs both in in vitro cultured conditions and in vivo 
when raised as xenografts6,17-20. Here, using microarrays we analyzed miRNA expression levels in 51 
molecularly well-characterized human BC cell lines. We explored the association of individual 
miRNA expression levels with intrinsic subtypes and the most common recurrent genetic 
aberrations. By doing this, we provide a catalog of miRNAs in human BC cell lines, which can be 
used to understand underlying biology of clinically relevant miRNAs and to reveal the genetic 
factors that may be involved in their regulation. 
 
MATERIALS AND METHODS 
 
Breast cancer cell lines 
The cohort of 51 human breast cancer cell lines used in this study is listed in Table 7.1. The origin of 
the cell lines has been described elsewhere21. Prior to expression profiling, all cell lines were 
established to be genetically unique, monoclonal and of correct identity by performing short 
tandem repeat (STR) profiling using the PowerPlex® 16 System (Promega, Madison, WI, USA). The 
PowerPlex® 16 system included fifteen STRs and one gender discriminating locus (Penta E, D18S51, 
D21S11, TH01, D3S1358, FGA, TPOX, D8S1179, vWA, Amelogenin, Penta D, CSF1PO, D16S539, 
D7S820, D13S317, and D5S818). The method involved isolation of the genomic DNA from each BC 
cell line using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and 10 ng of the isolated DNA was 
used as input for the multiplex PCR. The following PCR conditions were used: 95°C for 11 min, 96°C 
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for 1 min, 10x (94°C for 30 sec, 60°C for 30 sec, 70°C for 45 sec), 22x (90°C for 30 sec, 60°C for 30 sec, 
70°C for 45 sec), and then 60°C for 30 min. The PCR was carried out using primers linked with 
fluorescent dyes (6-carboxy-4’, 5’-dichloro-2’, 7’-dimethoxy-fluorescein, Fluorescein, and Carboxy-
tetramethylrhodamine). The labeled amplicons were detected using the 3130xl Genetic Analyzer 
(Applied Biosystems, USA) and data was analyzed using the Genemarker 1.91 software from 
Softgenetics. The end result for each cell line was an electropherogram with each STR allele 
represented as one or more peaks of an appropriate fluorophore. The authenticity of all cell lines 
except SUM cell lines, were assessed by comparing the generated STR profiles with the source STR 
profiles present in the American Type Culture Collection (ATCC) and the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ). As no reference is available, the STR profiles of the SUM 
cell lines were matched with the profiles generated from the earliest passage of these cell lines 
stored in the in-house culture collection. 
For experiments, each cell line was cultured in triplicate on collagen-coated petri dishes in RPMI 
1640 medium supplemented with 10% heat-inactivated fetal bovine serum and antibiotic agents 
(100 μg/ml penicillin G and 80 μg/m streptomycin (P/S). The petri dishes were placed in a 
humidified atmosphere of 5% CO2 and 95% air at 37°C until cultures were 70-80% confluent. 
 
Table 7.1 Molecular and biochemical characterization of 51 human breast cancer cell lines 
Cell lines 
Molecular classification Clinically relevant protein expression 
Intrinsic subtype$ ER PGR ERBB2 EGFR CK5 CK8-18 CK19 CK14
SUM185PE Luminal  – – – – – + + –
MDA-MB-175VII Luminal  + – – – – + + –
BT483 Luminal  + – – – – + + –
T47D Luminal  + + – + – + + –
MDA-MB-415 Luminal  + + – – – + + –
ZR75-1 Luminal  + + – – – + + –
MCF-7 Luminal  + + – – – + nd –
SUM52PE Luminal  + – – – – + nd –
UACC812 Luminal  + + ++ – – + + –
MDA-MB-361 Luminal  + + ++ – – + + –
ZR75-30 Luminal  + – ++ – – + + –
SK-BR-5 Luminal  – – ++ – – + + –
OCUB-F Luminal  – – ++ – + + + –
MPE600 Luminal  + – ++ – – + + –
MDA-MB-134VI Luminal  + – – – – + + –
SUM44PE Luminal  + + – – – + + –
CAMA-1 Luminal  + – – – – + + –
BT474 Luminal  + + ++ – – + + –
MDA-MB-330 Luminal -ERBB2 + + – ++ – – + + –
HCC1419 Luminal -ERBB2 + + – ++ – – + + –
HCC202 Luminal -ERBB2 + – – ++ – – + + –
SUM190PT Luminal -ERBB2 + – – ++ – – + + –
SUM225CWN Luminal -ERBB2 + – – ++ – – + + –
UACC893 Luminal -ERBB2 + – – ++ + – + + –
SK-BR-3 Luminal -ERBB2 + – – ++ – – + + –
EVSA-T Luminal -ERBB2 + – + ++ – – + + –
MDA-MB-453 Luminal -ERBB2 + – – ++ – – + + –
HCC1569 ER-negative-ERBB2 + – – ++ + – – – –
HCC1954 ER-negative-ERBB2 + – – ++ + + + – –
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Table 7.1 Continued  
Cell lines 
Molecular classification Clinically relevant protein expression 
Intrinsic subtype$ ER PGR ERBB2 EGFR CK5 CK8-18 CK19 CK14
HCC1500 ER-negative-ERBB2 + + + – – – + + –
DU4475 Other – – – – + – – –
SUM229PE Basal-like – – – + + + + –
HCC1937 Basal-like – – – + + + – –
MDA-MB-468 Basal-like – – – + + + + –
HCC1806 Basal-like – – – + + + + +
HCC70 Basal-like – – – + + + + –
HCC1143 Basal-like – – – + + + + –
BT20 Basal-like – – – + + + + –
SUM149PT Basal-like – – – + + + + –
HCC1395 Basal-like – – – + + – – –
SK-BR-7 Normal-like/claudin-low – – – + – + – –
Hs578T Normal-like/claudin-low – – – + – – – –
MDA-MB-231 Normal-like/claudin-low – – – + – – – –
SUM1315M02 Normal-like/claudin-low – – – + – – – –
MDA-MB-436 Normal-like/claudin-low – – – + – – – –
BT549 Normal-like/claudin-low – – – + – – – –
MDA-MB-157 Normal-like/claudin-low – – – + – – – –
SUM159PT Normal-like/claudin-low – – – + – – – –
MDA-MB-435s Normal-like/claudin-low – – – – – – – –
SUM102PT Normal-like/claudin-low nd nd nd nd nd nd nd nd
HCC38 Normal-like/claudin-low nd nd nd nd nd nd nd –
$ Cell lines are classified based on expression of the intrinsic gene set defined by Perou and colleagues 23 
For protein expression: +, expression; ++, overexpression; –, no expression; and nd, not determined. 
Other subtype includes DU4475 since it is not classified to any subtype of breast cancer by intrinsic gene set. 
 
Total RNA isolation  
Total RNA from all samples was isolated using RNAzol-B reagent (Campro Scientific BV, Veenendaal, 
The Netherlands) according to the manufacturer’s manual. Briefly, a biological sample was lysed in 
RNAzol-B reagent and the lysate was separated into an aqueous and an organic phase after the 
addition of chloroform. DNA and protein were subsequently removed by carefully transferring the 
aqueous phase containing RNA to a fresh eppendorf. The RNA was obtained from the aqueous 
phase by an isopropanol precipitation, washed with ethanol and air dried for subsequent 
procedures. The purity of the isolated RNA was checked using NanoDrop® ND-1000 ensuring 
spectrophotometric ratios of A260nm/A280nm ~ 2 and A260nm/A230nm ≥ 2 and the quality 
control checks were performed according to the previously described methodology22.  
 
Gene expression profiling 
Two hundred ng of total RNA was reverse transcribed, copied into double strand cDNA and labeled 
to yield biotin-labeled cRNA using the 3′ IVT express Kit (Affymetrix, Santa Clara, CA, USA) 
according to the manufacturer’s instructions. Biotin labeled cRNA was subsequently fragmented 
and loaded onto an Affymetrix GeneTitan instrument. The hybridization cocktail was applied to 
Human Genome HT_HG-U133_Plus_PM GeneChip 96-well arrays. All steps including hybridization, 
washing and scanning were carried out automatically inside the instrument. The raw data (.CEL 
files) were normalized by RMA method using the default settings of the Affymetrix® Expression 
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Console™ software and used for statistical analysis. The microarray data has been deposited to Gene 
Expression Omnibus (GEO) data repository under the accession number GSE41313. 
For subtype classification of the cell lines, Perou’s intrinsic gene set of 496 genes23 were matched to 
the Affymetrix probe sets using Unigene cluster numbers. Some of the genes have multiple probe 
sets present. To ensure analysis of only the informative probe sets, the probe sets that did not vary 
across all samples were removed, leaving the most variable ones for analysis (66% of the probe 
sets). These genes were then used to cluster the BC cell lines. The intrinsic molecular subtypes were 
assigned as follows: luminal-type cell lines that exhibited higher expression of ESR1, GATA3, TFF3, 
FOXA1; ERBB2-positive cell lines that showed higher expression of ERBB2, GRB7, STARD3; basal-like 
cell lines, which were characterized by higher expression of KRT5, KRT17, BST2, FABP7; and normal-
like/claudin-low cell lines that did not show KRT5, KRT17 expression and have low expression of 
claudin 3, 4, and 7 genes. The ERBB2-positive cell lines were further designated as luminal-ERBB2-
positive and ER-negative/ERBB2-positive cell lines as the former in addition to ERBB2 
overexpression also show ESR1 gene expression on microarray while the latter do not. 
 
miRNA expression analysis 
The miRNA expression profiling was performed using miRNA microarrays according to previously 
published method24. In brief, 1 μg of total RNA was labeled with Cy3 using the ULS aRNA labeling 
kit (Kreatech, Amsterdam, The Netherlands). The LNA™ modified oligonucleotide capture probe set 
(Exiqon Vedbaek, Denmark, miRBase version 10.0, annotation version 13) was spotted in duplicate 
on Nexterion E glass slides in Nexterion Spot buffer using a Virtek Chipwriter Pro. The RNA sample 
with a labeling efficiency over 15 pmol Cy3/μg RNA was used for hybridization in a salt-based 
hybridization buffer (Ocimum Biosolutions) overnight at 60°C using a Tecan HS4800 pro 
hybridization station. Hybridized slides were scanned in a Tecan LS Reloaded scanner. Data was 
extracted using Imagene software (6.0 standard edition). The raw data were normalized using 
quantile normalization and used for statistical analysis. The normalized expression data is provided 
in Additional file 7.1: Table S1. 
 
SNP arrays 
Genomic DNA from all cell lines was extracted using QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany). Five hundred ng of genomic DNA was used as starting material to capture genome-
wide chromosomal aberrations with the aid of the Affymetrix Genome-Wide Human SNP 6.0 array 
technology. The steps were performed according to Affymetrix's recommended protocols 
(Affymetrix, Santa Clara, CA, USA). In summary, after digestion of the genomic DNA using either 
restriction enzymes NspI or StyI, adaptors were ligated to the obtained DNA fragments. These 
fragments were subsequently amplified using PCR, fragmented, end-labeled with biotin and 
hybridized onto GeneChip SNP 6.0 arrays. After hybridization the arrays were washed and scanned 
to generate the raw data (.CEL files) using the Affymetrix® Genotyping Console™ Software. The 
chromosomal gains and losses were calculated using SNP copy numbers variation on the same 
chromosome. The chromosomal regions containing gains or losses were correlated with the 
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expression level of the miRNAs located on the same genomic regions. The SNP data have been 
deposited to GEO data repository under the accession number GSE41313. 
 
Protein expression and mutational analysis 
Protein expression data of ER, PGR, ERBB2, EGFR, and cytokeratin (CK) 5, CK8-18, CK19, and CK14 
were used from previously published work25 except for 10 HCC cell lines, which were characterized 
by immunohistochemistry using the same protocols as described before25. Mutational analysis of 
p16INK4a, BRCA1, E-cadherin, PIK3CA, and PTEN genes and promoter hypermethylation analysis of E-
cadherin gene were previously reported for all cell lines except for HCC cell lines. These were 
separately analyzed according to the previously published methods25 and the data is provided in 
Additional file7.1: Table S2.  
 
Hierarchical clustering and statistical analyses 
Hierarchical clustering analyses of significant miRNAs were performed using Cluster 3 software26 
and the expression patterns of miRNAs and mRNAs in the heat maps were visualized using 
Treeview 1.1.6 R2. Average linkage clustering was carried out on both samples and mRNA and 
miRNA expression data respectively, using Pearson correlation as a distance measure. Differential 
expression of miRNAs between two groups was determined using univariate t-tests in BRB-array 
tools 3.7. A permutation P-value <0.05 was considered to be statistically significant and used to 
select differentially expressed miRNAs for supervised hierarchical cluster analysis. The associations 
between continuous variables were tested using Spearman Rank correlation (Rs). Kruskal-Wallis 





Molecular features of human breast cancer cell lines  
The 51 human BC cell lines that were used in this study are listed in Table 7.1 together with the 
protein expression results of ER, PGR, ERBB2, EGFR and CK5, 8-18, 19, and 14. All cell lines were first 
profiled for global mRNA expression using microarrays and the cell lines in Table 1 are grouped 
into molecular subtypes based on the expression of the intrinsic genes originally described by 
Perou and colleagues23. A Pearson correlation based on the top 10% variably expressed genes 
classified the cell line cohort into two obvious groups (Figure 1). The first major group included 27 
cell lines of which 17 expressed ER protein. All cell lines in this group showed higher expression of 
luminal intrinsic genes as defined by Perou and colleagues23. We therefore defined this group of BC 
cell lines as “luminal-group” (Figure 7.1, left block). On the other hand, the second group included 
23 BC cell lines, all of them were ER-negative and showed a predominant expression of basal 
intrinsic genes. We defined this group of BC cell lines as “ER-negative/basal-group” (Figure 7.1, 
right block). Moreover, according to classification using the intrinsic gene expressions23, the 
luminal-group included 9 ERBB2 overexpressing BC cell lines, which did not cluster as a separate 
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The other two cell lines (HCC38 and SUN102PT) remained undetermined for protein analysis due to 
technical reasons. On the other hand 29 of 33 BC cell lines present in the major cluster were of the 
luminal-type, and all cell lines except SUM185 exhibited either one of the hormone receptor 
proteins or showed ERBB2 protein expression. The DU4475 cell line, which was previously 
proposed to have a stem cell-like phenotype due to activation of the Wnt signaling pathway25,28, 
clustered at the edge of the major cluster. As a whole, similar to mRNA expression, miRNA 
expression profiling discriminated cell lines into two major subtypes of breast cancer.  
Among the 87 most-variable expressed miRNAs across the entire panel, a group of 15 miRNAs (hsa-
miR-130a, hsa-miR-886-5p, hsa-miR-886-3p, hsa-miR-222, hsa-miR-21*, hsa-miR-29a, hsa-miR-23a, 
hsa-miR-24, hsa-miR-30a, hsa-miR-27a, hsa-miR-22, hsa-miR-532-3p, hsa-miR-100, hsa-miR-125b, hsa-
miR-221) was significantly higher expressed in the minor cluster as opposed to other miRNAs 
(Figure 7.2, top red box). Another group of 17 miRNAs (hsa-miR-575, hsa-miR-155, hsa-miR-26b, hsa-
miR-200a, hsa-miR-200b, hsa-miR-141, hsa-miR-200c, hsa-miR-190b, hsa-miR-492, hsa-miR-640, hsa-
miR-196a, hsa-miR-29c, hsa-miR-93, hsa-miR-193a-3p, hsa-miR-191, hsa-miR-26a, hsa-miR-182) 
showed significantly higher expression in the major cluster compared to the other miRNAs (Fold 
change > 1.5) (Figure 7.2, bottom red box).  
As the miRNA-driven major and minor clusters included ER-positive (18 of 33) and ER-negative (all) 
cell lines, respectively, we determined whether differential expression of miRNAs between the two 
clusters is driven by ER status of the cell lines. For this, we grouped cell lines into ER-positive and 
ER-negative based on mRNA expression of ER and performed supervised cluster analysis on these 
groups. We identified 79 differentially expressed miRNAs between ER-positive and ER-negative cell 
lines (P <0.05) (Additional file 7.2: Figure S1 and Additional file 7.1: Table S3), of which 54 miRNAs 
were common to the 113 miRNAs that were differentially expressed between the two clusters 
identified through unsupervised analysis (Additional file 7.1: Table S4). Interestingly, however, 59 
miRNAs were uniquely differentially expressed between the two miRNA-driven clusters whereas 25 
miRNAs were uniquely related to ER status of the cell lines (Additional file 7.1: Table S5).   
 
MiRNAs expression of cell lines associated with molecular intrinsic subtypes of breast cancer  
Next, we aimed to identify miRNAs, which are differentially expressed between the intrinsic 
subtypes of breast cancer. As expected, we observed a substantial overlap of differentially 
expressed miRNAs between the luminal-group and ER-negative/basal-group of cell lines and those 
between ER-positive and ER-negative cell lines (Additional file2: Figure S1, Additional file7.1: Tables 
S3 and S6). To identify additional miRNAs, which are related to intrinsic subtypes but to avoid the 
confounding effect of ER, we compared cell lines with and without ERBB2 overexpression within 
the luminal-group. Likewise we compared the intrinsic basal-like cell lines with normal-like/claudin-
low cell lines within the ER-negative/basal-group. These comparisons revealed 39 differentially 
expressed miRNAs  in luminal cell lines with or without overexpressed ERBB2; 40 miRNAs were 
found differentially expressed between basal-like and normal-like/claudin-low cell lines (P <0.05) 
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MiRNA genes show genomic aberrations in breast cancer cell lines 
It is evident from previous studies that DNA copy number variations (CNVs) in breast tumor tissues 
can lead to differential expression of genes and miRNAs32-34. To investigate this in our cohort of BC 
cell lines, we first determined the DNA copy number variations of the cell lines by performing 
whole genome SNP profiling. These CNVs were then correlated with the expression levels of the 87 
most variably expressed miRNAs in the cell lines. The correlation revealed 12 miRNAs, which were 
significantly associated with DNA CNVs (Kruskal-Wallis test, P <0.05) (Additional file 7.1: Table S17). 
The top 4 most significantly associated miRNAs; hsa-miR-130a (11q12.1), hsa-miR-22 (17p13.1), hsa-




Human BC cell lines are renewable resources that are extensively utilized as reliable workhorses to 
explore biological functions of clinically relevant molecules in breast cancer. An extensive 
molecular characterization and gene mutation analysis by us and others have suggested that BC 
cell lines have retained significant molecular features that are commonly observed in clinical breast 
tumors35,36. This prompted us to use 51 human BC cell lines as a discovery cohort to identify 
differentially expressed miRNAs between known intrinsic subtypes of breast cancer as well as those 
associated with common genetic aberrations present in the cell lines.  
In this study, we demonstrated that global miRNA expression profiling can assign our cell line 
collection into two clusters. These two clusters predominantly mirror the ER-based dichotomy 
present in human BC cell lines, which may point to the fact that like mRNA, miRNA expression 
profiling allows the discrimination between ER-positive and ER-negative cell lines. This suggests 
that a significant number of miRNAs may be under the control of ER regulation. Interestingly, not 
all miRNA discriminating ER-positive and ER-negative cell lines are associated with ER status and 
therefore the division of the cell lines into two clusters may not be purely dictated by the 
expression of ER related miRNAs, but is likely that these miRNAs are also related to luminal versus 
basal cellular differentiation. 
Our supervised analysis revealed a signature of 79 differentially expressed miRNAs between ER-
positive and ER-negative cell lines, which included some of the previously known ER related 
miRNAs, such as a cluster of hsa-miR-221/22212,37. These miRNAs have been shown to interact 
directly with ER and cause a phenotypic shift from ER-positive to ER-negative tumor cells37. Our 
miRNA analyses in this cohort of cell lines therefore not only confirm some of the previous findings 
but also reveal new miRNAs (mentioned below), which may have potentially interesting biological 
roles in ER-driven cancer.  
Among these potentially ER-related miRNAs, four miRNAs; hsa-miR-26a, hsa-miR-92b, hsa-miR-191, 
and hsa-miR-492 appear to show consistently higher expression across all the ER-positive cell lines 
(Fold change > 1.5) and as yet have not been implicated in breast carcinogenesis. Among them, 
hsa-miR-26a and hsa-miR-92b have previously been implicated in brain tumors38,39. The hsa-miR-26 
miRNA interacts with CDK4 and CENTG1 oncogenes and forms an integrated oncomir/oncogene 
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DNA cluster, which promotes glioblastoma tumor growth via RB1, PI3K/AKT, and JNK pathways38. 
On the other hand, hsa-miR-92b has been found to be exclusively over expressed in primary brain 
tumors but serves as a biomarker to discriminate brain primary cancer from metastasis39. The other 
two miRNAs, hsa-miR-191 and hsa-miR-492 have been linked to hepatic cancer. The increased 
expression of hsa-miR-191 stimulates proliferation in hepatocellular carcinoma cell lines and its 
therapeutic targeting suppresses tumor masses in vivo40. The hsa-miR-492 miRNA has been shown 
to be processed from keratin 19 gene and upregulated in metastatic hepatoblastoma41. How these 
miRNAs play their biological roles in the context of breast cancer remains unknown and demands 
clinical and functional validation studies. 
Another major contribution to the overall miRNA profiling of this cell line cohort is the 
identification of a signature of 42 differentially expressed miRNAs, which discriminates between 
basal-like and normal-like/claudin-low BC cell lines. These miRNAs together with the ER-associated 
miRNAs are the major determinants of the overall clustering of the cell lines. Importantly, this 
signature includes all four members of hsa-miR-200 family (hsa-miR-200a, hsa-miR-200b, hsa-miR-
200c, hsa-miR-141), hsa-miR-155, and hsa-miR-622 miRNAs. Several studies have implicated these 
miRNAs to be involved in EMT, to be related to the stem cell like phenotype and to be associated 
with a switch in paclitaxel responsiveness42-45. In breast cancer, these miRNAs are known to regulate 
the EMT process by targeting the ZEB family of the transcription factors through an active negative 
feedback loop46,47. Importantly, the ZEB family of transcription factors was reported to be a 
repressor of E-cadherin expression in several epithelial carcinomas including breast carcinoma. Our 
finding that the hsa-miR-200 cluster showed lower expression in normal-like/claudin-low BC cell 
lines fits with the fundamental literature that these miRNAs are indeed involved in EMT as the 
majority of the normal-like/claudin-low cell lines lack E-cadherin protein expression, exhibit low 
claudin expression, and generally display EMT like features as well as the BC stem cell phenotype 
(CD44high/CD24low)48-50 and (Hollestelle et al, submitted). Other known significant miRNAs of this 
signature are hsa-miR-155 and hsa-miR-622, which were also linked to enhanced tumorigenesis in 
various cancer types besides breast cancer51,52. In concordance with this, we recently found that the 
normal-like/claudin-low cell lines with low expression of these EMT-related miRNAs show highly 
aggressive growth characteristics in vivo when raised as xenografts in nude mice (Riaz et al, 
unpublished data). Importantly, this signature includes three previously unknown miRNAs (hsa-
miR-492, hsa-miR-26b, hsa-miR-617; Fold change > 1.5) to be associated with cell lines frequently 
showing EMT like characteristics. 
We observed that the miRNA signatures associated with E-cadherin mutation and promoter 
hypermethylation include distinct miRNAs. This may point to an existence of unique biology at the 
miRNA level in tumors that show E-cadherin inactivation due to gene mutation rather than those 
that lose E-cadherin expression due to promoter hypermethylation. It is important to mention that 
E-cadherin promoter hypermethylated cell lines include all normal-like/claudin-low cell lines and 
most EMT-related miRNAs were also associated with E-cadherin promoter hypermethylation.  
With respect to common genetic aberrations present in BC, our study reveals differentially 
expressed miRNA signatures associated with commonly mutated tumor suppressors and 
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oncogenes. Most significantly, a signature of 30 miRNAs associated with p16INK4a mutant cell lines 
can strongly discriminate between mutant and wild-type ER-negative cell lines. P16INK4a is a tumor 
suppressor gene, which is located on chromosomal band 9p21 that has been frequently altered in 
many human cancers 53. It regulates the cell cycle by targeting CDK 4/6 through the pRb signaling 
pathway. Interestingly, this signature includes some miRNAs, which are involved in cell cycle 
regulation. For instance, miRNAs hsa-miR-100, which is highly expressed in the p16INK4a wild-type 
cell lines, targets the RBSP3 gene that in acute myeloid leukemia regulates the cell cycle through 
partial modulation of pRB/E2F154. Hsa-miR-34a has been reported as a suppressor of cell 
proliferation and migration in colon cancer55 and its mechanism of growth inhibition also involves 
cell cycle arrest followed by apoptosis56. Besides this, we found a few miRNAs to be only associated 
with mutation in BRCA1, TP53 and PIK3CA/PTEN; these observed associations require further 
independent validation in breast cancer specimen. 
Our finding that the differential expression of miRNAs is associated with ERBB2 overexpressing 
luminal-type cell lines is also intriguing since the miRNAs showing elevated expression in ERBB2-
positive cell lines (Fold change > 1.5) are not located on the ERBB2 amplicon (17q12) and thus may 
be regulated indirectly by genes in the ERBB2 amplicon. It is also important to mention that a 
majority of these miRNAs have already been implicated in various types of epithelial carcinoma 
including breast cancer57-61. It should however be noted that our study is associative and does not 
necessarily reveal causality. We therefore propose functional studies on these miRNAs to reveal 
more biological insights into their role regarding ERBB2 overexpression in breast cancer.   
Finally, we also identified 12 miRNAs to be associated with CNVs in BC cell lines (Additional file 7.1: 
Table S17). Majority of these miRNAs (hsa-miR-130a, hsa-miR-93, hsa-miR-383, hsa-miR29c, hsa-miR-
382, hsa-miR-31) were already found to be located in regions that exhibited DNA copy number 
abnormalities in breast cancer tumors62. Importantly, this repertoire of miRNAs includes hsa-miR-22 
previously shown to be regulated by ER63 and we provide evidence that it can also be regulated by 
the loss of the locus containing this miRNA. Six miRNAs of this repertoire are located in the 
genomic regions containing known protein coding. All miRNAs of this repertoire have also been 
implicated in various cancers but a thorough validation of these miRNAs with respect to DNA copy 




In summary, our analyses show that the dichotomy in breast cancer cell lines is, in line with the 
general consensus in the field, related to ER status. However, part of this dichotomy may be related 
to ER-independent luminal versus basal differentiation status of cell lines. Secondly, another 
prominent dichotomy observed among BC cell lines discriminating basal-like from normal-
like/claudin-low cell lines involves miRNAs related to EMT and/or stemness. Furthermore, we reveal 
sets of miRNAs associated with genes frequently amplified (ERBB2) or mutated (p16INK4a, PIK3CA 
and/or PTEN, E-cadherin, BRCA1) in BC cell lines and thus these miRNAs may contribute to the 
function of these oncogenes/tumor suppressors. Finally, certain miRNAs themselves are located in 
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genomic regions, which frequently show genetic aberrations implying that these miRNAs 
themselves may have a potential driver role or contribute to known drivers in these genomic 
regions. Our current findings call for further validation of these signatures in clinical specimens. 
Importantly, our study provides a unique molecular miRNA portrait of human breast cancer cell 




ATCC, american type culture collection; BC, breast cancer; BRB, biometric research branch; BRCA1, 
breast cancer 1; BST2, bone marrow stromal cell antigen 2; CK, cytokeratin; CDKs, cyclin-dependent 
kinases; CNVs, copy number variations; DSMZ, deutsche sammlung von mikroorganismen und 
zellkulturen; EMT, epithelial to mesenchymal transition; ER, estrogen receptor-α; ERBB2, 
erythroblastic leukemia viral oncogene homolog 2; ESR1, estrogen receptor; EGFR, epidermal 
growth factor receptor; FABP7, fatty acid binding protein 7; FOXA1, forkhead box protein A1; GEO, 
gene expression omnibus;  GRB7, growth factor receptor-bound protein 7; JNKs, c-Jun N-terminal 
kinases; KRT, keratin; PGR, progesterone receptor; PI3K, phosphoinositide 3-kinase; PTEN, 
phosphatase and tensin homolog; RB, retinoblastoma protein; STR, short tandem repeat; STARTD3, 
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ABSTRACT 
 
Introduction Conventional and molecular profiling has shown that breast cancer (BC) is a group of 
multiple diseases with a considerable amount of intra- and inter-tumor heterogeneity. This 
heterogeneity has led to the subdivision of BC into several molecular subtypes, each with a distinct 
type of response to therapy, metastatic potential and prognosis. Human BC cell lines are available 
as model systems; however few are used as in vivo experimental models. Thus, models 
representing the wide variety of breast cancer phenotypes in the clinic are largely not available. 
Here, we explored the in vivo growth potential and metastatic behavior of 24 human BC cell lines 
representing four molecular subtypes to generate useful models for experimentation and to 
determine whether these cell lines recapitulate in mice their subtype-related biological behavior.  
Methods To study and image biological behavior of BC cell lines in mice, the cells were transduced 
using lentivirus particles with a luciferase reporter gene. Subsequently, per cell line 3 independent 
monoclonal clones with similar luciferase activity and molecular features comparable to the 
parental lines were generated and implanted orthotopically under the mammary fat pad of nude 
mice. Xenograft tumor growth was monitored by measuring tumor size twice a week for a period 
of 12 months. At the end of the experiment, using the IVIS Imaging System, tumor size and 
presence of distant organ metastases were assessed by measuring the tumor bioluminescence. 
Subtype specific differences in tumor growth and mice survival were compared using a Kruskal-
Wallis test and Cox regression analysis. A P-value < 0.05 was considered to be statistically 
significant. 
Results 87.5% of the cell lines gave rise to xenografts in the mammary fat pad of recipient mice. A 
clear difference in BC xenograft growth and tumor-related survival was observed between 
molecular subtypes (P =0.01 Kruskal-Wallis test). Normal-like/claudin-low and basal-like BC cell 
lines were found to be more aggressive in mice and showed poor tumor-related survival (HR: 6.89; 
95% CI: 1.96-24.22; P =0.003 and HR: 4.30; 95% CI: 1.11-16.75; P =0.04, respectively). The most 
common sites colonized by BC cell lines in mice were lymph-nodes, lungs, liver, and ovaries. 
Relapses to other sites such as bone, brain, and pancreas were rarely observed during the 
maximum of 12 months of the experiments. No clear association between BC subtype and type of 
distant organ metastasis was observed.  
Conclusions We established a panel of 21 xenografts from a molecularly diverse collection of 
human BC cell lines. Comparable to clinical behavior in human, we observed that normal-
like/claudin-low cell lines were more aggressive in mice than the cell lines of other molecular 
subtypes. Although no relationships between subtype and site of relapse was observed, a large 
variety of clinical manifestations of clinical breast cancers is represented in this panel of BC cell line 
xenografts, which indicates that this panel can serve as very useful preclinical model for studying 
the biology of these phenotypes and for screening for interfering drugs.   




Breast cancer is not a single disease but rather a group of multiple distinct diseases with an 
extensive intra- and inter-tumor heterogeneity. The heterogeneous nature of breast tumors has 
been captured histologically decades ago by pathologists and by clinicians during clinical 
examinations.  Based on such differences breast tumors were classified into various histological 
subtypes with a different prognosis 1. The classical pathology-based classification has been refined 
and at times replaced by modern molecular classifications, which have the potential to combine 
disease mechanisms with clinical outcome measures 2. Molecular classification, an ongoing 
process, is currently mainly driven by differences in the expression of several thousands of genes 
detectable in the human breast tissues, and such changes are generally measured using gene 
expression microarray technology3.  
Using cDNA microarrays, five main molecular subtypes have initially been identified3. These 
subtypes include two luminal-like subtypes: luminal A and luminal B subtypes, an ERBB2 
overexpressing subtype, a basal-like subtype, and a less well defined normal-like subtype. The 
existence of these five subtypes in breast cancer is very stable and has been observed and 
validated by a number of subsequent studies in independent series of tumors from breast cancer 
patients with different ethnic background4. These subtypes not only display distinct gene 
expression patterns, they also show a significant difference in disease-free as well as overall 
survival5. Additionally, these subtypes show distinct preferences for organ-specific metastases6,7. 
For instance, the luminal subtypes of breast cancer preferentially metastasize to bone and the 
basal-like subtype more frequently metastasize to lungs and brain6. Furthermore, the stability of 
the genome as well as the response to certain types of chemotherapy of these subtypes is also 
diverse8. 
In the past decade, the molecular classification of breast cancer has been further refined and based 
on similarity in specific gene expression patterns more molecular subtypes have been identified9,10. 
Recently, Lehmann and colleagues identified 6 molecular subtypes within triple-negative breast 
cancer (ER-, PGR-, ERBB2-)11. This grouping of breast tumors based on gene expression analysis 
allowed the identification of several subtype-specific molecular drivers, which have been 
successfully targeted therapeutically using human BC cell lines as model systems11. Human BC cell 
lines are well-known and widely used model systems to understand breast cancer biology and 
pharmacology. Recently, a large collection of cell lines including BC cell lines have been used as in 
vitro pre-clinical model systems to uncover new biomarkers of sensitivity to the currently applied 
therapeutic drugs12,13. Furthermore, accumulating evidence suggests that the currently available BC 
cell lines mirror the molecular portraits of primary breast tumors. For instance, BC cell lines cluster 
into luminal-type, ERBB2 positive, basal-like, and normal-like/claudin low molecular subtypes, as do 
primary tumors14. Additionally, the cell lines exhibit a comparable degree of heterogeneity in copy 
number and expression abnormalities as observed in primary tumors, and they carry many of the 
genetic abnormalities commonly found in primary breast tumors15.  
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The interpretation and extrapolation of cell-line related data, however, require an understanding of 
how uniformly and stably these cell lines mimic primary breast tumors at both in vitro and in vivo 
levels. Previous studies have suggested that the cell lines, despite of considerable similarities, also 
show some discrepancies with clinical breast tumors. These discrepancies include higher frequency 
of TP53 gene mutation and over representation of ER-negative cell lines compared with human 
clinical breast tumors. In this study we explored in nude mice the in vivo growth potential and 
metastatic capacity of a panel of 24 human breast cancer cell lines representing four major 
molecular subtypes.  
 
MATERIALS AND METHODS  
 
Cell lines culture conditions  
The 24 human breast cancer cell lines used in this study are listed in Table 8.1. Cells were 
maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) and antibiotic agents (100 μg/mL penicillin G and 80 μg/mL streptomycin (P/S)) in a 
humidified atmosphere of 5% CO2 and 95% air at 37°C. For experiments, cells were seeded in T-162 
tissue culture flasks in normal culture medium containing 10% FBS until the cultures were 70-80% 
confluent. 
 




ER PGR ERBB2 EGFR 
CAMA-1 + + – – Luminal  
MCF-7 + + – – Luminal  
MDA-MB-175VII + – – – Luminal  
SUM52PE + – – – Luminal  
T47D + + – + Luminal  
ZR75-1 + + – – Luminal  
EVSA-T – + Amp – ERBB2-positive
MDA-MB-453 – – Amp – ERBB2-positive
SK-BR-3 – + Amp – ERBB2-positive
UACC812 + + Amp – ERBB2-positive
UACC893 – – Amp + ERBB2-positive
BT20 – – – + Basal-like 
HCC1937 – – – + Basal-like 
MDA-MD-468 – – – + Basal-like 
SUM229PE – – – + Basal-like 
BT549 – – – + Normal-like/Claudin-low
Hs578T – – – + Normal-like/Claudin-low
MDA-MB-231 – – – – Normal-like/Claudin-low
MDA-MD-436 – – – + Normal-like/Claudin-low
SK-BR-7 – – – + Normal-like/Claudin-low
SUM159PT – – – + Normal-like/Claudin-low
SUM149PT – – – + Normal-like/Claudin-low
SUM1315MO2 – – – + Normal-like/Claudin-low
DU4475 – – – + Other 
+, protein expression; –, no expression; Amp, amplification 
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Lentivirus production 
Lentivirus-containing luciferase construct was produced as described below. On day 1, 8-10 ×106 
HEK293T cells were seeded in 100 mm × 20 mm tissue culture petri dishes using 14 mL RPMI-P/S 
culture medium. On day 2, cells were transfected using polyethyleneimine (PEI) transfection 
reagent. For each petri dish, a DNA mixture of viral plasmid and three helper plasmids were 
prepared in 0.5 mL of HBS (150 mM NaCl, 20 mM HEPES, pH 7.3) in a 50 mL falcon tube. The DNA 
mixture contained 20 μg of the viral vector with the luciferase gene (Cag-Luc), 10 μg of 
pMDLg/RRE, 5 μg of pRSV-REV 16, and 5 μg of pVSVG 17. Then, PEI solution was prepared by adding 
120 μg of PEI in 0.5 mL of HBS. The transfection mixture was then prepared by mixing PEI solution 
dropwise to the DNA mixture (1:4 μg; PEI and DNA) and subsequent incubation for 15 min at room 
temperature18. The medium in each dish was replaced with serum-free culture medium. Then, the 
transfection mixture was added dropwise to the HEK cells while swirling the dish to allow 
homogenous mixing. After 3 h of incubation, the medium-containing transfection mixture was 
replaced with 10 mL fresh culture medium and incubated for 24 h. 
On day 3, after 24 h of transfection, the old medium was replaced with 6 mL fresh medium and 
incubated for an additional 24 h. On day 4, at 48 h, the medium-containing virus particles was 
collected from all dishes into a 50 mL tube and 6 mL fresh medium was added to the dishes. On 
day 5, at 72 h of transfection, the medium-containing viruses was again collected. The media 
collected at 48 h and 72 h were pooled, centrifuged at 300 × g for 5 min, and passed through a 
0.45-μm PVDF filter to eliminate cellular debris. The virus particles were concentrated by adding 
PEG-it virus precipitation solution (System Bioscience) to the supernatant-containing virus particles 
with 1:4 by volume. The mixture was incubated for 24 h at 4°C and then centrifuged at 1,500 x g for 
30 min at 4°C to precipitate lentivirus particles. Finally, the precipitated virus particles were 
resuspended in 200 μL of cold sterile Phosphate Buffered-Saline (PBS). Aliquots of 50 μL were 
stored at -80°C for future transduction experiments.  
 
Transduction and clone selection 
The cells to be transduced were seeded in a 24-well tissue culture plate in 0.5 mL culture medium. 
When the culture was approximately 50-60% confluent, 50 μL of concentrated virus particles were 
added to the well and incubated for 6-8 h at 37°C to allow transduction. After transduction, the 
transduced cells were trypsinized, subjected to the serial dilution from theoretically 50,000 cells to 
2 cells per mL in normal culture medium and all dilutions were seeded in 96-well round-bottomed 
plates with 150 μL volume per well. To collect monoclonal populations of the cells, only plates in 
which colonies of cells were theoretically grown out from a single seeded cell were used. These 
colonies were screened for luciferase expression by adding D-luciferin (150 mg/mL medium) in the 
well and then bioluminescence was measured using the IVIS camera system (Xenogen, Alameda, 
CA, USA) as explained below. Multiple bioluminescent clones of each cell line were harvested and 
the clones showing similar luciferase activity with each other were further propagated. 
Additionally, a morphological and molecular comparison was performed between the propagated 
clones and their corresponding parental cell lines. The clones showing similar phenotypic and 
























































d the cell p
y, the cells 





















L). For the 
unted on th
ading 100 μ
 130 g for 5
parated fro
ll as for ER, P
) experime
d in 10% bu
, and H & E
 (clone 1D5
and with t

































































s with cold 
e scraped c
lution for o
d and the c
ong with th
 the paper 


























 at 1:40, 
Growth dynamics of human breast cancer cell lines in mice  | 139 
 
PGR (A0098; Dako; Glostrup, Denmark) was diluted at 1:50, ERBB2 ready to use kit (HercepTest™; 
Dako, Glostrup, Denmark), and EGFR ready to use kit (EGFR pharmDx™; Dako, Glostrup, Denmark), 
were used for the cytospins. On the cytospins, these antibodies were developed using EnvsionTM 
Plus system (mouse, K4006; rabbit, K4008, Dako, Glostrup, Denmark). In the xenografts, the ER 
primary antibody was developed using animal research kit horse reddish peroxidise (K3954, Dako, 
Glostrup, Denmark). For EGFR expression in the xenograft, a Rabbit EGFR (D38B1; Cell Signaling, BZ 
Leiden, The Netherlands) diluted at 1:100 was used, and for PGR and ERBB2, rabbit primary 
antibodies at same dilution as described for cytospin staining were used. 
 
Mouse strain and animal care   
NMRI/Nu-Nu nude female mice aged 6-8 week (Charles River Laboratories, USA) were used in this 
study. Experiments were carried out according to the approved animal research protocol [EMC 
2541 (136-11-03)] by the Institutional Animal Ethical Committee (DEC), Erasmus University Medical 
Center, Rotterdam, the Netherlands. 
 
Cell line implantation and tumor size determination  
Three mice were used to implant three selected clones from each cell line. The mice were 
anesthetized by the exposure of 2% isoflurane and placed ventral side up on a pre-warmed 
injecting pad. Approximately 10-12 million cells from each clone suspended in 200 μL fresh culture 
medium with 20% serum were implanted under the mammary fat pad of the 4th nipple (either left 
or right side of the body) with a 1-cc syringe and 24-gauge needle. Two weeks after implantation, 
xenograft tumor viability was checked by bioluminescence as explained below. The size of 
xenografts was measured twice a week using a vernier calliper [xeno-tumor size (mm2) = length x 
width] and the mice were followed for a total period of maximal 12 months until they were 
sacrificed. To allow growth of ER-positive cell lines, a pellet of β-estradiol (Innovative Research of 
America) was implanted under the skin on the dorsal side of the neck of the mouse. Due to ethical 
reasons, primary xenograft tumors reaching the size of 225 mm2 were surgically removed while 
leaving an approximately 16 mm2 portion on the site to further facilitate invasion and metastasis. 
After the follow-up period, the intact animals alive were imaged to visualize distant organ 
metastasis. Subsequently, animals were sacrificed and body organs were excised. The excised body 
organs were re-imaged to assess organ micrometastases. The primary tumors and body organs 




Bioluminescence imaging was performed using IVIS Imaging System (Xenogen product from 
Caliper Life Sciences) according to manufacturer’s instructions. Briefly, for in vivo imaging, at 
indicated time points, the substrate 200 μL of D-luciferin (10 μg/gram of mice weight) was injected 
into the mice body intraperitoneally approximately 10-15 min before imaging. The mice were then 
anesthetized with 2% isoflurane and placed onto the warmed stage inside the light-tight camera 
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box with a continuous exposure of 2% isoflurane. Bioluminescence images were acquired with an 
acquisition time ranging from 0.1 sec to 5 min depending upon the cell line used. For ex vivo 
imaging of cells, 150 μg/mL of D-luciferin in culture media was added to each well of a 96-well 
plate that contained cells, and the plate was imaged for 10-40 sec. For ex vivo imaging of mice 
tissues (body organs), 150 μg/gram D-luciferin was injected into the mouse body before necropsy. 
For imaging of body organs, 300 μg/mL of D-luciferin in PBS was used in a petri dish containing the 
excised organs. The imaging time ranged from 0.1 sec to 5 min. The body organs were 
subsequently fixed in 10% formalin and prepared for standard histopathology. Imaging and 
quantification of signals were controlled by acquisition and analysis software Living Imaging 3.0 
(Xenogen), and data was expressed as total number of photon/sec/cm2.  
 
Data analyses  
Cox regression analysis was used to reveal subtype-specific tumor-related survival in the mice. 
Kruskal-Wallis and Mann-Whitney tests were used to evaluate significant differences in growth rate 
of the cell lines across the intrinsic subtype. A P-value of < 0.05 was considered to be statistically 
significant.  
 
RESULTS AND DISCUSSION 
 
Implantation of 24 breast cancer cell lines in mice 
To follow BC cells in the body of the mice, all cell lines were first stably transduced with a luciferase 
reporter gene using lentiviruses as vehicles. The luciferase expression was driven by the CAG 
promoter, which was previously shown to be a potent driver of the transgene expression in stem 
cell differentiation19,20. To overcome variable copy numbers of the luciferase gene due to random 
integration of the transgene by the lentiviruses, from each cell line 3 clones with equivalent 
luciferase activity were selected. Additionally, molecular characterizations of the selected clones 
were performed and it appeared that these clones showed a similar expression of ER, PGR, ERBB2, 
and EGFR proteins compared with their respective parental cell lines (Supplementary Figure 8.1). 
To determine the intrinsic molecular subtype-specific growth characteristics of the BC cell lines in 
vivo, 6 luminal-subtype, 5 ERBB2-positive, 4 basal-like, and 8 normal-like/claudin-low subtype cell 
lines were implanted in nude mice. In addition, 2 clones of the DU4475 cell line, which, according 
to microarray gene expression analysis did not cluster to either of the known intrinsic subtypes 
(chapter 7; Figure 7.1) and previously proposed to have cancer stem cell-like features due to 
activation of the Wnt signaling pathway14, were implanted. 
 
Subtype specific growth characteristics of BC xenografts 
All 6 luminal-type cell lines, which included CAMA-1, MCF-7, MDA-MD-175VII, SUM52PE, T47D, and 
ZR-75-1 showed growth at the primary site in mice. However, for 5 of these 6 cell lines [CAMA-1 (2 
of 3 clones), MDA-MD-175VII (2 of 3 clones), SUM52PE (2 of 2 clones), T47D (3 clones), and ZR-75-1 
(3 clones)], a dramatic loss in body weight within one month after cell implantation was observed. 
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Therefore, these mice had to be taken off study and were censored at this time point in survival 
analyses. Interestingly, one clone of the CAMA-1 cell line at month 10 and all three clones of the 
MCF-7 cell line at month 1, 5 and 8, respectively, successfully gave rise to primary tumor xenografts 
of the maximal allowed size of 225 cm2 (Supplementary Figure 8.2; Luminal-like cell lines). The 
cause of loss of body weight in mice bearing luminal-type xenografts remains unknown as 
pathological and microbiological analyses of these mice did not reveal any peculiar cell line-related 
concerns. It is however important to note that all the luminal-type cell lines are ER-positive 14 and 
therefore required a suitable concentration of estrogen for their steady growth under these in vivo 
conditions. To provide sufficient estrogen for optimal growth of these cell lines in mice, an 
estrogen pellet was implanted subcutaneously to each mouse 2 days before implantation of the 
cells. As this weight loss phenomenon was not observed in mice not receiving an estrogen pellet, a 
surplus of released estrogen above the physiological level in the mice carrying the luminal 
xenografts could have caused the unexpected decline in body weight. 
Among the 5 ERBB2-positive cell lines (EVSA-T, MDA-MB-453, SK-BR-3, UACC812, and UACC893), all 
except MDA-MB-453 showed primary tumor growth in mice albeit with variable growth rates. As a 
whole, UACC812 and UACC893 cell lines exhibited the fastest growth rate compared with the other 
3 ERBB2-positive cell lines (Supplementary Figure 8.2; ERBB2-positive cell lines). Similarly, xenograft 
tumors from all 4 basal-like cell lines (BT20, HCC1937, MDA-MB-468, and SUM229PE) were 
successfully established. Notably, only 1 out of the 3 BT20 implanted clones could grow in the 
mouse mammary fat pad while the other two regressed after establishing xenograft tumors of 36 
mm2 within two months post-implantation (Supplementary Figure 8.2, Basal-like cell lines). 
Among 8 normal-like/claudin-low cell lines (BT549, Hs578T, MDA-MB-231, MDA-MB-436, SK-BR-7, 
SUM149PT, SUM159PT, and SUM1315 M02), xenografts were raised from 6 cell lines, while the 
BT549 and SUM1315M02 cell lines did not grow in mice. For the SUM159PT cell line, one of its 
clones (SUM159PT-luc-8A4) showed a very rapid growth rate and could give rise to a primary 
xenograft of the maximal size in 3.3 months, while one clone did not grow beyond the size of 4 
mm2 within the set maximum 12 months of follow-up time. The third clone of SUM159PT did not 
grow in the mouse mammary fat pad. Of the Hs578T cell lines, also one clone showed aggressive 
behavior and could give rise to the maximal tumor size in 2.5 months, whereas the other two 
clones could only reach 81 mm2 in the set maximal follow-up time of 12 months. All other normal-
like/claudin-low cell lines exhibited very aggressive patterns of growth and all three labeled clones 
of each of the cell lines gave rise to primary xenografts of the maximum size in a short time span 
(range 24 days to 6.5 months) (Supplementary Figure 8.2, Normal-like/claudin-low cell lines). Two 
clones of the WNT driven cell line DU447514 have also been implanted. Interestingly, these two 
clones showed an extremely aggressive growth behavior in the mice and the primary xenograft 
tumors reached the maximal allowed size in 2 weeks (Supplementary Figure 8.3). This may point to 
the fact that this cell line has an activated Wnt signaling pathway, which has been implicated in 
breast carcinogenesis21. 
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Our findings that normal-like/claudin-low cell lines showed rapid growth are in line with the 
currently published in vitro growth behavior of these cell lines with doubling times for normal-
like/claudin-low and basal-like cell lines being shorter compared with cell lines of the other 
subtypes22. These data suggest that the innate growth ability of these cell lines, which were 
propagated in vitro for years, did not significantly alter when implanted into the mouse mammary 
fat pad. Interestingly, these results also confirm clinical findings showing normal-like/claudin-low 
tumors to be associated with a worse prognosis. Additionally, similar to clinical specimen, these cell 
lines do not exhibit ER, PGR, and ERBB2 expression (triple-negative)23 and a rather high expression 
of mesenchymal markers such as CD44high/CD24low (known breast cancer stem cell markers)10 
(Hollestelle, submitted paper) has been reported. In contrast to the clinical observations24,25, none 
of the ERBB2-positive cell lines exhibited aggressive growth and poor survival in mice (Figure 8.2B 
and C). This may be, on the one hand, due to the small number of ERBB2-positive cell lines that 
successfully were implanted in the mice. On the other hand, ERBB2-positive cell lines showed a 
slower growth rate in in vitro culture conditions compared with basal-like and normal-like/claudin-
low cell lines14.  
 
Subtype specific metastatic potential and distant organ specificity 
Besides variable growth patterns associated with the cell lines, the propensity of these cell lines to 
colonies common distant sites in mice were determined, as well as whether this behavior was 
molecular subtype related. For this, we only focused on those mice in which primary xenograft 
tumors were able to reach the maximal allowed size (225mm2) because smaller sized xenograft 
tumors did not metastasize to the distant sites. As expected, the most common sites of relapse 
were the adjacent lymph nodes (73%). Second in line to lymph nodes were lungs (43%). Liver and 
uterus/ovaries (27% each) were the third most frequently colonized distant organs by the cell lines 
(Figure 8.3 and Supplementary Table 8.1).  
Relapses to spleen, bone, and brain were also observed though less frequently compared with 
those to lymph nodes and lungs. Additionally, occasional relapses to some uncommon sites with 
regard to breast cancer, such as to the kidney and pancreas were also observed in the mice 
(Supplementary Table 8.1). It should however be noted that the majority of these micrometastases 
were only detectable by the bioluminescence and could not be confirmed histologically except for 
the metastases to lymph nodes and lungs (Figure 8.4).  
It has been previously observed that the intrinsic molecular subtypes show preferential sites of 
distant relapses6,7; and also intravenously injected breast cancer cells show organ-specific relapse26-
28. Unfortunately, in mice, these subtype-specific preferences in the cell lines of 4 molecular 
subtypes could not be reproduced. One explanation could be that our panel of cell lines is small 
and therefore lacks sufficient power to observe subtype-specific sites of relapse in the mice. 
Another possible reason could be that the xenografts raised in the mammary fat pads are more 
prone to shed off cells directly into the body lumen, which subsequently can metastasize non-
preferentially to various body organs. 
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CONCLUSIONS 
 
In this study we show that human breast cancer cell lines, which have been propagated on plastic 
for years, have retained their innate abilities to exploit the (orthotopic) microenvironment of the 
implantation site and can give rise to xenografts when implanted into the mammary fat pad of the 
mice. The most common sites colonized by all types of cell lines in mice are lymph nodes, lungs, 
liver and ovaries/uterus, whereas some other sites of relapse such as kidneys, bone, brain and 
pancreas were also rarely observed. Importantly, xenografts from breast cancer cell lines of the 
normal-like/claudin-low, and to a lesser extent of the basal-like subtype, showed a more aggressive 
growth behavior and worse tumor-related survival of the mice compared with xenografts of cell 
lines from the other molecular subtypes. Finally, the serially generated xenografts in the recipient 
mice grew reproducibly and robustly and can serve as diverse and practically feasible preclinical 
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GENERAL DISCUSSION 
 
Breast cancer is the most common cancer among women world-wide. Like many other diseases, 
breast cancer is also a genetic disease that emerges due to accumulation of mutations in 
biologically important genes. The mutated genes are either inherited from parents (hereditary 
breast cancer) or the mutations are acquired de novo (sporadic breast cancer) during the course of 
life. Hereditary breast cancer mainly includes familial breast cancer in which gene mutations cluster 
into a family and therefore affected individuals in the family are at higher risk of developing breast 
cancer compared to the general population. The genetic basis of inherited breast cancer has been 
investigated for the past three decades and has been the subject of several recent discoveries. 
Three reasonably well-defined groups of breast cancer susceptibility genes have become apparent: 
rare high-risk and moderate-risk genes and common low-risk loci. The rare high-risk genes were 
discovered through genetic linkage mapping and positional cloning1-8 and the mutations in these 
genes confer a risk of approximately 30-60% of developing breast cancer by the age of 60, 
compared to 3% in the general population9. The moderate-risk genes were discovered through a 
direct interrogation of the candidate genes in genetically enriched cases and controls10-14. 
Mutations in these genes are relatively rare and they confer a risk of about 20-40% by the age of 
6015. The low-risk breast cancer alleles have been discovered through genome-wide association 
studies (GWAS) studying hundreds of thousands of single nucleotide polymorphisms (SNPs) in 
large populations of breast cancer cases and controls16,17. The low-risk alleles are very common 
(population frequency 5-50%) and they confer a modest risk of 10-20% by the age of 60. 
Altogether, these three groups of breast cancer susceptibility genes/loci can currently only explain 
about 35% of familial breast cancer cases, whereas 65% of the familial breast cancer risk still 
remains to be elucidated. 
Based on the extent to which breast cancer risk has been estimated in twin and sibling studies, it is 
expected that a considerable part of the familial breast cancer risk is genetic, which indicates that a 
large number of risk loci and/or SNPs are still to be discovered. In line with this, Park and colleagues 
estimated that if SNPs explain all the unexplained risk approximately 60-70 SNPs with effects 
similar in size to those already known are likely to be around18. Next to the discovery of novel risk 
factors, the complete clinical significance and the biological function of the newly discovered low-
risk breast cancer susceptibility loci is still to be understood. Furthermore, a wide variety of well-
characterized in vivo models to study genetic and biological factors are lacking, which hampers the 
understanding of their role in disease progression.  
In the first experimental chapter of the thesis, using candidate gene approach we tried to discover 
a new gene or variant in CHEK2 mutation carrier breast cancer families. This putative gene or 
variant would in our view not only explain a part of yet unexplained familial breast cancer risk but 
also act as a partner of the CHEK2 gene in a polygenic setting. Furthermore, in the two follow-up 
chapters we investigated in cell lines and in primary breast tumors the biological mechanisms and 
additional clinical significance associated with the first series of common low-risk breast cancer loci 
previously identified via GWAS. In the second part of the thesis, we investigated breast cancer 
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subtype-specific biological entities such as genes and micro-RNAs (miRNAs) using either primary 
breast tumors or in vitro propagated breast cancer cell lines. Lastly, we developed breast cancer 
cell line xenograft mice models to determine if subtype-related clinical behavior of breast cancer is 
recapitulated in these models and also to functionally explore the biology of the clinically relevant 
factors as well as to investigate interference of currently existing as well as novel targeted drugs.  
 
Discovering the polygenic partner of CHEK2 for breast cancer susceptibility 
Our group has previously shown that the CHEK2 1100delC variant confers a moderate risk of 
approximately 2-fold in breast cancer families with no BRCA1 and BRCA2 mutations. The 
inheritance pattern of breast cancer in CHEK2 1100delC carrier families suggested that these 
families are of as much high-risk families as BRCA1 and BRCA2 families10,19 E.g. a meta-analysis of 
unselected 26,000 CHEK2 1100delC mutation carrier cases and 27,000 controls have estimated an 
odd ratio (OR) of 4.820. Furthermore, it was shown that the CHEK2 1100delC variant alone conferred 
only an about 2-fold increased risk of breast cancer and the variant did not completely segregate 
with breast cancer in these families10,19. These observations have led to the hypothesis that CHEK2 
1100delC co-segregates with an as-yet unknown gene, which may function with the CHEK2 
1100delC variant in a polygenic setting in CHEK2 1100delC carrier breast cancer families21,22. 
Looking at the OR of 4.8 determined in the meta-analyses and considering that CHEK2 1100delC 
may operate in a multiplicative polygenic model, either one putative gene ‘X’ with a moderate-risk 
susceptibility comparable to the CHEK2 1100delC variant or two putative alleles ‘X and Y’ both with 
a low-risk susceptibility comparable to common variants are expected in CHEK2 1100delC mutation 
carrier families (Figure 9.1). To reveal this CHEK2 1100delC polygenic partner, we previously 
evaluated mutations in a couple of candidate genes for their possible involvement in the polygenic 
CHEK2 cancer model. The evaluation of the three most common Dutch MUTYH mutations, MUTYH 
Y179C, G396D, and P405L, in 70 Hereditary Breast Colorectal Cancer (HBCC) families, which were 
also evaluated for the CHEK2 1100delC variant, revealed only one of the 70 HBCC families carriers 
having mutations in both CHEK2 and MUTYH genes. This finding suggested that the MUTYH 
mutations do not play a major role in the polygenic CHEK2 cancer model23. Secondly, screening of a 
SNP in the promoter of the MDM2 gene (MDM2 SNP209) in 20 CHEK2 1100delC familial breast 
cancer cases and 126 geographically-matched controls also showed no evidence of MDM2 SNP209 
to be of major importance in the polygenic CHEK2 cancer model23 (Figure 9.1). In chapter 3 of this 
thesis, we evaluated the MSH6 gene as a possible polygenic partner of CHEK2 in breast cancer by 
performing mutation analysis of the MSH6 gene in breast cancer families. Though, while we did not 
find any mutations in the coding part of the MSH6 gene in breast cancer families, we did observe 
some rare variants having a population frequency of less than 1% to be associated with increased 
breast cancer risk.  
Our choice of considering MSH6 as a likely candidate of being the polygenic partner CHEK2 was 
based on previous observations that germline mutations in all mismatch repair genes including 
MSH6 are associated with colorectal cancer24-26. Also, it was shown previously by our group that 
CHEK2 1100delC also confers colorectal cancer risk in breast cancer families with the HBCC 
















































6 gene in re
rovide clue


















c and the u
 as suggest
9 one may s
 or other ch
y or speci





s and future 
uencing effo












often in a c
riants with b
nderlying d





 the same l
se rare varia
r a putative
n of the CHE
recommenda



























 model for b























































6 in 68 HBC
















































General discussion  | 153 
 
carrier breast cancer families are expected to be genetically enriched for this putative gene/allele. 
These families would therefore serve as the most promising candidates to discover a putative 
gene/allele by whole exome or whole genome sequencing and to provide evidence that this 
putative gene/allele indeed acts in concert with the CHEK2 1100delC variant. The discovery of such 
gene would likely explain the remaining magnitude of unexplained risk of developing breast 
cancer in high-risk CHEK2 1100delC families and thus potentially be paving the way for genetic 
counseling of high risk cases in these families. In this regard our lab has anticipated the potential of 
whole exome genome sequencing and is already on the way towards applying this approach to 
search for the CHEK2 polygenic partner for breast cancer susceptibility. 
 
Common low-risk breast cancer loci and their biological and clinical significance 
In the past two decades, the high- and moderate-risk breast cancer susceptibility genes have been 
extensively studied. The underlying biology and disease mechanism associated with these genes 
have been comprehensively explored. Accordingly, different strategies were developed to design 
preventative therapeutics to fight breast cancer associated with these genes. A prime example is 
the clinical development of PARP inhibitors in oncology, which became only possible due to a 
thorough fundamental biological knowledge in BRCA1/BRCA2-deficient tumors30. Likewise, it is of 
great importance to discover disease mechanisms and related biological pathways that underlie 
the emerging common low-risk breast cancer loci that have been discovered through GWAS using 
SNPs in breast cancer cases and controls. The thorough mechanistic understanding of these loci 
would allow the design of effective drugs to target breast cancer associated with these loci in the 
clinic. The fact that the majority of these low-risk SNPs are mapped to non-coding regions of the 
genome has made it less obvious how such a locus would functionally contribute to breast 
carcinogenesis. In 2007 the Breast Cancer Association Consortium (BCAC) postulated two 
hypotheses6 about disease mechanisms through which low-risk loci may confer their increased 
breast cancer risk: 
 
1. The disease-associated SNPs tagging low-risk breast cancer susceptibility loci are linked 
with yet unknown causal variants in protein coding genes located in the same LD block 
(Figure 9.2A).  
2. The low-risk breast cancer susceptibility loci may function through expression modulation 
of nearby located genes and such expression changes are causally related to breast 
carcinogenesis (Figure 9.2B). 
To explore the first hypothesis that risk-associated SNPs are linked with causal variants in nearby 
genes, BCAC performed deep sequencing of the genes containing these loci or all the genes 
located in the same LD block. Such sequencing efforts, however, did not reveal any pathogenic 
variants correlated with the minor allele of the identified loci16. So the first hypothesis was 
therefore considered unlikely to be of great significance.  
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In chapter 4 and 5 of this thesis, we evaluated the second hypothesis, i.e., the low-risk breast 
cancer loci are associated with expression modulation of the nearest genes. For this, we correlated 
in 1,401 primary breast cancer patients mRNA expression levels of the genes nearest to the 
genotyped risk-conferring SNPs. Among the seven loci explored (FGFR2-rs2981282, LSP1-
rs3817198, MAP3K1-rs889312, TOX3-rs3803662, H19-rs2107425, 2q35-rs13387042, and 8q24-
rs13281615), we found that only the risk-associated allele of rs3803662 SNP around the TOX3 gene 
was statistically significantly associated with lower mRNA expression of the TOX3 gene. This 
significant association of the rs3803662 SNP with lower expression of TOX3 suggests a tumor 
suppressor role of this gene in breast carcinogenesis. Of note, expression of TOX3, a high mobility 
group box nuclear protein involved in calcium dependent transcription and structural modification 
of chromatin, has previously been implicated by us in bone metastasis in the breast cancer 
patients31. Our findings that the risk-associated locus (rs3803660) nearby TOX3 at 16q12.1 was 
indeed associated with lower expression of TOX3 in breast cancer cells and that the TOX3 gene is a 
new tumor suppressor gene in breast cancer have been recently reproduced by Cowper-Sal Lari 
and colleagues32. They annotated breast cancer-risk associated SNPs in the non-coding regions of 
the genome in breast cancer cells and provided functional evidence that these SNPs are enriched 
in binding sites for FOXA1 and ESR1 transcription factors and carry more frequently H3K4me1 
chromatin marks in cancer in a cell-type specific manner. They further showed that the most 
significantly associated SNP rs4784227 with breast cancer loci at 16q12.1 regulates the TOX3 
expression in an allele-specific manner. This SNP rs4784227 is in significant LD with rs3803660 SNP 
(r = 0.864, D’ = 1), which was originally shown by BCAC to be associated with increased breast 
cancer risk to the same locus and we showed it to be associated with lower expression of the TOX3 
gene. The risk-associated allele of rs4784227 [T] allows an increased binding affinity for FOXA1 
transcription factor on the enhancer, which tempers TOX3 transcription via a chromatin loop 
interacting with TOX3 promoter. Additionally, Cowper-Sal Lari and colleagues silenced TOX3 in ZR-
75-1 breast cancer cell lines to determine whether TOX3 acts as a tumor suppressor gene. Indeed, 
knockdown of the TOX3 gene resulted in enhanced proliferation of ZR-75-1 cells providing 
functional evidence that TOX3 indeed has a tumor suppressor role in breast carcinogenesis.   
A similar mechanism has been reported for rs2981582 and rs13281615 breast cancer risk-
associated SNPs, which are located in intron 2 of FGFR2 and in the 8q24 locus, respectively33,34. The 
rs2981582 SNP was shown to be a causal variant by itself, as it regulates increased FGFR2 
expression by altering the binding affinity of transcription factors Oct1/Runx2 and C/EBPβ on the 
genomic region containing this SNP33. Likewise, risk variant of rs13281615 on 8q24 was shown to 
differentially regulate the expression level of the MYC gene through physical interaction with 
tissue-specific enhancers from the 8q24 region containing the SNP34. This biological mechanism for 
a breast cancer risk-associated SNPs, which involves the disruption of transription factor binding at 
a distal enhancer and the subsequent modulation of the gene expression as reported for TOX3, 
FGFR2, and MYC genes, appears to be a common mechanism of action. In general, this mechanism 
involves immunoprecipitation of the regulatory elements suspected to bind to genomic region 
containing risk-associated variant and also interact with the target gene. The captured DNA in the 
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precipitates is subsequently sequenced to determine the exact genomic parts invoveld in the 
interaction (Figure 9.2C). Such mechanism has recently gained support on a global scale as the 
findings published by the ENCODE consortium also provided support for enrichment of regulatory 
elements at SNPs linked by the GWAS to various diseases. It is important to mention however that 
we in our cohort of 1,401 primary breast cancers do not find support for FGFR2 and MYC expression 
changes in relation to the risk-associated SNPs, nor for the other 4 loci investigated, indicating a 
need for replication of our studies in even larger cohorts of tumors. Alternatively, these SNPs are 
not linked to expression changes of the indicated genes, or the expression changes are not of 
relevance in the tumor tissue but in the normal tissue from which the tumor is derived.  
The number of GWAS-identified breast cancer risk-associated SNPs is large and this number is still 
growing. Now it is the time for the scientific community to be more focused on the post-GWAS 
phase of human genetics. A comprehensive set of priniciples has already been proposed for the 
post-GWAS functional characterizations of low-risk cancer loci35. However, the major complication 
associated with the functional characterization of these SNPs is that they themselves are not likely 
causal but are associated with hundreds or even a thousand of linked SNPs in the genome of which 
one is likely to be causal. Each of these linked SNPs may have multiple potential target genes 
through a number of potential interactions mediated by chromatin loops. This makes it difficult to 
discriminate causal SNPs from a SNP that is only associated with the increased cancer risk. Our 
current knowlegde calls for a systematic approach that can tell them apart effectively. In this 
regard, the methods recently developed and applied by Cowper-Sal Lari and colleagues32 seem 
promising as they first reveal the most promising transcription factors, histone modifications or 
other annotations that are specific to the genomic regions containing the risk-associated SNP. 
Secondly, they identify for experimental follow-up studies from thousands of associated SNPs a 
candidate SNP that affects the interaction of annotated factors with the chromatin. This approach 
would eventually pave the way leading to an integrated post-GWAS characterization of low-risk 
cancer susceptibilty loci. 
The second question that we addressed in Chapter 5 is whether these low-risk loci besides being 
associated with breast cancer onset also predict progression of the disease in breast cancer 
patients. Our study identified only one SNP that is rs2107425, near H19 gene, which was associated 
with shorter metastasis free-survival in patients with primary breast cancer. A recent BCAC study 
also investigated 11 SNPs that were associated with breast cancer risk and 62 other SNPs, which 
were suggested as breast cancer risk SNPs by a GWAS or identified as candidate SNPs from 
individual studies, for their prognostic relevance36. The 11 SNPs investigated in this study also 
include the 7 SNPs that we tested in our study. One of the 11 SNPs, rs3803662 (TOX3) and none of 
the 62 candidate/GWAS SNPs were associated with overall survival (OS) and/or breast cancer-
related survival (BCS)36. The genotypic-specific survival for rs3803662 suggested a recessive mode 
of action [hazard ratio (HR) of rare homozygous carriers = 1.21; 95% CI: 1.09–1.35, P =0.0002 and HR 
= 1.29; 95% CI: 1.12–1.47, P =0.0003 for OS and BCS, respectively]36. However, we were not able to 
detect a prognostic association of rs3803662 (TOX3) SNP in our relatively small cohort of 1,290 
lymph node-negative patients. The major difference between our cohort and the BCAC cohort is 
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that our SNP genotyping data have been derived from tumor DNA, which mainly comprised of 
sporadic tumors, whereas BCAC SNP genotypes were derived from blood-based and thus germ-
line DNA. Also, a significant percentage of patients in BCAC study were treated with adjuvant 
systemic therapy, which may have confounding effect on the progression of the disease. The data 
from both studies however suggest that low-risk breast cancer loci are mostly, if not solely, related 
to the onset of the disease and it is less likely that they affect progression of the disease in patients. 
 
TWIST1 expression and its clinical and biological significance 
In chapter 6 of this thesis, we determined mRNA expression levels of the TWIST1 gene as a marker 
of progression of primary breast cancer particularly in untreated lymph node-negative patients. 
Importantly, we found that high TWIST1 mRNA expression was significantly associated with poor 
prognosis only in the estrogen receptor(ER)- positive lymph node-negative subgroup of patients. 
These findings are in line with two previous studies showing that TWIST1 protein expression 
determined by IHC predicts poor prognosis in ER-positive breast cancer37,38. In addition to that, we 
observed particularly in ER-positive tumors that TWIST1 mRNA expression levels are significantly 
higher in stromal-rich compared with stromal-poor tumors, implying that the stroma of the ER-
positive tumor tissue could be an important factor involved in TWIST1-related breast cancer 
progression. Interestingly, a connection between TWIST1 expression and tumor stroma in the 
breast tissue has also recently been demonstrated by Roman-Perez and colleagues39, who 
measured global gene expression patterns of 72 breast cancer tissues and identified two distinct 
subtypes, active and inactive, in the cancer-adjacent extra-tumoral microenvironment of breast 
tissues. The data showed that the TWIST1 was highly expressed along with other stroma-associated 
genes such as VIM, ADAMTS2, COL4A2, COL4A1, ITGA7, and ITGB1 in the active subtype. Fitting with 
this, we showed in microdissected tumor tissues that TWIST1 gene at the mRNA level is almost 
exclusively expressed in the stromal compartment of the tissue. Also, our in silico pathway analysis 
using TWIST1 co-expressed genes showed an enrichment of extracellular matrix (ECM)-related 
gene ontology (GO) terms and biological pathways. Importantly, similar to mRNA expression, 
TWIST1 protein expression was higher, but not exclusively, expressed in the stroma of the ER-
positive tumor tissues compared with that of ER-negative tissues. Our results suggest a biological 
relationship among stromal components, TWIST1 and prognosis specifically in ER-positive breast 
tumor tissue. Historically, TWIST1 has repeatedly been linked to tumor invasion and metastasis40. A 
significant body of evidence demonstrated that TWIST1 induces metastasis by promoting an 
epithelial-to-mesenchymal transition (EMT) in various cancer types including breast cancer41,42. The 
TWIST1-mediated EMT process in epithelial cells generally involves transcriptional repression of the 
E-cadherin gene by TWIST1 expression, which leads to loosening of cell-cell adhesion and 
activation of mesenchymal markers. Consequently, malignant epithelial cells become more motile 
and metastatic. In breast cancer, it has been observed that TWIST1 induces EMT preferentially in 
basal-like breast tumors43, which are typically ER-negative cancers. Consistent with this, the 
majority of ER-negative cell lines display EMT features44. In our study, we observed that TWIST1 
mRNA expression levels in ER-positive breast cancers was positively correlated with the known EMT 
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metalloproteinase enzymes, which not only degrade ECM of the tissue but also breach the 
basement membrane thereby facilitating malignant epithelial cells to escape into the blood 
circulation without undergoing full-blown EMT-like changes. The clues about how malignant 
epithelial cells themselves or induce stromal cells to secrete so called stroma activating factors 
come from the work of Eckert and colleagues. They showed that TWIST1 expression induces the 
development of subcellular protrusions known as invadopodia45. These invadopodia-bearing cells 
secrete metalloproteinases45, which not only degrade ECM of the tissue but also activate stromal 
components in the tissue. It is therefore clear that more work is needed to completely unfold these 
scenarios in the context of breast cancer. 
A fundamental question with regard to the two proposed TWIST1-related scenarios of disease 
progression would be: what factor would determine which TWIST1 scenario should prevail in the 
context of breast cancer progression? Based on our data, we think that ER would be a determining 
factor. In ER-positive breast tissue TWIST1-mediated disease progression would therefore follow, 
the TWIST1-induced stroma activation scenario’, whereas ER-negative breast tissue favors the 
‘TWIST1-induced EMT scenario’. To provide functional evidence that ‘TWIST1-induced stroma 
activation’ contributes to ER-positive/luminal breast cancer progression, TWIST1 expression has to 
be manipulated to determine if and how it can affect the tumor stroma cells to cooperate with 
epithelial cells in the process of invasion and metastasis. Once evidence is provided that the 
‘TWIST1-induced stroma activation scenario’ is of importance, drugs targeting this route may prevent 
TWIST1-mediated metastasis in luminal breast cancer. 
 
Human breast cancer cell lines as models to understand breast cancer 
In chapter 7 and chapter 8 of this thesis, we performed molecular characterization of human 
breast cancer cell lines to evaluate in vitro and in vivo subtype-specific biological differences and to 
further establish how reliably the in vitro cultured human breast cancer cell lines recapitulate the 
biology of the primary breast tumors. In chapter 7, we extended the molecular characterization of 
our large panel of breast cell lines to study differential expression of 725 human miRNAs using a 
microarray carrying 1,344 LNA™ modified oligonucleotide capture probes. We studied the 
association of these miRNAs with clinically important factors such as the intrinsic molecular 
subtypes and ER, PGR, as well as ERBB2 expression and with genetic factors such as TP53, PIK3CA, 
and E-cadherin mutation status as well as global genomics data such as SNP copy number 
variations and global gene expression. 
To identify molecular subtypes we first performed a microarray gene expression analysis to retrieve 
global gene expression patterns of our collection of 51 human breast cancer cell lines. Pearson 
correlation as well as cluster analysis using the intrinsic gene-set defined by Perou and colleagues46 
revealed three prominent independent clusters of cell lines. These clusters mainly represent 
luminal-subtype, basal-like, and normal-like/claudin-low subtypes. Cell lines with an ERBB2 
overexpression representing the ERBB2-positive intrinsic subtype were also observed. However, 
these cell lines did not constitute an independent group and mostly clustered together with the 
luminal-type cell lines. Based unsupervised analysis of 413 miRNAs we observed a similar division 
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into two main clusters driven by ER status. MiRNAs that were differentially expressed between ER-
positive and ER-negative cell lines showed a considerable overlap with those differentially 
expressed between primary tumors of different ER status47. However, not all miRNAs are 
concordantly differentially expressed. Notably, expression of hsa-miR-100 miRNA was high in ER-
positive primary breast tumors48 while in the cell lines this miRNA displayed high expression in ER-
negative cell lines. Such discrepancies could be explained by a significant contribution of the 
tumor microenvironment to the expression of some individual miRNAs47. The second miRNA 
signature driving the unsupervised division of breast cancer cell lines involved miRNAs that were 
previously implicated in the EMT process (hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, hsa-miR-141) 
in metastatic breast tumors and are associated with the normal-like/claudin-low cell lines, which 
also show a prominent EMT and stem cell-like phenotype49,50.  
To evaluate relevant biological parameters of tumor progression (E.g., tumor growth, incidence 
and type of metastasis) in the final chapter (chapter 9) of this thesis, we developed xenograft mice 
models from 21 breast cancer cell lines representing four molecular subtypes. Each cell line was 
first equipped with a luciferase reporter gene to image and to follow breast cancer cells in growing 
xenografts in living animals in real-time manner. The ability of most of these cell lines to grow as 
xenografts suggests that the cell lines, despite of their in vitro growth for many years, still retain 
their natural capacity to exploit and communicate with the host microenvironment. Consistent 
with clinical breast tumors, the growth rate of the xenografts from normal-like/claudin-low cell 
lines was high and mice bearing these xenografts showed poor tumor-related survival. In contrast 
to observation made in the clinic, ERBB2-positive cell lines behave significantly less aggressive 
compared to cell lines of other molecular subtypes. Furthermore, in contrast to the clinical 
observation that molecular subtypes of primary breast tumors exhibits preferences to relapse to 
specific sites (i.e. bone, lungs, brain)51, breast cancer cell lines in xenografts did not show such 
subtype-specific relapse to specific organs. Rather, cell lines from all molecular subtypes shared 
common organs for metastasis in the mouse, which mostly were lymph nodes and lungs. One 
obvious explanation is that the small number of cell lines that we were able to use to generate 
xenografts, which have not given us the power to study this property. Importantly, xenografts from 
these cell lines grow in recipient mice in a reasonable time span, which makes these cell line 
xenografts unique models to screen potential breast cancer drugs in the presence of host stroma. 
As a whole, based on the analysis by others and us, it is concluded that breast cancer cell lines 
despite being propagated in vitro for decades, to a significant extent, reflect the features of primary 
breast tumor cells in vivo E.g., with regard to genomics, Neve and colleagues in 2006 using a BAC 
array CGH-based comparative analysis52 reported recurrent gains at chromosomes q1, 8q, 11q, 12q, 
17q, and 20q and losses at chromosomes 3q, 13q, 16q, 17p, and 22q52,53 in both 185 primary breast 
tumors and 51 human breast cancer cell lines. Using SNP copy number in a global analysis, we also 
observed strikingly similar patterns of chromosomal aberrations in 303 primary tumors54 and 56 
breast cancer cell lines (unpublished). Furthermore, global mRNA and miRNA expression patterns 
divide cell lines and primary tumors into two major groups dictated by ER status. These immense 
ER-mediated differences have been recognized many years ago and confirmed that each of these 
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molecular subtypes represents a unique biology with a different prognosis and treatment 
options55. With regard to aggressive behavior of cell lines grown in mice, in line with observations 
found in primary clinical breast cancer, basal-like and in particular normal-like/claudin-low cell lines 
behave more aggressively. The latter is also in line with the requirement of EMT for rapid 
dissemination of ER-negative tumors. Overall, this indicates that the cell lines do not substantially 
accumulate new recurrent genomic and phenotypic alterations due to in vitro cultivation, but 
rather they globally have a similar genomic landscape as primary tumors from which they are 
derived. 
Despite of a general concordance between breast cancer cell lines and primary breast cancer 
tumors, this cell lines collection with regard to certain features represents a biased population. For 
example, ER-negative and triple-negative cell lines are over represented in the collection of cell 
lines while, in primary breast cancers, a minority of tumors (10-25%) is ER-negative or triple-
negative56. Another notable difference between cell lines and primary tumors is the absence of a 
luminal A and luminal B subdivision in the cell lines, whereas these two molecular subtypes have 
repeatedly been observed in primary breast tumors even from various ethnic backgrounds57. 
Moreover, tumors of the luminal A and B subtype a display diverse and distinct prognosis57. 
Furthermore, a substantial numbers of cancer cell lines exhibits a mesenchymal-cell like 
morphology, which according to pathologists is a rare phenomenon to be seen during histological 
examination of primary breast tumors. Additionally, the mutational frequency of certain genes is 
significantly higher in cell lines compared with primary breast tumors. For instance, mutation 
frequency of the TP53 gene is approximately twice as high in cell lines as compared with primary 
breast tumors58. Similar to TP53 mutations, E-cadherin mutations and amplification of ERBB2 are 
more frequently observed in breast cancer cell lines compared to primary tumors. Also with regard 
to aggressiveness, ERBB2-overexpressing cell lines do not behave as anticipated from ERBB2-
positive clinical specimens and also organ-specific relapse in cell lines is not molecular subtype-
related as it has been observed for clinical specimen. The observed differences between cell lines 
cultured in vitro or grown as xenografts might reflect a general aggressive nature of more 
dedifferentiated tumors, which might more easily adapt to in vitro conditions. Notably, the cell 
lines grown in vitro or as in pure tumor xenografts lack a stromal component and therefore obvious 
stromal-derived genes or miRNAs cannot be detected and thus potential stromal-related biology 
cannot be studied in cell lines. Although these cell lines could be very useful, one must take into 
account all these pros and corns of the breast cancer cell lines before considering them to model 
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SUMMARY 
 
Breast cancer is the second leading cause of cancer-related deaths in the western world and one of 
the most common diseases worldwide. About 1.4 million new cases of invasive breast cancer are 
expected to be diagnosed and approximately 0.7 million women will die from this disease in 2012. 
Breast cancer is a genetic disease, the onset of which has been associated with mutations in 
functionally important genes commonly known as breast cancer susceptibility genes. These genes 
can either be inherited or acquired somatically in the tumor tissue. Based on associated breast 
cancer risk and population prevalence, the breast cancer susceptibility genes can be classified as: 
(1) high-risk breast cancer susceptibility genes that are very rare in the general population but 
associated with high risk; (2) moderate-risk breast cancer susceptibility genes that are also rare and 
associated with moderate risk; and (3) low-risk breast cancer susceptibility loci, which are common 
in the general population but associated with a small increase in risk. Biological disease 
mechanisms that underlie the risk conferred by the high-risk and moderate-risk susceptibility 
genes and their role in the progression of the disease have previously been well studied. But, how 
low-risk breast cancer loci confer their increased breast cancer risk in patients is poorly understood. 
Moreover, whether these loci can predict the course of the disease in primary breast cancer 
patients has also not been previously addressed. The complete clinical significance and the 
biological function of the newly discovered low-risk breast cancer susceptibility loci is still to be 
understood. Furthermore, a wide variety of well-characterized in vivo models to study genetic and 
biological factors are lacking, hampering understanding of their role in disease progression. 
In the first part of this thesis, we applied a candidate gene approach to discover additional genetic 
aberrations in familial breast cancer and to gain more insight into the biology and prognosis of 
known low-risk loci and candidate genes. In chapter 3 of this thesis, we aimed to discover whether 
mutations in the MSH6 gene were associated with breast cancer risk in breast and colorectal cancer 
(HBCC) families. The HBCC phenotype was of interest since one-fifth of HBCC families carry a CHEK2 
1100delC mutation and this mutation was suggested to confer hereditary breast cancer risk in a 
polygenic setting. We therefore hypothesized that mutations in the MSH6 gene might act as 
partners of the CHEK2 1100delC mutation. The rationale to perform this study was based on the 
fact that both of these genes have previously been linked to the Lynch Syndrome. Thus, we 
analyzed the entire MSH6 coding sequence for genetic alterations in blood-derived DNA of 68 
HBCC breast cancer families. All rare MSH6 variants, with population frequencies below 1%, were 
identified in 11.8% of HBCC breast cancer families whereas the same variants were identified in 
only 1.5% of population controls. This suggests that rare MSH6 variants are associated with HBCC 
breast cancer (P <0.00001). However, screening of the entire MSH6 coding sequence in 68 non-
HBCC breast cancer families showed a similar association (8.8% vs. ~1.4% in controls, P <0.001), 
suggesting that rare MSH6 variants are not confined to HBCC breast cancer. Together, our data 
suggest that the rare MSH6 variants may predispose to familial breast cancer. However, none of the 
rare MSH6 variants are obviously pathogenic, suggesting that a more subtle disease mechanism 
may operate in breast carcinogenesis. 
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Then we focused on (i) how low-risk breast cancer susceptibility loci confer their increased risk of 
breast cancer and (ii) whether low-risk breast cancer susceptibility loci can affect the natural course 
of the disease progression in breast cancer patients. We genotyped nine candidate SNPs capturing 
seven risk-associated loci (FGFR2-rs2981282, LSP1-rs3817198, MAP3K1-rs889312, TOX3-rs3803662, 
H19-rs2107425, 2q35-rs13387042, and 8q24-rs13281615) in 40 human breast cancer cell lines 
(chapter 4) and in a retrospective cohort of 2,480 primary breast cancers with complete clinical 
follow-up (chapter 5). To explore underlying disease mechanisms, we tested the most plausible 
hypothesis in which low-risk breast cancer susceptibility loci were suspected to confer their 
increased risk, which is via the modulation of expression of the nearest genes. The minor allele 
frequency (MAF) of these loci was indeed higher in the breast cancer cell lines and in the tumors 
compared with blood-derived DNA of a control population of European ancestry. Our results 
revealed that except for SNP rs3803662, which was associated with lower expression of the TOX3 
gene in the clinical cohort, all tested low-risk breast cancer susceptibility loci generally do not affect 
the expression levels of the nearest genes in the cell lines as well as in the tumor samples. 
Pertaining to prognosis of these loci, we found that the disease course in patients is also largely not 
associated with low-risk breast cancer loci except for H19 SNP (rs2107425; G/A) near the H19 gene. 
The homozygous risk alleles (AA) of H19 SNP were associated with shorter metastasis-free survival. 
Thus, while these low-risk breast cancer susceptibility loci have been repeatedly associated with 
increased risk of breast cancer we conclude that the low-risk breast cancer susceptibility loci in 
general do not strongly associate with altered expression of the nearest gene nor are they linked to 
altered disease progression (chapter 5). 
In the second part of the thesis, we investigated breast cancer subtype-specific biological factors 
such as genes and micro-RNAs using either primary breast tumors or in vitro propagated breast 
cancer cell lines. Moreover, we developed breast cancer cell line xenograft mice models to 
determine whether subtype-related clinical behavior is maintained in these models. And also 
whether these models can be used to explore the biology of the clinical factors and to investigate 
interference of currently existing as well as novel targeted drugs. Using patient's primary tumor 
samples, we investigated the prognostic significance of TWIST1, a well-known transcription factor 
and marker of epithelial to mesenchymal transition (EMT), in a cohort of 1,427 patients with 
extensive clinical follow-up. In addition, using available gene expression array data we explored the 
underlying biology. Our study revealed that TWIST1 mRNA expression is an independent 
prognostic marker for poor prognosis in ER-positive lymph-node negative breast cancer. 
Additionally, our study provided evidence that the adverse effect of TWIST1 is likely connected to 
the tumor microenvironment and/or high stromal composition of tumor tissue (chapter 6). 
To show whether breast cancer cell lines as a model can mimic clinical tumors at mRNA and miRNA 
expression levels, we performed global mRNA and miRNA expression analyses of 51 human breast 
cancer cell lines (chapter 7). Both the mRNA and the miRNA expression profiles of the cell lines 
could discriminate ER-positive and ER-negative breast cancer cell lines, which is in line with the 
commonly accepted hypothesis that the ER-positive and ER-negative tumors are biologically very 
distinct. Additionally, we revealed that certain miRNAs were differentially expressed among 
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intrinsic breast cancer subtypes, among EMT status of the cell lines and also between wild-type cell 
lines versus those carrying mutations in tumor suppressor and oncogenes commonly present in 
clinical breast tumors. These results further underscore that breast cancer cell lines retain biological 
features that have been described for clinical tumors. Therefore, we argue that the breast cancer 
cell line model is of relevance for studying breast cancer biology. Moreover, our miRNA dataset 
generated from the cell lines is unique, and can be used to elucidate the underlying biology of 
clinically important miRNAs in breast cancer. 
Finally, we evaluated the propensity of our breast cancer cell line model to grow and metastasize in 
the mouse microenvironment and to assess its use as a preclinical xenograft model to study 
whether their metastatic behavior resembles the behavior of breast tumors in patients. For this, we 
stably transduced from each of the four common intrinsic molecular subtypes at least four breast 
cancer cell lines with a luciferase reporter gene and implanted them orthotopically in nude mice. 
Our findings revealed that in our hands the majority of the cell lines were able to grow and gave 
rise to xenograft tumors in mice (tumor take rate = 87.5%). As observed in clinical tumors, normal-
like/claudin-low cell lines displaying features of EMT and adult mammary stem cells showed a more 
aggressive growth pattern in mice compared to other subtypes of cells (Mann-Whitney test; P-
value =0.001). Following metastasis, we found that lymph-nodes, lungs, and liver were the most 
frequently invaded organs by all types of cell lines irrespective of their intrinsic subtype (chapter 
8). From these data we conclude that despite of being propagated in vitro for years, the human 
breast cancer cell lines retain their inherent potential to grow and metastasize in the mouse tissue 
microenvironment. We therefore argue that a collection of human breast cancer cell lines is a 
relevant model, which can not only be applied as an initial discovery tool to gain more global 
genetics and biological insights into human breast carcinogenesis, but can also be employed as a 







Borstkanker is één van de meest voorkomende ziektes in de wereld. In de westerse wereld is het op 
één na de belangrijkste kankergerelateerde doodsoorzaak. In 2012 zal bij 1.4 miljoen vrouwen de 
diagnose invasief borstkanker gesteld worden. Ongeveer de helft van deze vrouwen zal op termijn 
aan deze ziekte overlijden. Borstkanker is een genetische ziekte. Mutaties in functioneel belangrijke 
genen die vrouwen ontvankelijk maken voor het krijgen van borstkanker, de borstkanker 
predispositiegenen, spelen daarin een belangrijke rol. De predispositiegenen krijg je via overerving 
of ze kunnen ontstaan tijdens de ontwikkeling van de tumor. Borstkanker predispositiegenen 
kunnen op basis van het geassocieerde borstkankerrisico en hun voorkomen in de algehele 
populatie geclassificeerd worden als: (1) hoog-risico borstkanker predispositiegenen; zeldzaam in 
de algehele populatie, maar ze vertonen een sterke associatie met het optreden van borstkanker; 
(2) gematigd-risico borstkanker predispositiegenen, deze genen zijn minder zeldzaam en worden 
geassocieerd met een intermediair risico op het optreden van borstkanker; en (3) laag-risico 
borstkanker predispositiegenen; komen vaak voor in de algehele populatie en zijn geassocieerd 
met slechts een licht verhoogd risico op het optreden van borstkanker.  
De biologische mechanismen die ten grondslag liggen aan het risico van de hoog-risicogenen, en 
in mindere mate de gematigd-risicogenen, en hun rol in de progressie van de ziekte zijn in het 
verleden uitgebreid bestudeerd. Het biologisch mechanisme van de laag-risico borstkankergenen 
bij het ontstaan van borstkanker is nog onduidelijk. Ook is nog niet eerder vastgesteld of deze laag-
risico borstkankergenen het verloop van de ziekte na de diagnose in borstkankerpatiënten kan 
voorspellen. Helaas ontbreekt het aan goed gekarakteriseerde in vivo modelsystemen om 
genetische en biologische factoren te bestuderen. Dit belemmert het onderzoek naar hun rol in 
ziekteprogressie. 
In het eerste deel van het proefschrift hebben we een specifieke benaderingswijze gebruikt om 
genetische afwijkingen in familiair borstkanker te ontdekken en om inzicht te krijgen in de biologie 
van bekende laag-risicogenen en potentiële kandidaatgenen en hun effect op prognose. In 
hoofdstuk 3 van dit proefschrift was het doel om een mogelijke relatie tussen mutaties in het 
MSH6 gen met het risico tot het optreden van borstkanker in reeds geïdentificeerde borst- en 
darmkanker (HBCC) families vast te stellen. Het HBCC phenotype is interessant omdat één vijfde 
van de HBCC families drager is van een CHEK2 1100delC mutatie. Deze mutatie verhoogt mogelijk 
in combinatie met een mutatie in een of meer andere genen het risico voor het optreden van 
borstkanker. Onze hypothese was daarom dat mutaties in het MSH6 gen het effect van de CHEK2 
1100delC mutatie bij de ontwikkeling van borstkanker in HBCC families kan versterken. De reden 
voor deze studie was het feit dat beide genen al eerder in verband waren gebracht met het Lynch 
syndroom. Wij hebben de gehele coderende sequentie van het MSH6 gen geanalyseerd op 
genetische veranderingen in 68 HBCC families. Zeldzame (<1%) MSH6 varianten werden 
geïdentificeerd in 11.8% van de HBCC borstkankerfamilies, terwijl deze zelfde varianten in slechts 
1.5% van de controle populatie werden gevonden. Dit suggereert dat zeldzame MSH6 varianten 
geassocieerd zijn met een risico op HBCC borstkanker (P <0.00001). Echter, screening van de 
gehele coderende sequentie van het MSH6 gen in 68 non-HBCC borstkankerfamilies liet een 
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vergelijkbare associatie zien (8,8% t.o.v. ~1,4% in de controlegroep, P <0,001). Dit resultaat 
suggereert dat zeldzame MSH6 varianten niet beperkt zijn tot HBCC borstkanker. Samenvattend 
suggereren onze data dat zeldzame MSH6 varianten in het algemeen vrouwen ontvankelijk maken 
voor familiair borstkanker. Geen van de zeldzame MSH6 varianten is echter overduidelijk 
ziekteverwekkend, mogelijk ligt er een gecompliceerd ziektemechanisme aan ten grondslag 
tijdens het ontstaan van borstkanker door dergelijke varianten.  
Vervolgens hebben we onze aandacht gericht op de vragen (i) hoe laag-risico borstkanker 
predispositiegenen het risico op borstkanker verhogen (ii) of laag-risico borstkanker 
predispositiegenen de natuurlijke progressie van de ziekte in borstkankerpatiënten kunnen 
beïnvloeden. Samengevat hebben wij onderzocht of dergelijke single-nucleotide polymorfismes 
(SNPs) de prognose van een patiënt kunnen voorspellen nadat de ziekte geconstateerd is. Negen 
kandidaat SNPs in of in de buurt van een gen op zeven met risico geassocieerde loci (FGFR2-
rs2981282, LSP1-rs3817198, MAP3K1-rs889312, TOX3-rs3803662, H19-rs2107425, 2q35-
rs13387042, and 8q24-rs13281615) werden daarom gegenotypeerd in 40 humane 
borstkankercellijnen (hoofdstuk 4) en in een retrospectief cohort van 2480 primaire borsttumoren 
van patiënten van wie de volledige klinische follow-up bekend is (hoofdstuk 5). Om de 
onderliggende ziektemechanismen te onderzoeken hebben we de meest waarschijnlijke 
hypothese getest, waarbij laag-risico borstkanker SNPs een hoger risico opleveren door een 
verandering van de expressie van het gen dat het dichtst in de buurt van de SNP ligt. De frequentie 
van het minst voorkomende allel voor deze loci was inderdaad hoger in de tumorcellijnen en de 
tumoren dan in het bloed van de controle populatie van Europese afkomst. Dit bevestigt dat ook in 
ons cohort de allelen waarop deze SNPs gelegen zijn een verhoogd risico op borstkanker geven. 
Onze resultaten toonden verder aan dat alle zeven onderzochte laag-risico borstkanker 
predispositieloci over het algemeen niet het expressieniveau van het dichtstbijzijnde gen 
beïnvloeden. Dat gold voor de cellijnen en de tumorweefsels. Een uitzondering hierop was SNP 
rs3803662, welke geassocieerd was met een lagere expressie van het TOX3 gen. Met betrekking tot 
de prognose van deze loci vonden wij dat het ziekteverloop in patiënten niet is geassocieerd met 
laag-risico borstkankerloci, behalve in het geval van de H19 SNP (rs2107425 G/A) dat gelegen is bij 
het H19 gen. Homozygotie van het risico-allel (genotype AA) van de H19 SNP was geassocieerd met 
een kortere metastase-vrije overleving. Dus, hoewel deze laag-risico borstkanker predispositieloci 
herhaaldelijk geassocieerd zijn met een verhoogd risico op borstkanker moeten we concluderen 
dat deze SNPs geen effect hebben op het natuurlijk beloop van de progressie van borstkanker. Ook 
vonden we geen aanwijzingen dat deze SNPs over het algemeen een sterke associatie hebben met 
een gewijzigde genexpressie van het dichtstbijgelegen gen, de tot nog toe meest gangbare 
hypothese (hoofdstuk 5). 
In het tweede deel van het proefschrift hebben wij borstkankersubtype-specifieke biologische 
factoren, zoals genen en microRNAs, onderzocht in primaire borsttumoren en gekweekte 
borstkankercellijnen. Als laatste hebben wij muizen xenotransplantatie modellen ontwikkeld van 
borstkankercellijnen. Dit om te bepalen of het klinisch gedrag van de borstkanker-subtypes in de 
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muis behouden blijft en om in de toekomst functioneel onderzoek te kunnen doen aan 
verschillende borstkankersubtypes.  
In klinische borsttumorweefsels hebben wij de prognostische betekenis van TWIST1, een bekende 
transcriptiefactor en marker voor epitheliale naar mesenchymale transitie (EMT), onderzocht in een 
cohort van 1427 primaire borstkankerpatiënten met uitgebreide klinische follow-up. Daarnaast 
hebben wij de onderliggende biologie bestudeerd met behulp van beschikbare genexpressie array 
data. Onze studie wees uit dat TWIST1 mRNA expressie een onafhankelijke prognostische marker 
was voor een slechtere prognose in ER-positief, lymfeklier negatief borstkanker. Bovendien liet 
onze studie zien dat het ongunstige effect van TWIST1 waarschijnlijk samenhangt met de micro-
omgeving van de tumor en/of een rijke stromale samenstelling van het tumorweefsel (hoofdstuk 
6).  
Om te onderzoeken of een model van borstkankercellijnen de mRNA en miRNA expressieniveaus 
van klinische tumoren kan imiteren hebben wij genoom-brede mRNA and miRNA 
expressieanalyses uitgevoerd voor 51 humane borstkankercellijnen (hoofdstuk 7). Zowel de 
mRNA als de miRNA expressieprofielen van de cellijnen konden de ER-positieve van de ER-
negatieve borstkankercellijnen onderscheiden, dat is in overeenstemming met de algemeen 
geaccepteerde hypothese dat ER-positieve en ER-negatieve tumoren biologisch verschillend zijn. 
Daarnaast hebben wij kunnen aantonen dat bepaalde miRNAs differentieel geëxpresseerd werden 
tussen de verschillende moleculaire subtypes van borstkanker en dat ze overeen kwamen met de 
EMT status van de cellijnen. Ook lieten specifieke miRNAs verschillende expressieniveaus zien in 
wild-type cellijnen vergeleken met cellijnen die mutaties dragen in frequent gemuteerde 
tumorsuppressorgenen en oncogenen. Deze resultaten bevestigen dat borstkankercellijnen de 
biologische kenmerken behouden die beschreven worden voor primaire tumoren uit patiënten. 
Wij stellen daarom dat het borstkankercellijn model relevant is om de biologie van borstkanker te 
bestuderen. De miRNA dataset die we gegenereerd hebben voor de cellijnen is uniek en kan 
gebruikt worden om de onderliggende biologie van klinisch belangrijke miRNAs in borstkanker te 
ontrafelen.  
Als laatste hebben we in de intrinsieke capaciteit van de borstkankercellijnen om in een micro-
omgeving te groeien en uit te zaaien onderzocht met een muis-model. We hebben de 
toepasbaarheid van ons preklinisch xenotransplantatie model geëvalueerd door het 
metastaseringsgedrag in de muis te vergelijken met dat in de patiënt. Voor dit doel hebben we 
minimaal vier borstkankercellijnen van elk van de vier intrinsieke moleculaire subtypes stabiel 
getransduceerd met een luciferase reportergen en vervolgens geïmplanteerd in het orgaan van 
origine in naakte muizen. Onze bevindingen toonden aan dat de meerderheid van de gebruikte 
cellijnen (87%) in staat waren om te groeien en tumoren te vormen in de muis. Zoals ook 
waargenomen in klinische tumoren, hadden normal-like/claudine-lage cellijnen, welke kenmerken 
van EMT en borststamcellen vertonen, een agressiever groeipatroon in muizen dan de cellijnen van 
de andere borstkankersubtypes. Wij vonden dat de lymfeklieren, longen en lever het meest 
frequent aangedaan waren, ongeacht het intrinsieke borstkankersubtype (hoofdstuk 8). Uit deze 
data concluderen wij dat humane borstkankercellijnen, ondanks het feit dat ze vele jaren in kweek 
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zijn, hun inherente mogelijkheid om te groeien en te metastaseren behouden in de micro-
omgeving in de muis. Wij bepleiten daarom dat een collectie van humane borstkankercellijnen een 
relevant model is. De toepassing van het borstkanker xenotransplantatie muismodel hoeft zich niet 
te beperken tot het verkrijgen van genetische en biologische inzichten in het ontstaan van 
borstkanker in de mens. Het kan ook preklinisch gebruikt worden om de effectiviteit van potentiële 
borstkankermedicijnen te screenen.  
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